effect	The antimicrobial combinations of <e13> GL </e13> with four <e22> antibiotics </e22> resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances.
effect	Synergism was observed when <e13> GL </e13> was combined with <e20> cefazolin </e20> against Bacillus subtilis and Klebsiella oxytoca.
effect	<e13> Echistatin </e13> alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of <e23> contortrostatin </e23> when both are added simultaneously.
effect	<e13> Flavoridin </e13> alone was found to have no effect on CAS, but can completely block <e23> contortrostatin </e23> -induced phosphorylation of this protein in MDA-MB-435 cells.
effect	Using in situ hybridization, we observed that <e10> METH </e10> caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist <e23> SCH-23390 </e23> but not by an atypical_neuroleptic clozapine .
effect	The effects of <e13> DCG-IV </e13> were very strong and completely depressed the <e23> PCP </e23> -induced hyperlocomotion.
effect	Both <e13> ibogaine </e13> and 18-MC block <e20> morphine </e20> -induced and nicotine -induced dopamine release in the nucleus accumbens;
effect	Both <e13> ibogaine </e13> and 18-MC block morphine -induced and <e20> nicotine </e20> -induced dopamine release in the nucleus accumbens;
effect	Both ibogaine and <e13> 18-MC </e13> block <e20> morphine </e20> -induced and nicotine -induced dopamine release in the nucleus accumbens;
effect	Both ibogaine and <e13> 18-MC </e13> block morphine -induced and <e20> nicotine </e20> -induced dopamine release in the nucleus accumbens;
effect	only <e13> ibogaine </e13> enhances <e20> cocaine </e20> -induced increases in accumbal dopamine.
effect	<e13> Ibogaine </e13> attenuates, but 18-MC potentiates, the acute locomotor effects of <e20> morphine </e20> ;
effect	Ibogaine attenuates, but <e13> 18-MC </e13> potentiates, the acute locomotor effects of <e20> morphine </e20> ;
effect	<e13> Cytochalasin_D </e13> at # microM preferentially blocked the secretory effect of <e20> carbachol </e20> and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within # min.
effect	<e13> Cytochalasin_D </e13> inhibited the <e20> carbachol </e20> -stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store.
effect	Suppression by <e10> verapamil </e10> of <e23> bombesin </e23> -enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
effect	<e10> Verapamil </e10> also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by <e23> bombesin </e23> .
effect	<e10> PGF2alpha </e10> produced significantly increased vasoconstriction after a single administration of <e20> oxytocin </e20> .
effect	There is thus an enhancement effect of <e10> PGF2alpha </e10> upon the reaction of placental vessels to <e20> oxytocin </e20> in vitro.
effect	We report the case of an adolescent with altered consciousness caused by <e10> carbamazepine </e10> overdose with a positive <e22> tricyclic_antidepressant </e22> level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic_antidepressants .
effect	<e10> Cypermethrin </e10> -induced oxidative stress in rat brain and liver is prevented by <e20> vitamin_E </e20> or allopurinol .
effect	<e10> Cypermethrin </e10> -induced oxidative stress in rat brain and liver is prevented by vitamin_E or <e20> allopurinol </e20> .
effect	Pretreatment of rats with <e10> allopurinol </e10> (100 mg/kg, ip) or Vitamin_E (100 mg/kg per day, ig, for # days and a dose of # mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral <e20> cypermethrin </e20> administration within # h.
effect	Pretreatment of rats with allopurinol (100 mg/kg, ip) or <e10> Vitamin_E </e10> (100 mg/kg per day, ig, for # days and a dose of # mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral <e20> cypermethrin </e20> administration within # h.
effect	Thus, the results suggest that <e10> cypermethrin </e10> exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by <e20> allopurinol </e20> and Vitamin_E .
effect	Thus, the results suggest that <e10> cypermethrin </e10> exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and <e20> Vitamin_E </e20> .
effect	When combined with <e10> ofloxacin </e10> , <e23> KRM-1648 </e23> exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin ) and ofloxacin .
effect	When combined with ofloxacin , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of <e10> rifampicin </e10> (or rifabutin ) and <e20> ofloxacin </e20> .
effect	When combined with ofloxacin , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or <e10> rifabutin </e10> ) and <e20> ofloxacin </e20> .
effect	Administering <e13> InsP(3) </e13> together with <e23> RR </e23> (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.
effect	Pretreatment of megakaryocytes with extracellular <e13> RR </e13> (50 microM) also inhibited <e23> InsP(3) </e23> -induced responses.
effect	<e13> Buforin_II </e13> may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either <e20> azithromycin </e20> or minocycline .
effect	<e13> Buforin_II </e13> may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or <e20> minocycline </e20> .
effect	It is concluded that <e10> ketamine </e10> is not a short-acting drug and that concomitant use with <e20> halothane </e20> would be expected to prolong further the duration of its action on the central nervous system.
effect	The effect of <e10> rifampin </e10> on the <e20> warfarin </e20> requirement of our patient appeared to be maximal # to # days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
effect	<e10> Amprenavir </e10> plus <e20> rifabutin </e20> was poorly tolerated, and # of # subjects discontinued therapy.
effect	<e10> Etofibrate </e10> elicited 62% enhancement of post- <e20> heparin </e20> lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.
effect	Prior administration of <e10> 4-methylpyrazole </e10> (90 mg kg(-1) body weight) was shown to prevent the conversion of <e23> 1,3-difluoro-2-propanol </e23> (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol -intoxicated animals.
effect	We conclude that the prophylactic and antidotal properties of <e10> 4-methylpyrazole </e10> seen in animals treated with <e23> 1,3-difluoro-2-propanol </e23> derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.
effect	<e10> ADL_8-2698 </e10> , a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous <e20> morphine </e20> without affecting analgesia.
effect	<e10> ADL-8-2698 </e10> is a novel peripherally_restricted_opioid_antagonist that may selectively prevent <e22> opioid </e22> -induced gastrointestinal effects without reversing analgesia.
effect	<e10> Morphine </e10> prolonged gastrointestinal transit time from # to # minutes (P = #); this was prevented by <e20> ADL_8-2698 </e20> (P = #).
effect	We conclude that <e10> ADL_8-2698 </e10> prevents <e20> morphine </e20> -induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.
effect	Rhabdomyolysis secondary to a drug interaction between <e10> simvastatin </e10> and <e20> clarithromycin </e20> .
effect	The concomitant administration of <e12> macrolide_antibiotics </e12> and other <e22> hydroxymethylglutaryl_coenzyme_A_(HMG-CoA)_reductase_inhibitors </e22> have resulted in previous reports of rhabdomyolysis.
effect	Coingestion of <e10> acetaminophen </e10> with <e20> theophylline </e20> , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
effect	Coingestion of acetaminophen with theophylline , <e10> phenobarbital </e10> with <e20> acetaminophen </e20> , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
effect	Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and <e10> valproic_acid </e10> with <e20> phenobarbital </e20> at high to toxic concentrations decreases the binding of the target drug.
effect	<e10> Diazepam </e10> at doses of # mg/kg and # mg/kg injected with <e20> morphine </e20> was found to decrease the antinociceptive effect of morphine .
effect	Similarly, <e10> diazepam </e10> decreased the antinociceptive effect of <e20> metamizol </e20> (only in the tail-flick test) and indomethacin .
effect	Similarly, <e10> diazepam </e10> decreased the antinociceptive effect of metamizol (only in the tail-flick test) and <e20> indomethacin </e20> .
effect	<e10> Midazolam </e10> used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of <e20> morphine </e20> , metamizol (only in the tail-flick test) and indomethacin .
effect	<e10> Midazolam </e10> used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of morphine , <e20> metamizol </e20> (only in the tail-flick test) and indomethacin .
effect	<e10> Midazolam </e10> used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of morphine , metamizol (only in the tail-flick test) and <e20> indomethacin </e20> .
effect	Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) <e10> estradiol </e10> group were supersensitive to <e20> noradrenaline </e20> compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = #+/#, #+/# and #+/#, respectively).
effect	Endothelium-intact aortic rings from high- <e10> estradiol </e10> rats were supersensitive to <e20> noradrenaline </e20> when compared to vehicle-, progesterone - and progesterone + high- estradiol -treated rats (pD2 values = #+/#, #+/#, #+/# and #+/#, respectively).
effect	however, patients with moderate to severe cardiovascular disease or those taking <e12> nitrate </e12> therapy are at increased risk for potentially serious cardiovascular adverse effects with <e20> sildenafil </e20> therapy.
effect	In a comparison of digitalis tolerance in dogs anesthetized with <e10> ketamine </e10> , Innovar_Vet , or pentobarbital , the dosage of <e20> ouabain </e20> needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital .
effect	In a comparison of digitalis tolerance in dogs anesthetized with ketamine , <e11> Innovar_Vet </e11> , or pentobarbital , the dosage of <e20> ouabain </e20> needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital .
effect	In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or <e10> pentobarbital </e10> , the dosage of <e20> ouabain </e20> needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital .
effect	Ventricular tachycardia induced by <e10> ouabain </e10> was generally converted to sinus rhythm following administration of <e21> Innovar </e21> , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital .
effect	Ventricular tachycardia induced by <e10> ouabain </e10> was generally converted to sinus rhythm following administration of Innovar , <e20> ketamine </e20> , or droperidol but not after administration of fentayl alone or after pentobarbital .
effect	Ventricular tachycardia induced by <e10> ouabain </e10> was generally converted to sinus rhythm following administration of Innovar , ketamine , or <e20> droperidol </e20> but not after administration of fentayl alone or after pentobarbital .
effect	Combinations of <e10> clindamycin </e10> and <e20> gentamicin </e20> were indifferent for # strains and synergistic for # strains.
effect	Combinations of <e10> clindamycin </e10> and <e20> gentamicin </e20> were indifferent for # and synergistic for # of the resistant strains.
effect	Although this effect was noted even when <e10> cholestyramine </e10> was given # hours prior to <e20> fluvastatin </e20> , this regimen did not result in diminished efficacy.
effect	[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that <e13> picrotoxin </e13> (1 mg/kg) removes the antiedematous action of <e20> diazepam </e20> , phenazepam , phenibut and amizyl and reduces the action of phentolamine .
effect	[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that <e13> picrotoxin </e13> (1 mg/kg) removes the antiedematous action of diazepam , <e23> phenazepam </e23> , phenibut and amizyl and reduces the action of phentolamine .
effect	[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that <e13> picrotoxin </e13> (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , <e23> phenibut </e23> and amizyl and reduces the action of phentolamine .
effect	[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that <e13> picrotoxin </e13> (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , phenibut and <e23> amizyl </e23> and reduces the action of phentolamine .
effect	[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that <e13> picrotoxin </e13> (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , phenibut and amizyl and reduces the action of <e20> phentolamine </e20> .
effect	In the presence of <e10> ouabain </e10> (10(-5) M), <e23> PTX </e23> (10(-8) M) failed to cause the first contraction;
effect	When <e10> ouabain </e10> was applied to the muscle in the presence of <e20> phentolamine </e20> , both first and second contractile responses to PTX were abolished.
effect	Exposure of the muscle to <e10> ouabain </e10> (10(-5) M) markedly increased the <e23> PTX </e23> -induced release.
effect	Intrathecal injection of <e10> naloxone </e10> at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of <e23> beta-endorphin </e23> , and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms).
effect	Intrathecal injection of naloxone at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin , and a high dose of <e10> naloxone </e10> (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular <e23> beta-endorphin </e23> (16 micrograms).
effect	On the other hand, intrathecal <e10> naloxone </e10> (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular <e20> morphine </e20> (40 micrograms).
effect	Intraventricular injection of <e10> naloxone </e10> at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular <e23> beta-endorphin </e23> and morphine .
effect	Intraventricular injection of <e10> naloxone </e10> at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and <e20> morphine </e20> .
effect	It was observed that <e13> MPTP </e13> induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by <e20> pargyline </e20> pretreatment.
effect	The <e13> MPTP </e13> -induced neuronal damage produced a tolerance to the disruptive effects of <e20> amphetamine </e20> and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
effect	The <e13> MPTP </e13> -induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of <e20> apomorphine </e20> in rats responding in a schedule controlled paradigm.
effect	<e10> Methamphetamine </e10> , like MPTP , produced depletions of striatal dopamine but these actions were potentiated by <e20> pargyline </e20> pretreatment.
effect	<e10> Dexamethasone </e10> and retinyl_acetate similarly inhibit and stimulate <e23> EGF </e23> - or insulin -induced proliferation of prostatic epithelium.
effect	<e10> Dexamethasone </e10> and retinyl_acetate similarly inhibit and stimulate EGF - or <e20> insulin </e20> -induced proliferation of prostatic epithelium.
effect	Dexamethasone and <e10> retinyl_acetate </e10> similarly inhibit and stimulate <e23> EGF </e23> - or insulin -induced proliferation of prostatic epithelium.
effect	Dexamethasone and <e10> retinyl_acetate </e10> similarly inhibit and stimulate EGF - or <e20> insulin </e20> -induced proliferation of prostatic epithelium.
effect	Although neither <e10> dexamethasone </e10> nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of <e23> EGF </e23> and insulin .
effect	Although neither <e10> dexamethasone </e10> nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and <e20> insulin </e20> .
effect	Although neither dexamethasone nor <e10> retinyl_acetate </e10> affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of <e23> EGF </e23> and insulin .
effect	Although neither dexamethasone nor <e10> retinyl_acetate </e10> affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and <e20> insulin </e20> .
effect	<e10> Dexamethasone </e10> at 10(-10) M or retinyl_acetate at about # X 10(-9) M inhibits proliferation stimulated by <e23> EGF </e23> .
effect	Dexamethasone at 10(-10) M or <e10> retinyl_acetate </e10> at about # X 10(-9) M inhibits proliferation stimulated by <e23> EGF </e23> .
effect	Higher concentrations of <e10> dexamethasone </e10> (10(-8) - 10(-6) M) or retinyl_acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of <e23> EGF </e23> .
effect	Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or <e10> retinyl_acetate </e10> (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of <e23> EGF </e23> .
effect	However, <e10> retinyl_acetate </e10> stimulated, but did not significantly inhibit, proliferation in the presence of <e20> insulin </e20> .
effect	These results suggest that both <e10> dexamethasone </e10> and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of <e20> insulin </e20> and EGF .
effect	These results suggest that both <e10> dexamethasone </e10> and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and <e23> EGF </e23> .
effect	These results suggest that both dexamethasone and <e10> retinyl_acetate </e10> , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of <e20> insulin </e20> and EGF .
effect	These results suggest that both dexamethasone and <e10> retinyl_acetate </e10> , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and <e23> EGF </e23> .
effect	These results suggest that both dexamethasone and retinyl_acetate , and possibly other <e12> glucocorticoids </e12> and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of <e20> insulin </e20> and EGF .
effect	These results suggest that both dexamethasone and retinyl_acetate , and possibly other <e12> glucocorticoids </e12> and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and <e23> EGF </e23> .
effect	These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and <e12> retinoids </e12> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of <e20> insulin </e20> and EGF .
effect	These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and <e12> retinoids </e12> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and <e23> EGF </e23> .
effect	Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin , but not in <e10> pentazocine </e10> and <e20> tripelennamine </e20> , addicts) were completely inhibited by the drug combination.
effect	Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that <e10> tripelennamine </e10> was responsible for the inhibitory activity, which was partially antagonized by <e20> pentazocine </e20> .
effect	<e13> Misonidazole </e13> protects mouse tumour and normal tissues from the toxicity of oral <e20> CCNU </e20> .
effect	<e13> Misonidazole </e13> reduced the antitumour activity of oral <e20> CCNU </e20> by dose modifying factors (DMF) of ##.
effect	With combined use, clinicians should be aware, when <e10> phenytoin </e10> is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum <e20> theophylline </e20> concentrations.
effect	In both species, <e13> (-)-NANM </e13> , but not (+)-NANM , antagonized the rate-decreasing effects of <e20> morphine </e20> on FI and FR responding.
effect	In monkeys, the effects of <e13> (-)-NANM </e13> , but not (+)-NANM or PCP , were antagonized by <e20> naloxone </e20> ;
effect	the doses of <e10> naloxone </e10> required to antagonize the effects of <e23> (-)-NANM </e23> were more than # times higher than those required to antagonize the effects of morphine .
effect	the doses of <e10> naloxone </e10> required to antagonize the effects of (-)-NANM were more than # times higher than those required to antagonize the effects of <e20> morphine </e20> .
effect	<e10> Haloperidol </e10> reduced or eliminated the increases in FI responding produced by intermediate doses of either <e23> (+)-NANM </e23> or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM .
effect	<e10> Haloperidol </e10> reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or <e23> PCP </e23> in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM .
effect	Increased hepatotoxicity of <e10> acetaminophen </e10> by concomitant administration of <e20> caffeine </e20> in the rat.
effect	Careful observations on hepatotoxicity are suggested when <e10> acetaminophen </e10> is prescribed with <e20> caffeine </e20> .
effect	High-dose <e10> cisplatin </e10> with <e20> sodium_thiosulfate </e20> protection.
effect	<e10> Sodium_thiosulfate </e10> is a neutralizing agent for <e20> cisplatin </e20> that protects against renal damage.
effect	The treatment of ewes with an intravenous (IV) injection of <e13> trichlorfon </e13> , insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with # mg of <e23> coumaphos </e23> /kg/day.
effect	In ewes given # mg of <e10> phenobarbital_sodium </e10> /kg for # days intraperitoneally (IP), the anticholinesterase effect of # mg of <e23> coumaphos </e23> /kg was significantly reduced and signs of toxicity were not present.
effect	Studies in rats have shown that <e10> neomycin </e10> administration attenuates certain types of adrenocortical_steroid dependent hypertension, including <e22> ACTH </e22> hypertension.
effect	These results suggest that exposure to environmental <e13> lead </e13> may alter the biological and behavioral responsiveness of an animal to <e20> alcohol </e20> .
effect	<e10> Physostigmine </e10> pretreatment augmented the depressant effect of <e20> alcohol </e20> on the early components P1 and N1, while attenuating alcohol 's influence on components P2 and P3.
effect	<e10> Physostigmine </e10> pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating <e20> alcohol </e20> 's influence on components P2 and P3.
effect	Core temperature was decreased in rats in a dose-dependent manner when <e10> ethanol </e10> was administered to rats treated with <e20> disulfiram </e20> # hours before the ethanol challenge.
effect	It was shown that <e13> neurotensin </e13> antagonized evidently the antinociceptive effect of <e23> enkephalins </e23> and their analogue.
effect	On the contrary, <e13> neurotensin </e13> and <e23> tuftsin </e23> were agonists in induction of analgesia.
effect	It is concluded that <e13> neurotensin </e13> modulates in an opposite way the function of the enkephalinergic neurons and the central action of <e23> tuftsin </e23> .
effect	Among the risk factors studied, two appear to increase the risk of ARE: the prescription of <e10> thiabendazole </e10> to treat strongyloidiasis during the <e20> melarsoprol </e20> cure and the bad general clinical conditions of patients.
effect	Injection of <e10> estradiol </e10> # min before a nonlethal dose of <e23> endotoxin </e23> changed the serum sex steroid hormone response of male rats to endotoxin .
effect	Exogenous <e10> estradiol </e10> also appeared to influence the percentage of <e23> endotoxin </e23> -induced deaths in a dose-dependent manner.
effect	<e10> Loperamide </e10> and morphine (# and # mg/kg, s,c,) inhibited the <e23> dmPGE2 </e23> (# mg/kg, p,o,)-induced diarrhea in cecectomized rats.
effect	Loperamide and <e10> morphine </e10> (# and # mg/kg, s,c,) inhibited the <e23> dmPGE2 </e23> (# mg/kg, p,o,)-induced diarrhea in cecectomized rats.
effect	<e13> N-methyllevallorphan </e13> (5 mg/kg, s,c,) completely antagonized the inhibitory effect of <e20> loperamide </e20> and partly antagonized the effect of morphine .
effect	<e13> N-methyllevallorphan </e13> (5 mg/kg, s,c,) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of <e20> morphine </e20> .
effect	Therapeutic drug monitoring can avoid iatrogenic alterations caused by <e10> 99mTc-methylene_diphosphonate </e10> (MDP)- <e20> gentamicin </e20> interaction.
effect	These results suggest that the hepatoxicity of <e10> ethanol </e10> in alcoholic beverages is enhanced by interaction with its congeners and <e23> acetaldehyde </e23> ;
effect	Our data suggest that <e13> TAM </e13> significantly potentiates the reduction in cell number induced by <e20> 1,25(OH)2D3 </e20> alone.
effect	Combined treatment with <e10> 1,25(OH)2D3 </e10> and <e23> TAM </e23> enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation.
effect	The anxiogenic effects of <e10> theophylline </e10> were reduced by pretreatment with <e20> CGS_21680 </e20> , an A2-selective agonist, but not by N6-cyclopentyladenosine ( CPA ), an A1-selective agonist.
effect	However, the antagonism of the <e10> theophylline </e10> -induced anxiogenic effects by <e23> CGS21680 </e23> was only observed in the time spent in the light zone, and DPCPX -induced anxiogenic effects were neither reversed by CGS_21680 nor by CPA .
effect	Interaction between <e10> glycine </e10> and <e20> glutamate </e20> in the development of spontaneous motility in chick embryos.
effect	The successive application of <e10> glycine </e10> (5 or # mg/kg egg weight (e,w,) and <e20> glutamate </e20> (15 mg/kg e,w,) in a # min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone.
effect	The uptake inhibitors <e10> cocaine </e10> and desipramine (3 mumol/liter) potentiated the positive inotropic effects of <e20> norepinephrine </e20> in nonfailing myocardium (p < #) but not in functional class IV myocardium.
effect	The uptake inhibitors cocaine and <e10> desipramine </e10> (3 mumol/liter) potentiated the positive inotropic effects of <e20> norepinephrine </e20> in nonfailing myocardium (p < #) but not in functional class IV myocardium.
effect	Recovery of hoof twitch from 50% to 75% took # +/- # min for atracurium alone and # +/- # min for <e10> atracurium </e10> plus <e20> gentamycin </e20> (P = #).
effect	Recovery from 50% twitch to 75% fade recovery took # +/- # min for atracurium alone and # +/- # min for <e10> atracurium </e10> plus <e20> gentamycin </e20> .
effect	At 75% recovery of fade, hoof twitch was # +/- 3% for atracurium alone and # +/- 4% for <e10> atracurium </e10> plus <e20> gentamycin </e20> .
effect	It was concluded that, although <e10> gentamycin </e10> did augment the neuromuscular blockade of <e20> atracurium </e20> , the effect was minimal.
effect	Concurrent administration of a <e12> TNF_antagonist </e12> with <e21> ORENCIA </e21> has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF_antagonists alone.
effect	Patients taking <e10> Acamprosate </e10> concomitantly with <e22> antidepressants </e22> more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.
effect	<e12> Catecholamine-depleting_drugs </e12> , such as reserpine , may have an additive effect when given with <e22> beta-blocking_agents </e22> .
effect	Catecholamine-depleting_drugs , such as <e10> reserpine </e10> , may have an additive effect when given with <e22> beta-blocking_agents </e22> .
effect	Exaggerated hypertensive responses have been reported from the combined use of <e12> beta-adrenergic_antagonists </e12> and <e22> alpha-adrenergic_stimulants </e22> , including those contained in proprietary cold remedies and vasoconstrictive nasal drops.
effect	Blunting of the antihypertensive effect of <e12> beta-adrenoceptor_blocking_agents </e12> by <e22> nonsteroidal_anti-inflammatory_drugs </e22> has been reported.
effect	<e10> Acetazolamide </e10> may increase the effects of other <e22> folic_acid_antagonists </e22> .
effect	<e10> Acetazolamide </e10> may prevent the urinary antiseptic effect of <e20> methenamine </e20> .
effect	<e10> Acetazolamide </e10> and <e20> sodium_bicarbonate </e20> used concurrently increases the risk of renal calculus formation.
effect	Glibenclamide : In a study of # healthy male volunteers, <e10> acitretin </e10> treatment potentiated the blood glucose lowering effect of <e20> glibenclamide </e20> (a sulfonylurea similar to chlorpropamide ) in # of the # subjects.
effect	However, it has been established that <e10> acitretin </e10> interferes with the contraceptive effect of microdosed <e22> progestin </e22> minipill preparations.
effect	Methotrexate : An increased risk of hepatitis has been reported to result from combined use of <e10> methotrexate </e10> and <e20> etretinate </e20> .
effect	Tetracyclines : Since both <e10> acitretin </e10> and <e22> tetracyclines </e22> can cause increased intracranial pressure, their combined use is contraindicated.
effect	Anakinra : Concurrent administration of <e10> anakinra </e10> (an interleukin-1_antagonist ) and another <e22> TNF-blocking_agent </e22> has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
effect	Anakinra : Concurrent administration of anakinra (an <e12> interleukin-1_antagonist </e12> ) and another <e22> TNF-blocking_agent </e22> has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
effect	Therefore the, combination of <e10> anakinra </e10> with other <e22> TNF-blocking_agents </e22> , including HUMIRA , may also result i n similar toxicities.
effect	Therefore the, combination of <e10> anakinra </e10> with other TNF-blocking_agents , including <e21> HUMIRA </e21> , may also result i n similar toxicities.
effect	<e10> Digoxin </e10> and verapamil use may be rarely associated with ventricular fibrillation when combined with <e21> Adenocard </e21> .
effect	Digoxin and <e10> verapamil </e10> use may be rarely associated with ventricular fibrillation when combined with <e21> Adenocard </e21> .
effect	The use of <e11> Adenocard </e11> in patients receiving <e22> digitalis </e22> may be rarely associated with ventricular fibrillation.
effect	The effects of <e10> adenosine </e10> are antagonized by <e22> methylxanthines </e22> such as caffeine and theophylline .
effect	The effects of <e10> adenosine </e10> are antagonized by methylxanthines such as <e20> caffeine </e20> and theophylline .
effect	The effects of <e10> adenosine </e10> are antagonized by methylxanthines such as caffeine and <e20> theophylline </e20> .
effect	<e10> Adenosine </e10> effects are potentiated by <e20> dipyridamole </e20> .
effect	Thus, smaller doses of <e10> adenosine </e10> may be effective in the presence of <e20> dipyridamole </e20> .
effect	As the primary effect of <e10> adenosine </e10> is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of <e20> carbamazepine </e20> .
effect	Concurrent administration of drugs possessing nephrotoxic (e,g,, <e12> aminoglycosides </e12> , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with <e21> PROLEUKIN </e21> may increase toxicity in these organ systems.
effect	Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , <e10> indomethacin </e10> ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with <e21> PROLEUKIN </e21> may increase toxicity in these organ systems.
effect	Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, <e12> cytotoxic </e12> chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with <e21> PROLEUKIN </e21> may increase toxicity in these organ systems.
effect	Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, <e10> doxorubicin </e10> ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with <e21> PROLEUKIN </e21> may increase toxicity in these organ systems.
effect	Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, <e10> methotrexate </e10> , asparaginase ) effects with <e21> PROLEUKIN </e21> may increase toxicity in these organ systems.
effect	Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , <e10> asparaginase </e10> ) effects with <e21> PROLEUKIN </e21> may increase toxicity in these organ systems.
effect	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose <e11> PROLEUKIN </e11> and <e22> antineoplastic_agents </e22> , specifically, dacarbazine , cis-platinum , tamoxifen and interferon-alfa .
effect	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose <e11> PROLEUKIN </e11> and antineoplastic_agents , specifically, <e20> dacarbazine </e20> , cis-platinum , tamoxifen and interferon-alfa .
effect	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose <e11> PROLEUKIN </e11> and antineoplastic_agents , specifically, dacarbazine , <e20> cis-platinum </e20> , tamoxifen and interferon-alfa .
effect	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose <e11> PROLEUKIN </e11> and antineoplastic_agents , specifically, dacarbazine , cis-platinum , <e20> tamoxifen </e20> and interferon-alfa .
effect	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose <e11> PROLEUKIN </e11> and antineoplastic_agents , specifically, dacarbazine , cis-platinum , tamoxifen and <e20> interferon-alfa </e20> .
effect	Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving <e11> PROLEUKIN </e11> and <e20> interferon-alfa </e20> concurrently.
effect	Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of <e10> interferon-alfa </e10> and <e21> PROLEUKIN </e21> , including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.
effect	Although <e12> glucocorticoids </e12> have been shown to reduce <e21> PROLEUKIN </e21> -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .
effect	Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # <e12> Beta-blockers </e12> and other antihypertensives may potentiate the hypotension seen with <e21> PROLEUKIN </e21> .
effect	Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other <e10> antihypertensives </e10> may potentiate the hypotension seen with <e21> PROLEUKIN </e21> .
effect	Delayed Adverse Reactions to Iodinated_Contrast_Media : A review of the literature revealed that #% (range 11-28%) of # patients treated with various <e10> interleukin-2 </e10> containing regimens who were subsequently administered <e22> radiographic_iodinated_contrast_media </e22> experienced acute, atypical adverse reactions.
effect	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when <e11> ALFENTA </e11> is administered in combination with other <e22> CNS_depressants </e22> such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics .
effect	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when <e11> ALFENTA </e11> is administered in combination with other CNS_depressants such as <e22> barbiturates </e22> , tranquilizers , opioids , or inhalation general anesthetics .
effect	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when <e11> ALFENTA </e11> is administered in combination with other CNS_depressants such as barbiturates , <e22> tranquilizers </e22> , opioids , or inhalation general anesthetics .
effect	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when <e11> ALFENTA </e11> is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , <e22> opioids </e22> , or inhalation general anesthetics .
effect	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when <e11> ALFENTA </e11> is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general <e22> anesthetics </e22> .
effect	Thiazide_Diuretics : The reports that the concomitant use of <e10> allopurinol </e10> and <e22> thiazide_diuretics </e22> may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
effect	Ampicillin / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving <e10> ampicillin </e10> or amoxicillin concurrently with <e20> allopurinol </e20> compared to patients who are not receiving both drugs.
effect	Ampicillin / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or <e10> amoxicillin </e10> concurrently with <e20> allopurinol </e20> compared to patients who are not receiving both drugs.
effect	Cytotoxic_Agents : Enhanced bone marrow suppression by <e10> cyclophosphamide </e10> and other cytotoxic_agents has been reported among patients with neoplastic disease, except leukemia, in the presence of <e20> allopurinol </e20> .
effect	Cytotoxic_Agents : Enhanced bone marrow suppression by cyclophosphamide and other <e12> cytotoxic_agents </e12> has been reported among patients with neoplastic disease, except leukemia, in the presence of <e20> allopurinol </e20> .
effect	The risk of hypoglycemia secondary to this mechanism may be increased if <e10> allopurinol </e10> and <e20> chlorpropamide </e20> are given concomitantly in the presence of renal insufficiency.
effect	Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): <e12> SSRIs </e12> (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with <e22> 5-HT1_agonists </e22> .
effect	Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, <e10> fluoxetine </e10> , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with <e22> 5-HT1_agonists </e22> .
effect	Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , <e10> fluvoxamine </e10> , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with <e22> 5-HT1_agonists </e22> .
effect	Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , <e10> paroxetine </e10> , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with <e22> 5-HT1_agonists </e22> .
effect	Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , <e10> sertraline </e10> ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with <e22> 5-HT1_agonists </e22> .
effect	Although not studied with <e10> alosetron </e10> , inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as <e20> isoniazid </e20> , procainamide , and hydralazine .
effect	Although not studied with <e10> alosetron </e10> , inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid , <e20> procainamide </e20> , and hydralazine .
effect	Although not studied with <e10> alosetron </e10> , inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid , procainamide , and <e20> hydralazine </e20> .
effect	The <e12> benzodiazepines </e12> , including alprazolam , produce additive CNS depressant effects when co-administered with other <e22> psychotropic_medications </e22> , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression.
effect	The <e12> benzodiazepines </e12> , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , <e22> anticonvulsants </e22> , antihistaminics , ethanol , and other drugs which themselves produce CNS depression.
effect	The <e12> benzodiazepines </e12> , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , <e22> antihistaminics </e22> , ethanol , and other drugs which themselves produce CNS depression.
effect	The <e12> benzodiazepines </e12> , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , antihistaminics , <e20> ethanol </e20> , and other drugs which themselves produce CNS depression.
effect	The benzodiazepines , including <e10> alprazolam </e10> , produce additive CNS depressant effects when co-administered with other <e22> psychotropic_medications </e22> , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression.
effect	The benzodiazepines , including <e10> alprazolam </e10> , produce additive CNS depressant effects when co-administered with other psychotropic_medications , <e22> anticonvulsants </e22> , antihistaminics , ethanol , and other drugs which themselves produce CNS depression.
effect	The benzodiazepines , including <e10> alprazolam </e10> , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , <e22> antihistaminics </e22> , ethanol , and other drugs which themselves produce CNS depression.
effect	The benzodiazepines , including <e10> alprazolam </e10> , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , antihistaminics , <e20> ethanol </e20> , and other drugs which themselves produce CNS depression.
effect	In addition to bleeding associated with <e10> heparin </e10> and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after <e21> Activase </e21> therapy.
effect	In addition to bleeding associated with heparin and <e12> vitamin_K_antagonists </e12> , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after <e21> Activase </e21> therapy.
effect	In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , <e10> dipyridamole </e10> and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after <e21> Activase </e21> therapy.
effect	In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and <e10> Abciximab </e10> ) may increase the risk of bleeding if administered prior to, during, or after <e21> Activase </e21> therapy.
effect	Concurrent administration of <e11> HEXALEN </e11> and <e22> antidepressants_of_the_MAO_inhibitor_class </e22> may cause severe orthostatic hypotension, Cimetidine , an inhibitor of microsomal drug metabolism, increased altretamine s half-life and toxicity in a rat model.
effect	Data from a randomized trial of <e11> HEXALEN </e11> and <e20> cisplatin </e20> plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
effect	When <e10> amiloride </e10> HCl is administered concomitantly with an <e22> angiotensin-converting_enzyme_inhibitor </e22> , the risk of hyperkalemia may be increased.
effect	In some patients, the administration of a <e12> non-steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of <e22> loop_diuretics </e22> , potassium-sparing_diuretics and thiazide_diuretics .
effect	In some patients, the administration of a <e12> non-steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , <e22> potassium-sparing_diuretics </e22> and thiazide_diuretics .
effect	In some patients, the administration of a <e12> non-steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and <e22> thiazide_diuretics </e22> .
effect	Since <e10> indomethacin </e10> and <e22> potassium-sparing_diuretics </e22> , including MIDAMOR , may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
effect	Since <e10> indomethacin </e10> and potassium-sparing_diuretics , including <e21> MIDAMOR </e21> , may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
effect	<e10> Aminoglutethimide </e10> diminishes the effect of <e22> coumarin </e22> and warfarin .
effect	<e10> Aminoglutethimide </e10> diminishes the effect of coumarin and <e20> warfarin </e20> .
effect	Renal clearance measurements of <e10> PAH </e10> cannot be made with any significant accuracy in patients receiving <e22> sulfonamides </e22> , procaine , or thiazolesulfone .
effect	Renal clearance measurements of <e10> PAH </e10> cannot be made with any significant accuracy in patients receiving sulfonamides , <e20> procaine </e20> , or thiazolesulfone .
effect	Renal clearance measurements of <e10> PAH </e10> cannot be made with any significant accuracy in patients receiving sulfonamides , procaine , or <e20> thiazolesulfone </e20> .
effect	Therefore, patients receiving <e10> probenecid </e10> will have erroneously low ERPF and Tm <e20> PAH </e20> values.
effect	It is, however, possible that concomitant use of other known <e12> photosensitizing_agents </e12> such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the <e21> LEVULAN_KERASTICK </e21> for Topical Solution.
effect	It is, however, possible that concomitant use of other known photosensitizing_agents such as <e10> griseofulvin </e10> , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the <e21> LEVULAN_KERASTICK </e21> for Topical Solution.
effect	It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , <e12> thiazide_diuretics </e12> , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the <e21> LEVULAN_KERASTICK </e21> for Topical Solution.
effect	It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , <e12> sulfonylureas </e12> , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the <e21> LEVULAN_KERASTICK </e21> for Topical Solution.
effect	It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , <e12> phenothiazines </e12> , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the <e21> LEVULAN_KERASTICK </e21> for Topical Solution.
effect	It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , <e12> sulfonamides </e12> and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the <e21> LEVULAN_KERASTICK </e21> for Topical Solution.
effect	It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and <e12> tetracyclines </e12> might increase the photosensitivity reaction of actinic keratoses treated with the <e21> LEVULAN_KERASTICK </e21> for Topical Solution.
effect	The extent to which <e12> SSRI </e12> - <e22> TCA </e22> interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
effect	Hyperpyrexia has been reported when <e10> amitriptyline_HCl </e10> is administered with <e22> anticholinergic </e22> agents or with neuroleptic drugs, particularly during hot weather.
effect	Paralytic ileus may occur in patients taking <e12> tricyclic_antidepressants </e12> in combination with <e22> anticholinergic </e22> -type drugs.
effect	Clinically significant effects have been reported with the <e12> tricyclic_antidepressants </e12> when used concomitantly with <e20> cimetidine </e20> .
effect	Transient delirium has been reported in patients who were treated with one gram of <e10> ethchlorvynol </e10> and # - # mg of <e20> amitriptyline_HCl </e20> .
effect	When administered concurrently, the following drugs may interact with <e10> amphotericin_B </e10> : <e22> Antineoplastic_agents </e22> : may enhance the potential for renal toxicity, bronchospasm and hypotension.
effect	<e12> Corticosteroids </e12> and Corticotropin ( ACTH ): may potentiate <e20> amphotericin_B </e20> - induced hypokalemia which may predispose the patient to cardiac dysfunction.
effect	Corticosteroids and <e10> Corticotropin </e10> ( ACTH ): may potentiate <e20> amphotericin_B </e20> - induced hypokalemia which may predispose the patient to cardiac dysfunction.
effect	Corticosteroids and Corticotropin ( <e12> ACTH </e12> ): may potentiate <e20> amphotericin_B </e20> - induced hypokalemia which may predispose the patient to cardiac dysfunction.
effect	Digitalis_glycosides : <e10> amphotericin_B </e10> -induced hypokalemia may potentiate <e22> digitalis </e22> toxicity.
effect	Flucytosine : while a synergistic relationship with <e10> amphotericin_B </e10> has been reported, concomitant use may increase the toxicity of <e20> flucytosine </e20> by possibly increasing its cellular uptake and/or impairing its renal excretion.
effect	Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that <e12> imidazoles </e12> may induce fungal resistance to <e20> amphotericin_B </e20> .
effect	Skeletal_muscle_relaxants : <e10> amphotericin_B </e10> -induced hypokalemia may enhance the curariform effect of <e22> skeletal_muscle_relaxants </e22> (e,g,, tubocurarine ).
effect	Skeletal_muscle_relaxants : <e10> amphotericin_B </e10> -induced hypokalemia may enhance the curariform effect of skeletal_muscle_relaxants (e,g,, <e20> tubocurarine </e20> ).
effect	Leukocyte_transfusions : acute pulmonary toxicity has been reported in patients receiving intravenous <e10> amphotericin_B </e10> and <e23> leukocyte_transfusions </e23> .
effect	Bacteriostatic_Antibiotics : <e10> Chloramphenicol </e10> , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of <e22> penicillins </e22> .
effect	Bacteriostatic_Antibiotics : Chloramphenicol , <e10> erythromycins </e10> , sulfonamides , or tetracyclines may interfere with the bactericidal effect of <e22> penicillins </e22> .
effect	Bacteriostatic_Antibiotics : Chloramphenicol , erythromycins , <e12> sulfonamides </e12> , or tetracyclines may interfere with the bactericidal effect of <e22> penicillins </e22> .
effect	Bacteriostatic_Antibiotics : Chloramphenicol , erythromycins , sulfonamides , or <e12> tetracyclines </e12> may interfere with the bactericidal effect of <e22> penicillins </e22> .
effect	Methadone : Coadministration of <e10> amprenavir </e10> and <e20> methadone </e20> can decrease plasma levels of methadone .
effect	Laboratory Tests: The combination of <e10> Amprenavir </e10> and low-dose <e20> ritonavir </e20> has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.
effect	Taking <e10> amyl_nitrite </e10> after drinking <e20> alcohol </e20> may worsen side effects and may cause severe hypotension and cardiovascular collapse.
effect	<e10> Anagrelide </e10> alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by <e21> aspirin </e21> .
effect	The effects of medicinal products with similar properties such as inotropes <e10> milrinone </e10> , enoximone , amrinone , olprinone and cilostazol may be exacerbated by <e20> anagrelide </e20> .
effect	The effects of medicinal products with similar properties such as inotropes milrinone , <e10> enoximone </e10> , amrinone , olprinone and cilostazol may be exacerbated by <e20> anagrelide </e20> .
effect	The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , <e10> amrinone </e10> , olprinone and cilostazol may be exacerbated by <e20> anagrelide </e20> .
effect	The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , amrinone , <e13> olprinone </e13> and cilostazol may be exacerbated by <e20> anagrelide </e20> .
effect	The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , amrinone , olprinone and <e10> cilostazol </e10> may be exacerbated by <e20> anagrelide </e20> .
effect	In a study in which patients with active RA were treated for up to # weeks with concurrent <e11> Kineret </e11> and <e20> etanercept </e20> therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).
effect	Two percent of patients treated concurrently with <e11> Kineret </e11> and <e20> etanercept </e20> developed neutropenia (ANC # x 109/L).
effect	Drugs that have been reported to diminish oral <e12> anticoagulant </e12> response, ie, decreased prothrom-bin time response, in man significantly include: <e22> adrenocortical_steroids </e22> ;
effect	Drugs that reportedly may increase oral <e12> anticoagulant </e12> response, ie, increased prothrombin response, in man include: <e20> alcohol </e20> *;
effect	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as <e12> antineoplastic_agents </e12> ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by <e22> anticoagulants </e22> without altering prothrombin time determinations.
effect	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, <e11> aspirin </e11> and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by <e22> anticoagulants </e22> without altering prothrombin time determinations.
effect	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other <e12> non-steroidal_anti-inflammatory_drugs </e12> , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by <e22> anticoagulants </e22> without altering prothrombin time determinations.
effect	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , <e10> dipyridamole </e10> , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by <e22> anticoagulants </e22> without altering prothrombin time determinations.
effect	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , <e10> hydrochloroquine </e10> , clofibrate , dextran ) may increase the bleeding tendency produced by <e22> anticoagulants </e22> without altering prothrombin time determinations.
effect	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , <e10> clofibrate </e10> , dextran ) may increase the bleeding tendency produced by <e22> anticoagulants </e22> without altering prothrombin time determinations.
effect	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , <e10> dextran </e10> ) may increase the bleeding tendency produced by <e22> anticoagulants </e22> without altering prothrombin time determinations.
effect	5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when <e10> apomorphine </e10> was administered with <e20> ondansetron </e20> , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated .
effect	Antihypertensive_Medication s and Vasodilators : The following adverse events were experienced more commonly in patients receiving concomitant <e12> antihypertensive_medications </e12> or <e22> vasodilators </e22> (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
effect	Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that <e12> dopamine_antagonists </e12> , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or <e20> metoclopramide </e20> , may diminish the effectiveness of APOKYN .
effect	Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( <e12> phenothiazines </e12> , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e21> APOKYN </e21> .
effect	Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , <e12> butyrophenones </e12> , thioxanthenes ) or metoclopramide , may diminish the effectiveness of <e21> APOKYN </e21> .
effect	Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , <e12> thioxanthenes </e12> ) or metoclopramide , may diminish the effectiveness of <e21> APOKYN </e21> .
effect	Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or <e10> metoclopramide </e10> , may diminish the effectiveness of <e21> APOKYN </e21> .
effect	<e12> Tricyclic_antidepressants </e12> have been reported to blunt the hypotensive effect of systemic <e20> clonidine </e20> .
effect	An additive hypotensive effect has been reported with the combination of systemic <e10> clonidine </e10> and <e22> neuroleptic </e22> therapy.
effect	therefore, the efficacy of oral <e12> contraceptives </e12> during administration of <e20> Aprepitant </e20> may be reduced.
effect	<e12> Anticoagulants </e12> including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with <e20> ardeparin </e20> .
effect	Anticoagulants including coumarin derivatives, indandione derivatives, and <e12> platelet_aggregation_inhibitors </e12> such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with <e20> ardeparin </e20> .
effect	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as <e12> nonsteroidal_anti-inflammatory_drugs </e12> ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with <e20> ardeparin </e20> .
effect	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( <e12> NSAIDs </e12> ), and aspirin may increase the risk of bleeding when administered concomitantly with <e20> ardeparin </e20> .
effect	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and <e11> aspirin </e11> may increase the risk of bleeding when administered concomitantly with <e20> ardeparin </e20> .
effect	Concomitant treatment with <e12> methylxanthines </e12> ( aminophylline , theophylline ), steroids , or diuretics may potentiate any hypokalemic effect of <e22> adrenergic_agonists </e22> .
effect	Concomitant treatment with methylxanthines ( <e10> aminophylline </e10> , theophylline ), steroids , or diuretics may potentiate any hypokalemic effect of <e22> adrenergic_agonists </e22> .
effect	Concomitant treatment with methylxanthines ( aminophylline , <e10> theophylline </e10> ), steroids , or diuretics may potentiate any hypokalemic effect of <e22> adrenergic_agonists </e22> .
effect	Concomitant treatment with methylxanthines ( aminophylline , theophylline ), <e12> steroids </e12> , or diuretics may potentiate any hypokalemic effect of <e22> adrenergic_agonists </e22> .
effect	Concomitant treatment with methylxanthines ( aminophylline , theophylline ), steroids , or <e12> diuretics </e12> may potentiate any hypokalemic effect of <e22> adrenergic_agonists </e22> .
effect	The ECG changes and/or hypokalemia that may result from the administration of <e12> non-potassium_sparing_diuretics </e12> (such as loop_diuretics or thiazide_diuretics ) can be acutely worsened by <e22> beta-agonists </e22> , especially when the recommended dose of the beta-agonist is exceeded.
effect	The ECG changes and/or hypokalemia that may result from the administration of non-potassium_sparing_diuretics (such as <e12> loop_diuretics </e12> or thiazide_diuretics ) can be acutely worsened by <e22> beta-agonists </e22> , especially when the recommended dose of the beta-agonist is exceeded.
effect	The ECG changes and/or hypokalemia that may result from the administration of non-potassium_sparing_diuretics (such as loop_diuretics or <e12> thiazide_diuretics </e12> ) can be acutely worsened by <e22> beta-agonists </e22> , especially when the recommended dose of the beta-agonist is exceeded.
effect	BROVANA , as with other beta2-agonists , should be administered with extreme caution to patients being treated with <e12> monoamine_oxidase_inhibitors </e12> , tricyclic_antidepressants , or drugs known to prolong the QTc interval because the action of <e22> adrenergic_agonists </e22> on the cardiovascular system may be potentiated by these agents.
effect	BROVANA , as with other beta2-agonists , should be administered with extreme caution to patients being treated with monoamine_oxidase_inhibitors , <e12> tricyclic_antidepressants </e12> , or drugs known to prolong the QTc interval because the action of <e22> adrenergic_agonists </e22> on the cardiovascular system may be potentiated by these agents.
effect	<e12> Beta-adrenergic_receptor_antagonists </e12> ( beta-blockers ) and <e21> BROVANA </e21> may interfere with the effect of each other when administered concurrently.
effect	Beta-adrenergic_receptor_antagonists ( <e12> beta-blockers </e12> ) and <e21> BROVANA </e21> may interfere with the effect of each other when administered concurrently.
effect	<e12> Beta-blockers </e12> not only block the therapeutic effects of <e22> beta-agonists </e22> , but may produce severe bronchospasm in COPD patients.
effect	However, the concomitant use of <e10> Argatroban </e10> and <e20> warfarin </e20> (5# mg initial oral dose followed by #-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
effect	Co-administration: Concomitant use of <e10> Argatroban </e10> with <e22> antiplatelet_agents </e22> , thrombolytics , and other anticoagulants may increase the risk of bleeding.
effect	Co-administration: Concomitant use of <e10> Argatroban </e10> with antiplatelet_agents , <e22> thrombolytics </e22> , and other anticoagulants may increase the risk of bleeding.
effect	Co-administration: Concomitant use of <e10> Argatroban </e10> with antiplatelet_agents , thrombolytics , and other <e22> anticoagulants </e22> may increase the risk of bleeding.
effect	1- adrenergic receptor antagonism, <e10> aripiprazole </e10> has the potential to enhance the effect of certain <e22> antihypertensive_agents </e22> .
effect	Tissue culture and animal studies indicate that <e11> ELSPAR </e11> can diminish or abolish the effect of <e20> methotrexate </e20> on malignant cells# This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
effect	Uricosuric_Agents : <e11> Aspirin </e11> may decrease the effects of <e20> probenecid </e20> , sulfinpyrazone , and phenylbutazone .
effect	Uricosuric_Agents : <e11> Aspirin </e11> may decrease the effects of probenecid , <e20> sulfinpyrazone </e20> , and phenylbutazone .
effect	Uricosuric_Agents : <e11> Aspirin </e11> may decrease the effects of probenecid , sulfinpyrazone , and <e20> phenylbutazone </e20> .
effect	<e12> Corticosteroids </e12> : Concomitant administration with <e21> aspirin </e21> may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.
effect	<e12> Pyrazolone_Derivatives </e12> ( phenylbutazone , oxyphenbutazone , and possibly dipyrone ): Concomitant administration with <e21> aspirin </e21> may increase the risk of gastrointestinal ulceration.
effect	Pyrazolone_Derivatives ( <e10> phenylbutazone </e10> , oxyphenbutazone , and possibly dipyrone ): Concomitant administration with <e21> aspirin </e21> may increase the risk of gastrointestinal ulceration.
effect	Pyrazolone_Derivatives ( phenylbutazone , <e10> oxyphenbutazone </e10> , and possibly dipyrone ): Concomitant administration with <e21> aspirin </e21> may increase the risk of gastrointestinal ulceration.
effect	Pyrazolone_Derivatives ( phenylbutazone , oxyphenbutazone , and possibly <e10> dipyrone </e10> ): Concomitant administration with <e21> aspirin </e21> may increase the risk of gastrointestinal ulceration.
effect	Phenytoin : Serum <e10> phenytoin </e10> levels may be increased by <e21> aspirin </e21> .
effect	<e10> Propranolol </e10> : May decrease <e21> aspirins </e21> anti-inflammatory action by competing for the same receptors.
effect	Catecholamine-depleting drugs (eg, <e10> reserpine </e10> ) may have an additive effect when given with <e22> beta-blocking_agent </e22> s.
effect	<e12> Calcium_channel_blockers </e12> may also have an additive effect when given with <e21> TENORMIN </e21> .
effect	<e12> Beta_blockers </e12> may exacerbate the rebound hypertension which can follow the withdrawal of <e20> clonidine </e20> .
effect	Concomitant use of prostaglandin synthase inhibiting drugs, eg, <e10> indomethacin </e10> , may decrease the hypotensive effects of <e22> beta_blockers </e22> .
effect	However, LDL-C reduction was greater when <e10> atorvastatin </e10> and <e20> colestipol </e20> were coadministered than when either drug was given alone.
effect	Drugs which may enhance the neuromuscular blocking action of <e11> TRACRIUM </e11> include: <e20> enflurane </e20> ;
effect	Drugs which may enhance the neuromuscular blocking action of <e11> TRACRIUM </e11> include: <e20> enflurane </e20> ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine .
effect	Drugs which may enhance the neuromuscular blocking action of <e11> TRACRIUM </e11> include: enflurane ; <e20> isoflurane </e20> ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine .
effect	Drugs which may enhance the neuromuscular blocking action of <e11> TRACRIUM </e11> include: enflurane ; isoflurane ; <e20> halothane </e20> ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine .
effect	Drugs which may enhance the neuromuscular blocking action of <e11> TRACRIUM </e11> include: enflurane ; isoflurane ; halothane ;certain <e22> antibiotics </e22> , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine .
effect	Drugs which may enhance the neuromuscular blocking action of <e11> TRACRIUM </e11> include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the <e22> aminoglycosides </e22> and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine .
effect	Drugs which may enhance the neuromuscular blocking action of <e11> TRACRIUM </e11> include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and <e22> polymyxins </e22> ; lithium ; magnesium salts; procainamide ;and quinidine .
effect	Drugs which may enhance the neuromuscular blocking action of <e11> TRACRIUM </e11> include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; <e20> lithium </e20> ; magnesium salts; procainamide ;and quinidine .
effect	Drugs which may enhance the neuromuscular blocking action of <e11> TRACRIUM </e11> include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; <e20> magnesium </e20> salts; procainamide ;and quinidine .
effect	Drugs which may enhance the neuromuscular blocking action of <e11> TRACRIUM </e11> include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; <e20> procainamide </e20> ;and quinidine .
effect	Drugs which may enhance the neuromuscular blocking action of <e11> TRACRIUM </e11> include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and <e20> quinidine </e20> .
effect	The prior administration of <e10> succinylcholine </e10> does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by <e21> TRACRIUM </e21> .
effect	When <e10> atropine </e10> and <e20> pralidoxime </e20> are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine .
effect	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because <e10> pralidoxime </e10> may potentiate the effect of <e20> atropine </e20> .
effect	<e12> MAO_inhibitors </e12> prolong and intensify the effects of <e22> antihistamines </e22> .
effect	Concomitant use of <e12> antihistamines </e12> with <e20> alcohol </e20> , tricyclic_antidepressants , barbiturates , or other central_nervous_system_depressants may have an additive effect.
effect	Concomitant use of <e12> antihistamines </e12> with alcohol , <e22> tricyclic_antidepressants </e22> , barbiturates , or other central_nervous_system_depressants may have an additive effect.
effect	Concomitant use of <e12> antihistamines </e12> with alcohol , tricyclic_antidepressants , <e22> barbiturates </e22> , or other central_nervous_system_depressants may have an additive effect.
effect	Concomitant use of <e12> antihistamines </e12> with alcohol , tricyclic_antidepressants , barbiturates , or other <e22> central_nervous_system_depressants </e22> may have an additive effect.
effect	When <e12> sympathomimetic_drugs </e12> are given to patients receiving <e22> monoamine_oxidase_inhibitors </e22> , hypertensive reactions, including hypertensive crises, may occur.
effect	The antihypertensive effects of <e10> methyldopa </e10> , mecamylamine , reserpine , and veratrum_alkaloids may be reduced by <e22> sympathomimetics </e22> .
effect	The antihypertensive effects of methyldopa , <e10> mecamylamine </e10> , reserpine , and veratrum_alkaloids may be reduced by <e22> sympathomimetics </e22> .
effect	The antihypertensive effects of methyldopa , mecamylamine , <e10> reserpine </e10> , and veratrum_alkaloids may be reduced by <e22> sympathomimetics </e22> .
effect	The antihypertensive effects of methyldopa , mecamylamine , reserpine , and <e12> veratrum_alkaloids </e12> may be reduced by <e22> sympathomimetics </e22> .
effect	Increased ectopic pacemaker activity can occur when <e10> pseudoephedrine </e10> is used concomitantly with <e22> digitalis </e22> .
effect	Use with Angiotensln_Converting_Enzyme_Inhibitors : The use of <e12> angiotensin_converting_enzyme_inhibitors </e12> to control hypertension in patients on <e20> azathioprine </e20> has been reported to induce severe leukopenia.
effect	Co-administration of <e10> nelfinavir </e10> at steady-state with a single dose of <e20> azithromycin </e20> (2 x # mg tablets) results in increased azithromycin serum concentrations.
effect	Concurrent use of <e12> macrolides </e12> and <e20> warfarin </e20> in clinical practice has been associated with increased anticoagulant effects.
effect	Interactions attributed to the combined use of <e10> baclofen </e10> injection and epidural <e20> morphine </e20> include hypotension and dyspnea.
effect	Diuretics : Patients on <e12> diuretics </e12> , especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with <e21> Lotensin </e21> .
effect	Potassium Supplements and <e12> Potassium-Sparing_Diuretics </e12> Lotensin can attenuate potassium loss caused by <e22> thiazide_diuretics </e22> .
effect	If a <e12> diuretic </e12> is also used, the risk of <e20> lithium </e20> toxicity may be increased.
effect	<e10> Benazepril </e10> , like other ACE_inhibitors , has had less than additive effects with <e22> beta-adrenergic_blockers </e22> , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
effect	Benazepril , like other <e12> ACE_inhibitors </e12> , has had less than additive effects with <e22> beta-adrenergic_blockers </e22> , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
effect	May interact with the following: <e10> cholestyramine </e10> , colestipol (use with <e22> thiazide_diuretics </e22> may prevent the diuretic from working properly;
effect	May interact with the following: cholestyramine , <e10> colestipol </e10> (use with <e22> thiazide_diuretics </e22> may prevent the diuretic from working properly;
effect	Hypertensive crises have resulted when <e12> sympathomimetic_amines </e12> have been used concomitantly within14 days following use of <e22> monoamine_oxidase_inhibitors </e22> .
effect	<e12> Amphetamines </e12> may decrease the hypotensive effect of <e20> antihypertensives </e20> .
effect	<e12> Amphetamines </e12> may enhance the effects of <e22> tricyclic_antidepressants </e22> .
effect	<e12> Anti-arrhythmics </e12> and tricyclic_anti-depressants could exaggerate the prolongation of the QT interval observed with <e20> bepridil_hydrochloride </e20> .
effect	Anti-arrhythmics and <e12> tricyclic_anti-depressants </e12> could exaggerate the prolongation of the QT interval observed with <e20> bepridil_hydrochloride </e20> .
effect	<e12> Cardiac_glycosides </e12> could exaggerate the depression of AV nodal conduction observed with <e20> bepridil_hydrochloride </e20> .
effect	Catecholamine-depleting drugs (e,g,, <e10> reserpine </e10> ) may have an additive effect when given with <e20> beta-blocking </e20> agents.
effect	Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving <e12> beta-adrenergic_blocking_agents </e12> when an oral <e22> calcium_antagonist </e22> was added to the treatment regimen.
effect	Risk of Anaphylactic Reaction: Although it is known that patients on <e12> beta-blockers </e12> may be refractory to <e20> epinephrine </e20> in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
effect	When Bezalip or Bezalip_retard is used at the same time as other medicines or substances the following interactions must be taken into account: - <e11> Bezalip </e11> and Bezalip_retard may enhance the action of <e22> anticoagulants_of_the_coumarin_type </e22> .
effect	When Bezalip or Bezalip_retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and <e11> Bezalip_retard </e11> may enhance the action of <e22> anticoagulants_of_the_coumarin_type </e22> .
effect	- The action of <e12> sulphonylureas </e12> and insulin may be enhanced by <e21> Bezalip </e21> or Bezalip_retard .
effect	- The action of <e12> sulphonylureas </e12> and insulin may be enhanced by Bezalip or <e21> Bezalip_retard </e21> .
effect	- The action of sulphonylureas and <e10> insulin </e10> may be enhanced by <e21> Bezalip </e21> or Bezalip_retard .
effect	- The action of sulphonylureas and <e10> insulin </e10> may be enhanced by Bezalip or <e21> Bezalip_retard </e21> .
effect	- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving <e12> immuno-suppressant </e12> therapy and concomitant <e20> bezafibrate </e20> .
effect	Drug Interactions: The central <e12> anticholinergic </e12> syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain <e22> narcotic_analgesics </e22> such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central <e12> anticholinergic </e12> syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as <e20> meperidine </e20> , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central <e12> anticholinergic </e12> syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the <e22> phenothiazines </e22> and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central <e12> anticholinergic </e12> syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other <e22> antipsychotics </e22> , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central <e12> anticholinergic </e12> syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , <e22> tricyclic_antidepressants </e22> , certain antiarrhythmics such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central <e12> anticholinergic </e12> syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain <e22> antiarrhythmics </e22> such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central <e12> anticholinergic </e12> syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the <e20> quinidine </e20> salts, and antihistamines .
effect	Drug Interactions: The central <e12> anticholinergic </e12> syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and <e22> antihistamines </e22> .
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as <e11> AKINETON </e11> are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain <e22> narcotic_analgesics </e22> such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as <e11> AKINETON </e11> are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as <e20> meperidine </e20> , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as <e11> AKINETON </e11> are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the <e22> phenothiazines </e22> and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as <e11> AKINETON </e11> are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other <e22> antipsychotics </e22> , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as <e11> AKINETON </e11> are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , <e22> tricyclic_antidepressants </e22> , certain antiarrhythmics such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as <e11> AKINETON </e11> are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain <e22> antiarrhythmics </e22> such as the quinidine salts, and antihistamines .
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as <e11> AKINETON </e11> are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the <e20> quinidine </e20> salts, and antihistamines .
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as <e11> AKINETON </e11> are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and <e22> antihistamines </e22> .
effect	Patients receiving catecholamine-depleting drugs, such as <e10> reserpine </e10> or guanethidine , should be closely monitored, because the added beta-adrenergic blocking action of <e21> ZEBETA </e21> may produce excessive reduction of sympathetic activity.
effect	Patients receiving catecholamine-depleting drugs, such as reserpine or <e10> guanethidine </e10> , should be closely monitored, because the added beta-adrenergic blocking action of <e21> ZEBETA </e21> may produce excessive reduction of sympathetic activity.
effect	This allows <e10> bitolterol </e10> to open air passages, increasing the effectiveness of the <e22> steroid </e22> .
effect	In clinical trials in patients undergoing PTCA/PCI, co-administration of <e11> Angiomax </e11> with <e20> heparin </e20> , warfarin , thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
effect	In clinical trials in patients undergoing PTCA/PCI, co-administration of <e11> Angiomax </e11> with heparin , <e20> warfarin </e20> , thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
effect	In clinical trials in patients undergoing PTCA/PCI, co-administration of <e11> Angiomax </e11> with heparin , warfarin , <e22> thrombolytics </e22> or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
effect	Therefore, <e12> hormonal_contraceptives </e12> , including oral, injectable, transdermal, and implantable forms, may not be reliable when <e21> TRACLEER </e21> is co-administered.
effect	<e12> Digitalis </e12> toxicity may be aggravated by the initial release of norepinephrine caused by <e20> Bretylium_Tosylate </e20> Injection.
effect	The pressor effects of <e12> catecholamines </e12> such as dopamine or norepinephrine are enhanced by <e20> Bretylium_Tosylate </e20> .
effect	The pressor effects of catecholamines such as <e10> dopamine </e10> or norepinephrine are enhanced by <e20> Bretylium_Tosylate </e20> .
effect	The pressor effects of catecholamines such as dopamine or <e10> norepinephrine </e10> are enhanced by <e20> Bretylium_Tosylate </e20> .
effect	<e12> Tricyclic_antidepressants </e12> have been reported to blunt the hypotensive effect of systemic <e20> clonidine </e20> ,It is not known whether the concurrent use of these agents with ALPHAGAN_P in humans can lead to resulting interference with the IOP lowering effect.
effect	The risk of using bromocriptine_mesylate in combination with other drugs has not been systematically evaluated, but <e10> alcohol </e10> may potentiate the side effects of <e20> bromocriptine_mesylate </e20> .
effect	Compounds in these categories result in a decreased efficacy of <e10> bromocriptine_mesylate </e10> : <e22> phenothiazines </e22> , haloperidol , metoclopramide , pimozide .
effect	Compounds in these categories result in a decreased efficacy of <e10> bromocriptine_mesylate </e10> : phenothiazines , <e20> haloperidol </e20> , metoclopramide , pimozide .
effect	Compounds in these categories result in a decreased efficacy of <e10> bromocriptine_mesylate </e10> : phenothiazines , haloperidol , <e20> metoclopramide </e20> , pimozide .
effect	Compounds in these categories result in a decreased efficacy of <e10> bromocriptine_mesylate </e10> : phenothiazines , haloperidol , metoclopramide , <e20> pimozide </e20> .
effect	<e10> Dexbrompheniramine </e10> can interact with <e20> alcohol </e20> or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ).
effect	<e10> Dexbrompheniramine </e10> can interact with alcohol or other <e22> CNS_depressants </e22> (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ).
effect	<e10> Dexbrompheniramine </e10> can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), <e22> anticholinergics </e22> or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ).
effect	<e10> Dexbrompheniramine </e10> can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and <e22> monoamine_oxidase_(MAO)_inhibitors </e22> (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ).
effect	- Probenecid : Pretreatment with <e10> probenecid </e10> reduces both the natriuresis and hyperreninemia produced by <e20> bumetanide </e20> .
effect	- Indomethacin : <e10> Indomethacin </e10> blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the <e20> bumetanide </e20> -induced increase in plasma renin activity.
effect	- Antihypertensives : <e10> Bumetanide </e10> may potentiate the effect of various <e22> antihypertensive_drugs </e22> , necessitating a reduction in the dosage of these drugs.
effect	The administration of local anesthetic_solutions containing <e10> epinephrine </e10> or norepinephrine to patients receiving <e22> monoamine_oxidase_inhibitors </e22> or tricyclic_antidepressants may produce severe, prolonged hypertension.
effect	The administration of local anesthetic_solutions containing <e10> epinephrine </e10> or norepinephrine to patients receiving monoamine_oxidase_inhibitors or <e22> tricyclic_antidepressants </e22> may produce severe, prolonged hypertension.
effect	The administration of local anesthetic_solutions containing epinephrine or <e10> norepinephrine </e10> to patients receiving <e22> monoamine_oxidase_inhibitors </e22> or tricyclic_antidepressants may produce severe, prolonged hypertension.
effect	The administration of local anesthetic_solutions containing epinephrine or <e10> norepinephrine </e10> to patients receiving monoamine_oxidase_inhibitors or <e22> tricyclic_antidepressants </e22> may produce severe, prolonged hypertension.
effect	<e12> Phenothiazines </e12> and butyrophenones may reduce or reverse the pressor effect of <e20> epinephrine </e20> .
effect	Phenothiazines and <e12> butyrophenones </e12> may reduce or reverse the pressor effect of <e20> epinephrine </e20> .
effect	There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of <e10> buprenorphine </e10> and <e22> benzodiazepines </e22> by addicts.
effect	MAO_Inhibitors : Studies in animals demonstrate that the acute toxicity of <e10> bupropion </e10> is enhanced by the MAO_inhibitor <e20> phenelzine </e20> .
effect	Levodopa and Amantadine : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving <e10> bupropion </e10> concurrently with either <e20> levodopa </e20> or amantadine .
effect	Levodopa and Amantadine : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving <e10> bupropion </e10> concurrently with either levodopa or <e20> amantadine </e20> .
effect	Alcohol : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking <e10> alcohol </e10> during treatment with <e21> WELLBUTRIN </e21> .
effect	There is one report suggesting that the concomitant use of <e10> trazodone_hydrochloride </e10> ( Desyrel ) and <e20> buspirone_HCl </e20> may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
effect	There is one report suggesting that the concomitant use of trazodone_hydrochloride ( <e11> Desyrel </e11> ) and <e20> buspirone_HCl </e20> may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
effect	However, there has been one report of prolonged prothrombin time when <e10> buspirone </e10> was added to the regimen of a patient treated with <e20> warfarin </e20> .
effect	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( <e12> barbiturates </e12> may decrease the effectiveness of these oral <e22> contraceptives </e22> , and you may need to change to a different type of birth control).
effect	The CNS effects of <e10> butalbital </e10> may be enhanced by <e22> monoamine_oxidase_(MAO)_inhibitors </e22> .
effect	<e10> Butalbital </e10> , acetaminophen and caffeine may enhance the effects of: other <e22> narcotic_analgesic </e22> s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	<e10> Butalbital </e10> , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, <e20> alcohol </e20> , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	<e10> Butalbital </e10> , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general <e22> anesthetics </e22> , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	<e10> Butalbital </e10> , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , <e22> tranquilizers </e22> such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	<e10> Butalbital </e10> , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as <e20> chlordiazepoxide </e20> , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	<e10> Butalbital </e10> , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , <e22> sedative-hypnotics </e22> , or other CNS_depressants , causing increased CNS depression.
effect	<e10> Butalbital </e10> , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other <e22> CNS_depressants </e22> , causing increased CNS depression.
effect	Butalbital , <e10> acetaminophen </e10> and caffeine may enhance the effects of: other <e22> narcotic_analgesic </e22> s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , <e10> acetaminophen </e10> and caffeine may enhance the effects of: other narcotic_analgesic s, <e20> alcohol </e20> , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , <e10> acetaminophen </e10> and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general <e22> anesthetics </e22> , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , <e10> acetaminophen </e10> and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , <e22> tranquilizers </e22> such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , <e10> acetaminophen </e10> and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as <e20> chlordiazepoxide </e20> , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , <e10> acetaminophen </e10> and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , <e22> sedative-hypnotics </e22> , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , <e10> acetaminophen </e10> and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other <e22> CNS_depressants </e22> , causing increased CNS depression.
effect	Butalbital , acetaminophen and <e10> caffeine </e10> may enhance the effects of: other <e22> narcotic_analgesic </e22> s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , acetaminophen and <e10> caffeine </e10> may enhance the effects of: other narcotic_analgesic s, <e20> alcohol </e20> , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , acetaminophen and <e10> caffeine </e10> may enhance the effects of: other narcotic_analgesic s, alcohol , general <e22> anesthetics </e22> , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , acetaminophen and <e10> caffeine </e10> may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , <e22> tranquilizers </e22> such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , acetaminophen and <e10> caffeine </e10> may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as <e20> chlordiazepoxide </e20> , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , acetaminophen and <e10> caffeine </e10> may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , <e22> sedative-hypnotics </e22> , or other CNS_depressants , causing increased CNS depression.
effect	Butalbital , acetaminophen and <e10> caffeine </e10> may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other <e22> CNS_depressants </e22> , causing increased CNS depression.
effect	Concurrent use of <e10> butorphanol </e10> with <e22> central_nervous_system_depressants </e22> (e,g,, alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects.
effect	Concurrent use of <e10> butorphanol </e10> with central_nervous_system_depressants (e,g,, <e20> alcohol </e20> , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects.
effect	Concurrent use of <e10> butorphanol </e10> with central_nervous_system_depressants (e,g,, alcohol , <e22> barbiturates </e22> , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects.
effect	Concurrent use of <e10> butorphanol </e10> with central_nervous_system_depressants (e,g,, alcohol , barbiturates , <e22> tranquilizers </e22> , and antihistamines ) may result in increased central_nervous_system_depressant effects.
effect	Concurrent use of <e10> butorphanol </e10> with central_nervous_system_depressants (e,g,, alcohol , barbiturates , tranquilizers , and <e22> antihistamines </e22> ) may result in increased central_nervous_system_depressant effects.
effect	These results suggest that the analgesic effect of <e11> STADOL_NS </e11> may be diminished when it is administered shortly after <e20> sumatriptan </e20> nasal spray, but by # minutes any such reduction in effect should be minimal.
effect	Therefore, a slower onset can be anticipated if <e11> STADOL_NS </e11> is administered concomitantly with, or immediately following, a <e22> nasal_vasoconstrictor </e22> .
effect	<e10> Caffeine </e10> administered concurrently with <e20> ketoprofen </e20> reduced the urine volume in # healthy volunteers.
effect	Some reports have shown that the concomitant administration of <e12> thiazides </e12> with <e22> vitamin_D </e22> causes hypercalcemia.
effect	Some reports have shown that the concomitant administration of <e12> thiazides </e12> with <e22> vitamin_D </e22> causes hypercalcemia.
effect	Using <e10> calcium_acetate </e10> with <e22> digitalis_glycosides </e22> (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.
effect	Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking <e10> capecitabine </e10> concomitantly with <e22> coumarin-derivative_anticoagulants </e22> such as warfarin and phenprocoumon .
effect	Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking <e10> capecitabine </e10> concomitantly with coumarin-derivative_anticoagulants such as warfarin and <e20> phenprocoumon </e20> .
effect	Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly <e10> leucovorin </e10> and <e20> fluorouracil </e20> .
effect	Hypotension Patients on Diuretic Therapy: Patients on <e12> diuretics </e12> and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of <e20> captopril </e20> .
effect	The possibility of hypotensive effects with <e10> captopril </e10> can be minimized by either discontinuing the <e22> diuretic </e22> or increasing the salt intake approximately one week prior to initiation of treatment with captopril ( captopril tablets, USP) or initiating therapy with small doses (# or # mg).
effect	Agents Causing Renin Release <e10> Captopril </e10> 's effect will be augmented by <e22> antihypertensive_agents </e22> that cause renin release.
effect	<e12> Beta-adrenergic_blocking_drugs </e12> add some further antihypertensive effect to <e20> captopril </e20> , but the overall response is less than additive.
effect	Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that <e10> indomethacin </e10> may reduce the antihypertensive effect of <e20> captopril </e20> , especially in cases of low renin hypertension.
effect	Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant <e10> lithium </e10> and <e22> ACE_inhibitor </e22> therapy.
effect	If a <e12> diuretic </e12> is also used, it may increase the risk of <e20> lithium </e20> toxicity.
effect	Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of <e10> carbamazepine </e10> and <e20> lithium </e20> may increase the risk of neurotoxic side effects.
effect	Additionally, <e12> anti-malarial_drugs </e12> , such as chloroquine and mefloquine , may antagonize the activity of <e20> carbamazepine </e20> .
effect	Additionally, anti-malarial_drugs , such as <e10> chloroquine </e10> and mefloquine , may antagonize the activity of <e20> carbamazepine </e20> .
effect	Additionally, anti-malarial_drugs , such as chloroquine and <e10> mefloquine </e10> , may antagonize the activity of <e20> carbamazepine </e20> .
effect	<e12> Dopamine_D2_receptor_antagonists </e12> (e,g,, phenothiazines , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of <e20> levodopa </e20> .
effect	Dopamine_D2_receptor_antagonists (e,g,, <e12> phenothiazines </e12> , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of <e20> levodopa </e20> .
effect	Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , <e12> butyrophenones </e12> , risperidone ) and isoniazid may reduce the therapeutic effects of <e20> levodopa </e20> .
effect	Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , butyrophenones , <e10> risperidone </e10> ) and isoniazid may reduce the therapeutic effects of <e20> levodopa </e20> .
effect	Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , butyrophenones , risperidone ) and <e10> isoniazid </e10> may reduce the therapeutic effects of <e20> levodopa </e20> .
effect	In addition, the beneficial effects of <e10> levodopa </e10> in Parkinsons disease have been reported to be reversed by <e20> phenytoin </e20> and papaverine .
effect	In addition, the beneficial effects of <e10> levodopa </e10> in Parkinsons disease have been reported to be reversed by phenytoin and <e20> papaverine </e20> .
effect	<e10> Iodine </e10> or iodine excess may decrease the effect of <e20> Carbimazole </e20> , and an iodine deficiency can increase the effect of Carbimazole .
effect	Iodine or iodine excess may decrease the effect of Carbimazole , and an <e12> iodine </e12> deficiency can increase the effect of <e20> Carbimazole </e20> .
effect	<e12> Antithyroid_agents </e12> may decrease thyroidal uptake of <e20> sodium_iodide_I131 </e20> , a rebound in uptake may occur up to # days after sudden withdrawal of Carbimazole .
effect	<e10> Antihistamines </e10> may enhance the effects of <e22> tricyclic_antidepressants </e22> , barbiturates , alcohol , and other CNS_depressants .
effect	<e10> Antihistamines </e10> may enhance the effects of tricyclic_antidepressants , <e22> barbiturates </e22> , alcohol , and other CNS_depressants .
effect	<e10> Antihistamines </e10> may enhance the effects of tricyclic_antidepressants , barbiturates , <e20> alcohol </e20> , and other CNS_depressants .
effect	<e10> Antihistamines </e10> may enhance the effects of tricyclic_antidepressants , barbiturates , alcohol , and other <e22> CNS_depressants </e22> .
effect	<e12> MAO_inhibitors </e12> prolong and intensify the anticholinergic effects of <e22> antihistamines </e22> .
effect	<e12> Sympathomimetic_amines </e12> may reduce the antihypertensive effects of <e20> reserpine </e20> , veratrum_alkaloids , methyldopa and mecamylamine .
effect	<e12> Sympathomimetic_amines </e12> may reduce the antihypertensive effects of reserpine , <e22> veratrum_alkaloids </e22> , methyldopa and mecamylamine .
effect	<e12> Sympathomimetic_amines </e12> may reduce the antihypertensive effects of reserpine , veratrum_alkaloids , <e20> methyldopa </e20> and mecamylamine .
effect	<e12> Sympathomimetic_amines </e12> may reduce the antihypertensive effects of reserpine , veratrum_alkaloids , methyldopa and <e20> mecamylamine </e20> .
effect	Effects of <e12> sympathomimetics </e12> are increased with <e22> MAO_inhibitors </e22> and beta_adrenergic_blockers .
effect	Effects of <e12> sympathomimetics </e12> are increased with MAO_inhibitors and <e22> beta_adrenergic_blockers </e22> .
effect	<e11> HEMABATE </e11> may augment the activity of other <e22> oxytocic_agents </e22> .
effect	poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as <e10> quinidine </e10> , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of <e20> carvedilol </e20> .
effect	poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , <e10> fluoxetine </e10> , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of <e20> carvedilol </e20> .
effect	poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , <e10> paroxetine </e10> , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of <e20> carvedilol </e20> .
effect	poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and <e10> propafenone </e10> ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of <e20> carvedilol </e20> .
effect	Catecholamine-depleting Agents: Patients taking both <e12> agents_with_b-blocking_properties </e12> and a drug that can deplete catecholamines (e,g,, <e20> reserpine </e20> and monoamine_oxidase_inhibitors ) should be observed closely for signs of hypotension and/or severe bradycardia.
effect	Catecholamine-depleting Agents: Patients taking both <e12> agents_with_b-blocking_properties </e12> and a drug that can deplete catecholamines (e,g,, reserpine and <e22> monoamine_oxidase_inhibitors </e22> ) should be observed closely for signs of hypotension and/or severe bradycardia.
effect	Clonidine : Concomitant administration of <e10> clonidine </e10> with <e22> agents_with_b-blocking_properties </e22> may potentiate blood-pressure- and heart-rate-lowering effects.
effect	Both <e10> digoxin </e10> and <e21> COREG </e21> slow AV conduction.
effect	Calcium_Channel_Blockers : Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when <e11> COREG </e11> is co-administered with <e20> diltiazem </e20> .
effect	Insulin or Oral Hypoglycemics : <e12> Agents_with_b-blocking_properties </e12> may enhance the blood-sugar-reducing effect of <e20> insulin </e20> and oral hypoglycemics .
effect	Insulin or Oral Hypoglycemics : <e12> Agents_with_b-blocking_properties </e12> may enhance the blood-sugar-reducing effect of insulin and oral <e22> hypoglycemics </e22> .
effect	There were transient increases in liver ALT and AST when <e11> CANCIDAS </e11> and <e20> cyclosporine </e20> were co-administered.
effect	Nephrotoxicity has been reported following concomitant administration of other <e12> cephalosporins </e12> with potent <e22> diuretics </e22> such as furosemide .
effect	Nephrotoxicity has been reported following concomitant administration of other <e12> cephalosporins </e12> with potent diuretics such as <e20> furosemide </e20> .
effect	<e10> Warfarin </e10> and Anticoagulants : Increased prothrombin time, with or without clinical bleeding, has been reported when <e20> cefixime </e20> is administered concomitantly.
effect	Warfarin and <e12> Anticoagulants </e12> : Increased prothrombin time, with or without clinical bleeding, has been reported when <e20> cefixime </e20> is administered concomitantly.
effect	Increased nephrotoxicity has been reported following concomitant administration of <e12> cephalosporins </e12> and <e22> aminoglycoside_antibiotics </e22> .
effect	If <e11> CEFOTAN </e11> and an <e22> aminoglycoside </e22> are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.
effect	Increased nephrotoxicity has been reported following concomitant administration of <e12> cephalosporins </e12> and <e22> aminoglycoside_antibiotics </e22> .
effect	Nephrotoxicity has been reported following concomitant administration of <e12> aminoglycoside_antibiotics </e12> and <e22> cephalosporin_antibiotics </e22> .
effect	Nephrotoxicity has been reported following concomitant administration of <e12> cephalosporins </e12> with <e22> aminoglycoside_antibiotics </e22> or potent diuretics such as furosemide .
effect	Nephrotoxicity has been reported following concomitant administration of <e12> cephalosporins </e12> with aminoglycoside_antibiotics or potent <e22> diuretics </e22> such as furosemide .
effect	Nephrotoxicity has been reported following concomitant administration of <e12> cephalosporins </e12> with aminoglycoside_antibiotics or potent diuretics such as <e20> furosemide </e20> .
effect	<e10> Chloramphenicol </e10> has been shown to be antagonistic to <e22> beta-lactam_antibiotics </e22> , including ceftazidime , based on in vitro studies and time kill curves with enteric gram-negative bacilli.
effect	<e10> Chloramphenicol </e10> has been shown to be antagonistic to beta-lactam_antibiotics , including <e20> ceftazidime </e20> , based on in vitro studies and time kill curves with enteric gram-negative bacilli.
effect	Although the occurrence has not been reported with Cefizox , nephrotoxicity has been reported following concomitant administration of other <e12> cephalosporins </e12> and <e22> aminoglycosides </e22> .
effect	ACE_inhibitors : Reports suggest that <e12> NSAIDs </e12> may diminish the antihypertensive effect of <e22> Angiotensin_Converting_Enzyme_(ACE)_inhibitors </e22> .
effect	Furosemide : Clinical studies, as well as post marketing observations, have shown that <e12> NSAIDs </e12> can reduce the natriuretic effect of <e20> furosemide </e20> and thiazides in some patients.
effect	Furosemide : Clinical studies, as well as post marketing observations, have shown that <e12> NSAIDs </e12> can reduce the natriuretic effect of furosemide and <e22> thiazides </e22> in some patients.
effect	However, concomitant administration of <e11> aspirin </e11> with <e21> CELEBREX </e21> may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
effect	Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral <e12> anticoagulants </e12> and <e20> chlordiazepoxide </e20> .
effect	The administration of local <e12> anesthetic_solutions </e12> containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , <e22> tricyclic_antidepressants </e22> or phenothiazines may produce severe, prolonged hypotension or hypertension.
effect	The administration of local <e12> anesthetic_solutions </e12> containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or <e22> phenothiazines </e22> may produce severe, prolonged hypotension or hypertension.
effect	The administration of local anesthetic_solutions containing <e10> epinephrine </e10> or norepinephrine to patients receiving <e22> monoamine_oxidase_inhibitors </e22> , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
effect	The administration of local anesthetic_solutions containing <e10> epinephrine </e10> or norepinephrine to patients receiving monoamine_oxidase_inhibitors , <e22> tricyclic_antidepressants </e22> or phenothiazines may produce severe, prolonged hypotension or hypertension.
effect	The administration of local anesthetic_solutions containing <e10> epinephrine </e10> or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or <e22> phenothiazines </e22> may produce severe, prolonged hypotension or hypertension.
effect	The administration of local anesthetic_solutions containing epinephrine or <e10> norepinephrine </e10> to patients receiving <e22> monoamine_oxidase_inhibitors </e22> , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
effect	The administration of local anesthetic_solutions containing epinephrine or <e10> norepinephrine </e10> to patients receiving monoamine_oxidase_inhibitors , <e22> tricyclic_antidepressants </e22> or phenothiazines may produce severe, prolonged hypotension or hypertension.
effect	The administration of local anesthetic_solutions containing epinephrine or <e10> norepinephrine </e10> to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or <e22> phenothiazines </e22> may produce severe, prolonged hypotension or hypertension.
effect	Concurrent administration of <e12> vasopressor_drugs </e12> (for the treatment of hypotension related to obstetric blocks) and <e22> ergot-type_oxytocic_drugs </e22> may cause severe, persistent hypertension or cerebrovascular accidents.
effect	- Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a <e12> non-steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of <e22> loop_diuretics </e22> , potassium-sparing_diuretics and thiazide_diuretics .
effect	- Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a <e12> non-steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , <e22> potassium-sparing_diuretics </e22> and thiazide_diuretics .
effect	- Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a <e12> non-steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and <e22> thiazide_diuretics </e22> .
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an <e12> antipsychotic_drug </e12> (eg, chlorpromazine ), an <e22> antiparkinsonian_drug </e22> (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an <e12> antipsychotic_drug </e12> (eg, chlorpromazine ), an antiparkinsonian_drug (eg, <e20> trihexyphenidyl </e20> ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an <e12> antipsychotic_drug </e12> (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a <e22> tricyclic_antidepressant </e22> (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an <e12> antipsychotic_drug </e12> (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, <e20> amitriptyline </e20> )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, <e10> chlorpromazine </e10> ), an <e22> antiparkinsonian_drug </e22> (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, <e10> chlorpromazine </e10> ), an antiparkinsonian_drug (eg, <e20> trihexyphenidyl </e20> ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, <e10> chlorpromazine </e10> ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a <e22> tricyclic_antidepressant </e22> (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, <e10> chlorpromazine </e10> ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, <e20> amitriptyline </e20> )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an <e12> antiparkinsonian_drug </e12> (eg, trihexyphenidyl ), and/or a <e22> tricyclic_antidepressant </e22> (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an <e12> antiparkinsonian_drug </e12> (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, <e20> amitriptyline </e20> )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, <e10> trihexyphenidyl </e10> ), and/or a <e22> tricyclic_antidepressant </e22> (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, <e10> trihexyphenidyl </e10> ), and/or a tricyclic_antidepressant (eg, <e20> amitriptyline </e20> )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
effect	The hypoglycemic action of <e12> sulfonylurea </e12> may be potentiated by certain drugs including <e22> nonsteroidal_anti-inflammatory_agents </e22> and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylurea </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, <e22> salicylates </e22> , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylurea </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , <e22> sulfonamides </e22> , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylurea </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , <e20> chloramphenicol </e20> , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylurea </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , <e20> probenecid </e20> , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylurea </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , <e22> coumarins </e22> , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylurea </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , <e22> monoamine_oxidase_inhibitors </e22> , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylurea </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and <e22> beta_adrenergic_blocking_agents </e22> .
effect	Since animal studies suggest that the action of <e12> barbiturates </e12> may be prolonged by therapy with <e20> chlorpropamide </e20> , barbiturates should be employed with caution.
effect	A potential interaction between oral <e10> miconazole </e10> and oral <e22> hypoglycemic_agents </e22> leading to severe hypoglycemia has been reported.
effect	If chlorprothixene is given concomitantly with opioids , the opioid dose should be reduced (by approx, 50%), because <e10> chlorprothixene </e10> amplifies the therapeutic actions and side-effects of <e22> opioids </e22> massively.
effect	Consider additive sedative effects and confusional states to emerge, if <e10> chlorprothixene </e10> is given with <e22> benzodiazepines </e22> or barbituates .
effect	Consider additive sedative effects and confusional states to emerge, if <e10> chlorprothixene </e10> is given with benzodiazepines or <e22> barbituates </e22> .
effect	<e10> Chlorthalidone </e10> may add to or potentiate the action of other <e22> antihypertensive_drugs </e22> .
effect	<e10> Chlorthalidone </e10> and related drugs may increase the responsiveness to <e20> tubocurarine </e20> .
effect	<e10> Chlorthalidone </e10> and related drugs may decrease arterial responsiveness to <e20> norepinephrine </e20> .
effect	Some reports have shown that the concomitant administration of <e12> thiazides </e12> with <e22> vitamin_D </e22> causes hypercalcemia.
effect	Corticosteroids : A relationship of functional antagonism exists between <e12> vitamin_D </e12> analogues, which promote calcium absorption, and <e22> corticosteroids </e22> , which inhibit calcium absorption.
effect	Magnesium : <e10> Magnesium </e10> -containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with <e22> vitamin_D </e22> by patients on chronic renal dialysis.
effect	Magnesium : Magnesium -containing preparations (eg, <e12> antacids </e12> ) may cause hypermagnesemia and should therefore not be taken during therapy with <e22> vitamin_D </e22> by patients on chronic renal dialysis.
effect	There have been reports of theophylline -related side-effects in patients on concomitant <e10> theophylline </e10> - <e22> quinolone </e22> therapy.
effect	<e12> Quinolones </e12> , including cinoxacin , may enhance the effects of oral <e22> anticoagulants </e22> , such as warfarin or its derivatives.
effect	<e12> Quinolones </e12> , including cinoxacin , may enhance the effects of oral anticoagulants , such as <e20> warfarin </e20> or its derivatives.
effect	Quinolones , including <e10> cinoxacin </e10> , may enhance the effects of oral <e22> anticoagulants </e22> , such as warfarin or its derivatives.
effect	Quinolones , including <e10> cinoxacin </e10> , may enhance the effects of oral anticoagulants , such as <e20> warfarin </e20> or its derivatives.
effect	Seizures have been reported in patients taking another <e12> quinolone_class_antimicrobial </e12> and the <e22> nonsteroidal_anti-inflammatory_drug </e22> fenbufen concurrently.
effect	Seizures have been reported in patients taking another <e12> quinolone_class_antimicrobial </e12> and the nonsteroidal_anti-inflammatory_drug <e20> fenbufen </e20> concurrently.
effect	Some <e12> quinolones </e12> , including ciprofloxacin , have been associated with transient elevations in serum creatinine in patients receiving <e20> cyclosporine </e20> concomitantly.
effect	Some quinolones , including <e10> ciprofloxacin </e10> , have been associated with transient elevations in serum creatinine in patients receiving <e20> cyclosporine </e20> concomitantly.
effect	Glyburide : The concomitant administration of <e10> ciprofloxacin </e10> with the <e22> sulfonylurea </e22> glyburide has, on rare occasions, resulted in severe hypoglycemia.
effect	Glyburide : The concomitant administration of <e10> ciprofloxacin </e10> with the sulfonylurea <e20> glyburide </e20> has, on rare occasions, resulted in severe hypoglycemia.
effect	Warfarin : <e12> Quinolones </e12> have been reported to enhance the effects of the oral anticoagulant <e20> warfarin </e20> or its derivatives.
effect	Anticholinergics : Concurrent administration of certain <e12> anticholinergic_compounds </e12> , such as belladonna_alkaloids and dicyclomine , would be expected to compromise the beneficial effects of <e20> cisapride </e20> .
effect	Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as <e12> belladonna_alkaloids </e12> and dicyclomine , would be expected to compromise the beneficial effects of <e20> cisapride </e20> .
effect	Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as belladonna_alkaloids and <e10> dicyclomine </e10> , would be expected to compromise the beneficial effects of <e20> cisapride </e20> .
effect	A study in # normal male and female volunteers suggests that coadministration of <e10> cisapride </e10> and <e20> ketoconazole </e20> can result in prolongation of the QT interval on the ECG.
effect	Administration of #-mg/kg (2 x ED95) <e11> NIMBEX </e11> at 10% or 95% recovery following an intubating dose of <e20> succinylcholine </e20> (1 mg/kg) produced 95% neuromuscular block.
effect	The time to onset of maximum block following <e11> NIMBEX </e11> is approximately # minutes faster with prior administration of <e20> succinylcholine </e20> .
effect	Infusion requirements of NIMBEX in patients administered <e10> succinylcholine </e10> prior to infusions of <e21> NIMBEX </e21> were comparable to or slightly greater than when succinylcholine was not administered.
effect	<e10> Isoflurane </e10> or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of <e21> NIMBEX </e21> and decrease the required infusion rate of NIMBEX .
effect	<e10> Isoflurane </e10> or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of <e21> NIMBEX </e21> .
effect	Isoflurane or <e10> enflurane </e10> administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of <e21> NIMBEX </e21> and decrease the required infusion rate of NIMBEX .
effect	Isoflurane or <e10> enflurane </e10> administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of <e21> NIMBEX </e21> .
effect	Isoflurane or enflurane administered with <e10> nitrous_oxide </e10> / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of <e21> NIMBEX </e21> and decrease the required infusion rate of NIMBEX .
effect	Isoflurane or enflurane administered with <e10> nitrous_oxide </e10> / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of <e21> NIMBEX </e21> .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as <e21> NIMBEX </e21> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain <e22> antibiotics </e22> (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, <e22> aminoglycosides </e22> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , <e22> tetracyclines </e22> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , <e20> bacitracin </e20> , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , <e22> polymyxins </e22> , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , <e20> lincomycin </e20> , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e20> clindamycin </e20> , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e20> colistin </e20> , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e20> sodium_colistemethate </e20> ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), <e20> magnesium </e20> salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, <e20> lithium </e20> , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local <e22> anesthetics </e22> , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , <e20> procainamide </e20> , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of <e12> nondepolarizing_agents </e12> such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and <e20> quinidine </e20> .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain <e22> antibiotics </e22> (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, <e22> aminoglycosides </e22> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , <e22> tetracyclines </e22> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , <e20> bacitracin </e20> , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , <e22> polymyxins </e22> , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , <e20> lincomycin </e20> , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e20> clindamycin </e20> , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e20> colistin </e20> , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e20> sodium_colistemethate </e20> ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), <e20> magnesium </e20> salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, <e20> lithium </e20> , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local <e22> anesthetics </e22> , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , <e20> procainamide </e20> , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as <e11> NIMBEX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and <e20> quinidine </e20> .
effect	Resistance to the neuromuscular blocking action of <e12> nondepolarizing_neuromuscular_blocking_agents </e12> has been demonstrated in patients chronically administered <e20> phenytoin </e20> or carbamazepine .
effect	Resistance to the neuromuscular blocking action of <e12> nondepolarizing_neuromuscular_blocking_agents </e12> has been demonstrated in patients chronically administered phenytoin or <e20> carbamazepine </e20> .
effect	While the effects of chronic <e10> phenytoin </e10> or carbamazepine therapy on the action of <e21> NIMBEX </e21> are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
effect	While the effects of chronic phenytoin or <e10> carbamazepine </e10> therapy on the action of <e21> NIMBEX </e21> are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
effect	The concurrent administration of <e10> allopurinol </e10> and <e20> ampicillin </e20> increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
effect	It is not known whether this potentiation of <e10> ampicillin </e10> rashes is due to <e20> allopurinol </e20> or the hyperuricemia present in these patients.
effect	In common with other <e12> broad-spectrum_antibiotics </e12> , AUGMENTIN_XR may reduce the efficacy of oral <e22> contraceptives </e22>
effect	In common with other broad-spectrum_antibiotics , <e11> AUGMENTIN_XR </e11> may reduce the efficacy of oral <e22> contraceptives </e22>
effect	Additive CNS depression may occur when <e12> antihistamines </e12> are administered concomitantly with other <e22> CNS_depressants </e22> including barbiturates , tranquilizers , and alcohol .
effect	Additive CNS depression may occur when <e12> antihistamines </e12> are administered concomitantly with other CNS_depressants including <e22> barbiturates </e22> , tranquilizers , and alcohol .
effect	Additive CNS depression may occur when <e12> antihistamines </e12> are administered concomitantly with other CNS_depressants including barbiturates , <e22> tranquilizers </e22> , and alcohol .
effect	Additive CNS depression may occur when <e12> antihistamines </e12> are administered concomitantly with other CNS_depressants including barbiturates , tranquilizers , and <e20> alcohol </e20> .
effect	<e12> Monoamine_oxidase_(MAO)_inhibitors </e12> prolong and intensify the anticholinergic effects of <e22> antihistamines </e22> .
effect	<e10> Amantadine </e10> , tricyclic_antidepressants , and MAOIs may increase anticholinergic effect of <e20> clidinium </e20> .
effect	Amantadine , <e12> tricyclic_antidepressants </e12> , and MAOIs may increase anticholinergic effect of <e20> clidinium </e20> .
effect	Amantadine , tricyclic_antidepressants , and <e12> MAOIs </e12> may increase anticholinergic effect of <e20> clidinium </e20> .
effect	<e10> Clidinium </e10> may decrease the effect of <e22> phenothiazines </e22> , levodopa , and ketoconazole .
effect	<e10> Clidinium </e10> may decrease the effect of phenothiazines , <e20> levodopa </e20> , and ketoconazole .
effect	<e10> Clidinium </e10> may decrease the effect of phenothiazines , levodopa , and <e20> ketoconazole </e20> .
effect	<e10> Clindamycin </e10> has been shown to have neuromuscular blocking properties that may enhance the action of other <e22> neuromuscular_blocking_agents </e22> .
effect	Antagonism has been demonstrated between <e10> clindamycin </e10> and <e20> erythromycin </e20> in vitro.
effect	Preliminary data which suggest that <e10> dapsone </e10> may inhibit the anti-inflammatory activity of <e21> Lamprene </e21> have not been confirmed.
effect	The hypoglycemic effect of <e10> tolbutamide </e10> has been reported to increase when <e21> Atromid-S </e21> is given concurrently.
effect	Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another <e12> fibrate </e12> and <e20> lovastatin </e20> but may be seen after several months.
effect	For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with <e10> lovastatin </e10> and a <e22> fibrate </e22> do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.
effect	Several <e12> tricyclic_antidepressants </e12> have been reported to block the pharmacologic effects of <e20> guanethidine </e20> , clonidine , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic_antidepressants .
effect	Several <e12> tricyclic_antidepressants </e12> have been reported to block the pharmacologic effects of guanethidine , <e20> clonidine </e20> , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic_antidepressants .
effect	Several <e12> tricyclic_antidepressants </e12> have been reported to block the pharmacologic effects of guanethidine , clonidine , or similar agents, and such an effect may be anticipated with <e20> CMI </e20> because of its structural similarity to other tricyclic_antidepressants .
effect	Pharmacodynamic Interactions: The CNS-depressant action of the <e12> benzodiazepine_class </e12> of drugs may be potentiated by <e20> alcohol </e20> , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs .
effect	Pharmacodynamic Interactions: The CNS-depressant action of the <e12> benzodiazepine_class </e12> of drugs may be potentiated by alcohol , <e22> narcotics </e22> , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs .
effect	Pharmacodynamic Interactions: The CNS-depressant action of the <e12> benzodiazepine_class </e12> of drugs may be potentiated by alcohol , narcotics , <e22> barbiturates </e22> , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs .
effect	Pharmacodynamic Interactions: The CNS-depressant action of the <e12> benzodiazepine_class </e12> of drugs may be potentiated by alcohol , narcotics , barbiturates , <e22> nonbarbiturate_hypnotics </e22> , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs .
effect	Pharmacodynamic Interactions: The CNS-depressant action of the <e12> benzodiazepine_class </e12> of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , <e22> antianxiety_agents </e22> , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs .
effect	Pharmacodynamic Interactions: The CNS-depressant action of the <e12> benzodiazepine_class </e12> of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the <e22> phenothiazines_classes_of_antipsychotic_agents </e22> , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs .
effect	Pharmacodynamic Interactions: The CNS-depressant action of the <e12> benzodiazepine_class </e12> of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , <e22> thioxanthene_classes_of_antipsychotic_agents </e22> and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs .
effect	Pharmacodynamic Interactions: The CNS-depressant action of the <e12> benzodiazepine_class </e12> of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and <e22> butyrophenone_classes_of_antipsychotic_agents </e22> , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs .
effect	Pharmacodynamic Interactions: The CNS-depressant action of the <e12> benzodiazepine_class </e12> of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , <e22> monoamine_oxidase_inhibitors </e22> and the tricyclic_antidepressants , and by other anticonvulsant_drugs .
effect	Pharmacodynamic Interactions: The CNS-depressant action of the <e12> benzodiazepine_class </e12> of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the <e22> tricyclic_antidepressants </e22> , and by other anticonvulsant_drugs .
effect	Pharmacodynamic Interactions: The CNS-depressant action of the <e12> benzodiazepine_class </e12> of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other <e22> anticonvulsant_drugs </e22> .
effect	Tablet If a patient receiving <e10> clonidine_hydrochloride </e10> is also taking <e22> tricyclic_antidepressants </e22> , the effect of clonidine may be reduced, thus necessitating an increase in dosage.
effect	<e10> Clonidine_hydrochloride </e10> may enhance the CNS-depressive effects of <e20> alcohol </e20> , barbiturates or other sedatives .
effect	<e10> Clonidine_hydrochloride </e10> may enhance the CNS-depressive effects of alcohol , <e22> barbiturates </e22> or other sedatives .
effect	<e10> Clonidine_hydrochloride </e10> may enhance the CNS-depressive effects of alcohol , barbiturates or other <e22> sedatives </e22> .
effect	<e10> Amitriptyline </e10> in combination with <e20> clonidine </e20> enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs .
effect	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection <e10> Clonidine </e10> may potentiate the CNS-depressive effect of <e20> alcohol </e20> , barbiturates or other sedating_drugs .
effect	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection <e10> Clonidine </e10> may potentiate the CNS-depressive effect of alcohol , <e22> barbiturates </e22> or other sedating_drugs .
effect	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection <e10> Clonidine </e10> may potentiate the CNS-depressive effect of alcohol , barbiturates or other <e22> sedating_drugs </e22> .
effect	<e12> Narcotic_analgesics </e12> may potentiate the hypotensive effects of <e20> clonidine </e20> .
effect	<e12> Tricyclic_antidepressants </e12> may antagonize the hypotensive effects of <e20> clonidine </e20> .
effect	<e12> Beta_blockers </e12> may exacerbate the hypertensive response seen with <e20> clonidine </e20> withdrawl.
effect	There is one reported case of a patient with acute delirium associated with the simultaneous use of <e10> fluphenazine </e10> and oral <e20> clonidine </e20> .
effect	Epidural <e10> clonidine </e10> may prolong the duration of pharmacologic effects of epidural local <e22> anesthetics </e22> , including both sensory and motor blockade.
effect	Animal experience indicates that <e10> clorazepate_dipotassium </e10> prolongs the sleeping time after <e20> hexobarbital </e20> or after ethyl_alcohol , increases the inhibitory effects of chlorpromazine , but does not exhibit monoamine oxidase inhibition.
effect	Animal experience indicates that <e10> clorazepate_dipotassium </e10> prolongs the sleeping time after hexobarbital or after <e20> ethyl_alcohol </e20> , increases the inhibitory effects of chlorpromazine , but does not exhibit monoamine oxidase inhibition.
effect	Animal experience indicates that <e10> clorazepate_dipotassium </e10> prolongs the sleeping time after hexobarbital or after ethyl_alcohol , increases the inhibitory effects of <e20> chlorpromazine </e20> , but does not exhibit monoamine oxidase inhibition.
effect	The actions of the <e12> benzodiazepines </e12> may be potentiated by <e22> barbiturates </e22> , narcotics , phenothiazines , monoamine_oxidase_inhibitors or other antidepressants .
effect	The actions of the <e12> benzodiazepines </e12> may be potentiated by barbiturates , <e22> narcotics </e22> , phenothiazines , monoamine_oxidase_inhibitors or other antidepressants .
effect	The actions of the <e12> benzodiazepines </e12> may be potentiated by barbiturates , narcotics , <e22> phenothiazines </e22> , monoamine_oxidase_inhibitors or other antidepressants .
effect	The actions of the <e12> benzodiazepines </e12> may be potentiated by barbiturates , narcotics , phenothiazines , <e22> monoamine_oxidase_inhibitors </e22> or other antidepressants .
effect	The actions of the <e12> benzodiazepines </e12> may be potentiated by barbiturates , narcotics , phenothiazines , monoamine_oxidase_inhibitors or other <e22> antidepressants </e22> .
effect	Given the primary CNS effects of <e10> Clozapine </e10> , caution is advised in using it concomitantly with other CNS-active drugs or <e20> alcohol </e20> .
effect	<e10> Clozapine </e10> may potentiate the hypotensive effects of <e22> antihypertensive_drugs </e22> and the anticholinergic effects of atropine -type drugs.
effect	<e10> Clozapine </e10> may potentiate the hypotensive effects of antihypertensive_drugs and the anticholinergic effects of <e20> atropine </e20> -type drugs.
effect	<e10> Codeine </e10> in combination with other <e22> narcotic_analgesics </e22> , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects.
effect	<e10> Codeine </e10> in combination with other narcotic_analgesics , general <e22> anesthetics </e22> , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects.
effect	<e10> Codeine </e10> in combination with other narcotic_analgesics , general anesthetics , <e22> phenothiazines </e22> , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects.
effect	<e10> Codeine </e10> in combination with other narcotic_analgesics , general anesthetics , phenothiazines , <e22> tranquilizers </e22> , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects.
effect	<e10> Codeine </e10> in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , <e22> sedative-hypnotics </e22> , or other CNS_depressants (including alcohol ) has additive depressant effects.
effect	<e10> Codeine </e10> in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other <e22> CNS_depressants </e22> (including alcohol ) has additive depressant effects.
effect	<e10> Codeine </e10> in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including <e20> alcohol </e20> ) has additive depressant effects.
effect	<e10> Colchicine </e10> may increase sensitivity to the <e22> CNS_depressants </e22> .
effect	Response to <e12> sympathomimetic_agents </e12> may be enhanced by <e20> colchicine </e20> .
effect	Particular caution should be observed with <e12> digitalis_preparations </e12> since there are conflicting results for the effect of <e20> colestipol_hydrochloride </e20> on the availability of digoxin and digitoxin .
effect	<e11> Curariform_muscle_relaxants </e11> (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with <e21> Coly-Mycin_M </e21> Parenteral.
effect	Curariform_muscle_relaxants (eg, <e10> tubocurarine </e10> ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with <e21> Coly-Mycin_M </e21> Parenteral.
effect	Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, <e10> succinylcholine </e10> , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with <e21> Coly-Mycin_M </e21> Parenteral.
effect	Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , <e10> gallamine </e10> , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with <e21> Coly-Mycin_M </e21> Parenteral.
effect	Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , <e10> decamethonium </e10> and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with <e21> Coly-Mycin_M </e21> Parenteral.
effect	Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and <e10> sodium_citrate </e10> , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with <e21> Coly-Mycin_M </e21> Parenteral.
effect	<e10> Sodium_cephalothin </e10> may enhance the nephrotoxicity of <e21> Coly-Mycin_M </e21> Parenteral.
effect	<e10> Corticotropin </e10> may accentuate the electrolyte loss associated with <e22> diuretic </e22> therapy.
effect	<e12> Corticosteroids </e12> may increase the clearance of chronic high dose <e21> aspirin </e21> .
effect	This could lead to decreased salicylate serum levels or increase the risk of <e12> salicylate </e12> toxicity when <e22> corticosteroid </e22> is withdrawn.
effect	The effect of <e12> corticosteroids </e12> on oral <e22> anticoagulants </e22> is variable.
effect	There are reports of enhanced as well as diminished effects of <e12> anticoagulants </e12> when given concurrently with <e22> corticosteroids </e22> .
effect	<e10> Corticotropin </e10> may accentuate the electrolyte loss associated with <e22> diuretic </e22> therapy.
effect	The addition of # mg/kg/day of <e10> cromolyn_sodium </e10> (approximately # times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to # mg/kg/day of <e20> isoproterenol </e20> (approximately # times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.
effect	<e11> FLEXERIL </e11> may enhance the effects of <e20> alcohol </e20> , barbiturates , and other CNS_depressants .
effect	<e11> FLEXERIL </e11> may enhance the effects of alcohol , <e22> barbiturates </e22> , and other CNS_depressants .
effect	<e11> FLEXERIL </e11> may enhance the effects of alcohol , barbiturates , and other <e22> CNS_depressants </e22> .
effect	<e12> Tricyclic_antidepressants </e12> may block the antihypertensive action of <e20> guanethidine </e20> and similarly acting compounds.
effect	<e12> Tricyclic_antidepressants </e12> may enhance the seizure risk in patients taking <e20> tramadol </e20>
effect	<e10> Cyclopentolate </e10> may interfere with the anti-glaucoma action of <e20> carbachol </e20> or pilocarpine ;
effect	<e10> Cyclopentolate </e10> may interfere with the anti-glaucoma action of carbachol or <e20> pilocarpine </e20> ;
effect	<e10> Cyclophosphamide </e10> treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of <e20> succinylcholine_chloride </e20> .
effect	<e12> MAO_inhibitors </e12> prolong and intensify the anticholinergic effects of <e22> antihistamines </e22> .
effect	<e10> Antihistamines </e10> may have additive effects with <e20> alcohol </e20> and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents .
effect	<e10> Antihistamines </e10> may have additive effects with alcohol and other <e22> CNS_depressants </e22> , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents .
effect	<e10> Antihistamines </e10> may have additive effects with alcohol and other CNS_depressants , e,g,, <e22> hypnotics </e22> , sedatives , tranquilizers , antianxiety_agents .
effect	<e10> Antihistamines </e10> may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , <e22> sedatives </e22> , tranquilizers , antianxiety_agents .
effect	<e10> Antihistamines </e10> may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , <e22> tranquilizers </e22> , antianxiety_agents .
effect	<e10> Antihistamines </e10> may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , <e22> antianxiety_agents </e22> .
effect	Administration of <e10> dantrolene </e10> may potentiate <e20> vecuronium </e20> -induced neuromuscular block.
effect	With oral <e10> dapsone </e10> treatment, <e22> folic_acid_antagonists </e22> such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
effect	With oral <e10> dapsone </e10> treatment, folic_acid_antagonists such as <e20> pyrimethamine </e20> have been noted to possibly increase the likelihood of hematologic reactions
effect	The concomitant use of <e11> ENABLEX </e11> with other <e22> anticholinergic_agents </e22> may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.
effect	H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by <e12> H2_blockers </e12> or proton_pump_inhibitors (eg, famotidine and omeprazole ) is likely to reduce <e20> dasatinib </e20> exposure.
effect	H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by H2_blockers or <e12> proton_pump_inhibitors </e12> (eg, famotidine and omeprazole ) is likely to reduce <e20> dasatinib </e20> exposure.
effect	H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by H2_blockers or proton_pump_inhibitors (eg, <e10> famotidine </e10> and omeprazole ) is likely to reduce <e20> dasatinib </e20> exposure.
effect	H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by H2_blockers or proton_pump_inhibitors (eg, famotidine and <e10> omeprazole </e10> ) is likely to reduce <e20> dasatinib </e20> exposure.
effect	Use of <e11> Cerubidine </e11> in a patient who has previously received <e20> doxorubicin </e20> increases the risk of cardiotoxicity.
effect	<e10> Cyclophosphamide </e10> used concurrently with <e21> Cerubidine </e21> may also result in increased cardiotoxicity.
effect	Since bacteriostatic drugs, such as the <e12> tetracycline_class </e12> of antibiotics , may interfere with the bactericidal action of <e22> penicillins </e22> , it is not advisable to administer these drugs concomitantly.
effect	Concurrent use of <e12> tetracyclines </e12> with oral <e22> contraceptives </e22> may render oral contraceptives less effective.
effect	Taking a <e12> rauwolfia_alkaloid </e12> while you are taking or within # weeks of taking <e22> MAO_inhibitors </e22> may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.
effect	If <e10> desipramine_hydrochloride </e10> is to be combined with other <e22> psychotropic_agents </e22> such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive.
effect	If <e10> desipramine_hydrochloride </e10> is to be combined with other psychotropic_agents such as <e22> tranquilizers </e22> or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive.
effect	If <e10> desipramine_hydrochloride </e10> is to be combined with other psychotropic_agents such as tranquilizers or <e22> sedative </e22> / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive.
effect	If <e10> desipramine_hydrochloride </e10> is to be combined with other psychotropic_agents such as tranquilizers or sedative / <e22> hypnotics </e22> , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive.
effect	If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of <e10> desipramine </e10> and <e22> benzodiazepines </e22> (e,g,, chlordiazepoxide or diazepam ) are additive.
effect	If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of <e10> desipramine </e10> and benzodiazepines (e,g,, <e20> chlordiazepoxide </e20> or diazepam ) are additive.
effect	If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of <e10> desipramine </e10> and benzodiazepines (e,g,, chlordiazepoxide or <e20> diazepam </e20> ) are additive.
effect	Both the sedative and anticholinergic effects of the <e12> major_tranquilizers </e12> are also additive to those of <e20> desipramine </e20> .
effect	Aminoglutethimide : <e10> Aminoglutethimide </e10> may diminish adrenal suppression by <e22> corticosteroids </e22> .
effect	In addition, there have been cases reported in which concomitant use of <e10> amphotericin_B </e10> and <e20> hydrocortisone </e20> was followed by cardiac enlargement and congestive heart failure.
effect	Anticholinesterases : Concomitant use of <e12> anticholinesterase_agents </e12> and <e22> corticosteroids </e22> may produce severe weakness in patients with myasthenia gravis.
effect	Anticoagulants , oral: Co-administration of <e12> corticosteroids </e12> and <e20> warfarin </e20> usually results in inhibition of response to warfarin , although there have been some conflicting reports.
effect	Antidiabetics : Because <e12> corticosteroids </e12> may increase blood glucose concentrations, dosage adjustments of <e22> antidiabetic_agents </e22> may be required.
effect	Cyclosporine : Increased activity of both <e10> cyclosporine </e10> and <e22> corticosteroids </e22> may occur when the two are used concurrently.
effect	In addition, <e10> ketoconazole </e10> alone can inhibit adrenal <e22> corticosteroid </e22> synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.
effect	Nonsteroidal_anti-inflammatory_agents ( NSAIDS ): Concomitant use of <e11> aspirin </e11> (or other nonsteroidal_antiinflammatory_agents ) and <e22> corticosteroids </e22> increases the risk of gastrointestinal side effects.
effect	Nonsteroidal_anti-inflammatory_agents ( NSAIDS ): Concomitant use of aspirin (or other <e12> nonsteroidal_antiinflammatory_agents </e12> ) and <e22> corticosteroids </e22> increases the risk of gastrointestinal side effects.
effect	Vaccines : Patients on <e12> corticosteroid </e12> therapy may exhibit a diminished response to toxoids and <e22> live_vaccines </e22> or inactivated_vaccines due to inhibition of antibody response.
effect	Vaccines : Patients on <e12> corticosteroid </e12> therapy may exhibit a diminished response to toxoids and live_vaccines or <e22> inactivated_vaccines </e22> due to inhibition of antibody response.
effect	<e12> Corticosteroids </e12> may also potentiate the replication of some organisms contained in <e22> live_attenuated_vaccines </e22> .
effect	In patients receiving nonselective <e12> monoamine_oxidase_inhibitors </e12> ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with <e22> serotoninergic_agents </e22> (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective <e12> monoamine_oxidase_inhibitors </e12> ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, <e20> fluoxetine </e20> , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective <e12> monoamine_oxidase_inhibitors </e12> ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , <e20> fluvoxamine </e20> , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective <e12> monoamine_oxidase_inhibitors </e12> ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , <e20> paroxetine </e20> , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective <e12> monoamine_oxidase_inhibitors </e12> ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , <e20> sertraline </e20> , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective <e12> monoamine_oxidase_inhibitors </e12> ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , <e20> venlafaxine </e20> ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( <e12> MAOIs </e12> ) (e,g,, selegiline_hydrochloride ) in combination with <e22> serotoninergic_agents </e22> (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( <e12> MAOIs </e12> ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, <e20> fluoxetine </e20> , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( <e12> MAOIs </e12> ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , <e20> fluvoxamine </e20> , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( <e12> MAOIs </e12> ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , <e20> paroxetine </e20> , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( <e12> MAOIs </e12> ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , <e20> sertraline </e20> , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( <e12> MAOIs </e12> ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , <e20> venlafaxine </e20> ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, <e10> selegiline_hydrochloride </e10> ) in combination with <e22> serotoninergic_agents </e22> (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, <e10> selegiline_hydrochloride </e10> ) in combination with serotoninergic_agents (e,g,, <e20> fluoxetine </e20> , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, <e10> selegiline_hydrochloride </e10> ) in combination with serotoninergic_agents (e,g,, fluoxetine , <e20> fluvoxamine </e20> , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, <e10> selegiline_hydrochloride </e10> ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , <e20> paroxetine </e20> , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, <e10> selegiline_hydrochloride </e10> ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , <e20> sertraline </e20> , venlafaxine ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, <e10> selegiline_hydrochloride </e10> ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , <e20> venlafaxine </e20> ), there have been reports of serious, sometimes fatal, reactions.
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of <e12> selective_serotonin_reuptake_inhibitors </e12> ( SSRIs ) and agents for migraine therapy, such as <e21> Imitrex </e21> ( sumatriptan_succinate ) and dihydroergotamine .
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of <e12> selective_serotonin_reuptake_inhibitors </e12> ( SSRIs ) and agents for migraine therapy, such as Imitrex ( <e20> sumatriptan_succinate </e20> ) and dihydroergotamine .
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of <e12> selective_serotonin_reuptake_inhibitors </e12> ( SSRIs ) and agents for migraine therapy, such as Imitrex ( sumatriptan_succinate ) and <e20> dihydroergotamine </e20> .
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective_serotonin_reuptake_inhibitors ( <e12> SSRIs </e12> ) and agents for migraine therapy, such as <e21> Imitrex </e21> ( sumatriptan_succinate ) and dihydroergotamine .
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective_serotonin_reuptake_inhibitors ( <e12> SSRIs </e12> ) and agents for migraine therapy, such as Imitrex ( <e20> sumatriptan_succinate </e20> ) and dihydroergotamine .
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective_serotonin_reuptake_inhibitors ( <e12> SSRIs </e12> ) and agents for migraine therapy, such as Imitrex ( sumatriptan_succinate ) and <e20> dihydroergotamine </e20> .
effect	Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of <e11> PRECEDEX </e11> with <e22> anesthetics </e22> , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects.
effect	Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of <e11> PRECEDEX </e11> with anesthetics , <e22> sedatives </e22> , hypnotics , and opioids is likely to lead to an enhancement of effects.
effect	Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of <e11> PRECEDEX </e11> with anesthetics , sedatives , <e22> hypnotics </e22> , and opioids is likely to lead to an enhancement of effects.
effect	Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of <e11> PRECEDEX </e11> with anesthetics , sedatives , hypnotics , and <e22> opioids </e22> is likely to lead to an enhancement of effects.
effect	Adrenergic_blockers : <e12> Adrenergic_blockers </e12> are inhibited by <e20> amphetamines </e20> .
effect	Antidepressants , tricyclic : <e12> Amphetamines </e12> may enhance the activity of <e22> tricyclic </e22> or sympathomimetic_agents ;
effect	Antidepressants , tricyclic : <e12> Amphetamines </e12> may enhance the activity of tricyclic or <e22> sympathomimetic_agents </e22> ;
effect	Antihistamines : <e12> Amphetamines </e12> may counteract the sedative effect of <e22> antihistamines </e22> .
effect	Antihypertensives : <e12> Amphetamines </e12> may antagonize the hypotensive effects of <e20> antihypertensives </e20> .
effect	Chlorpromazine : <e10> Chlorpromazine </e10> blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of <e20> amphetamines </e20> , and can be used to treat amphetamine poisoning.
effect	Haloperidol : <e10> Haloperidol </e10> blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of <e20> amphetamines </e20> .
effect	Lithium_carbonate : The stimulatory effects of <e10> amphetamines </e10> may be inhibited by <e20> lithium_carbonate </e20> .
effect	Meperidine : <e12> Amphetamines </e12> potentiate the analgesic effect of <e20> meperidine </e20> .
effect	Norepinephrine : <e12> Amphetamines </e12> enhance the adrenergic effect of <e20> norepinephrine </e20> .
effect	Propoxyphene : In cases of <e10> propoxyphene </e10> overdosage, <e20> amphetamine </e20> CNS stimulation is potentiated and fatal convulsions can occur.
effect	Veratrum_alkaloids : <e12> Amphetamines </e12> inhibit the hypotensive effect of <e22> veratrum_alkaloids </e22> .
effect	Ingestion of <e10> diclofenac </e10> may increase serum concentrations of digoxin and methotrexate and increase <e20> cyclosporine </e20> s nephrotoxicity.
effect	Patients who begin taking <e10> diclofenac </e10> or who increase their diclofenac dose or any other NSAID while taking <e20> digoxin </e20> , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs.
effect	Patients who begin taking <e10> diclofenac </e10> or who increase their diclofenac dose or any other NSAID while taking digoxin , <e20> methotrexate </e20> , or cyclosporine may develop toxicity characteristics for these drugs.
effect	Patients who begin taking <e10> diclofenac </e10> or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or <e20> cyclosporine </e20> may develop toxicity characteristics for these drugs.
effect	Patients who begin taking diclofenac or who increase their diclofenac dose or any other <e12> NSAID </e12> while taking <e20> digoxin </e20> , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs.
effect	Patients who begin taking diclofenac or who increase their diclofenac dose or any other <e12> NSAID </e12> while taking digoxin , <e20> methotrexate </e20> , or cyclosporine may develop toxicity characteristics for these drugs.
effect	Patients who begin taking diclofenac or who increase their diclofenac dose or any other <e12> NSAID </e12> while taking digoxin , methotrexate , or <e20> cyclosporine </e20> may develop toxicity characteristics for these drugs.
effect	In patients taking <e10> diclofenac </e10> and <e20> lithium </e20> concomitantly, lithium toxicity may develop.
effect	There are rare reports, however, from marketing experiences, of changes in effects of <e10> insulin </e10> or oral hypoglycemic_agents in the presence of <e20> diclofenac </e20> that necessitated changes in the doses of such agents.
effect	There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral <e12> hypoglycemic_agents </e12> in the presence of <e20> diclofenac </e20> that necessitated changes in the doses of such agents.
effect	A direct causal relationship has not been established, but physicians should consider the possibility that <e10> diclofenac </e10> may alter a diabetic patient s response to <e20> insulin </e20> or oral hypoglycemic_agents .
effect	A direct causal relationship has not been established, but physicians should consider the possibility that <e10> diclofenac </e10> may alter a diabetic patient s response to insulin or oral <e22> hypoglycemic_agents </e22> .
effect	Diuretics : <e10> Diclofenac </e10> and other NSAIDs can inhibit the activity of <e22> diuretics </e22> .
effect	Diuretics : Diclofenac and other <e12> NSAIDs </e12> can inhibit the activity of <e22> diuretics </e22> .
effect	Phenobarbital toxicity has been reported to have occurred in a patient on chronic <e10> phenobarbital </e10> treatment following the initiation of <e20> diclofenac </e20> therapy.
effect	<e10> Tetracycline </e10> , a bacteriostatic_antibiotic , may antagonize the bactercidal effect of <e20> penicillin </e20> and concurrent use of these drugs should be avoided.
effect	Antacids : Concomitant administration of <e12> antacids </e12> containing magnesium or aluminum with <e21> VIDEX </e21> Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
effect	Antacids : Concomitant administration of antacids containing <e10> magnesium </e10> or aluminum with <e21> VIDEX </e21> Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
effect	Antacids : Concomitant administration of antacids containing magnesium or <e10> aluminum </e10> with <e21> VIDEX </e21> Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
effect	Concurrent use of <e12> phenothiazines </e12> may antagonize the anorectic effect of <e20> diethylpropion </e20> .
effect	<e10> Diflunisal </e10> decreased the hyperuricemic effect of <e20> hydrochlorothiazide </e20> .
effect	<e10> Diflunisal </e10> decreased the hyperuricemic effect of <e20> furosemide </e20> .
effect	Concomitant administration of <e10> diflunisal </e10> and <e20> acetaminophen </e20> in dogs, but not in rats, at approximately # times the recommended maximum human therapeutic dose of each (40 to # mg/kg/day of diflunisal / acetaminophen ) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
effect	In some patients the combined use of <e10> indomethacin </e10> and <e20> diflunisal </e20> has been associated with fatal gastrointestinal hemorrhage.
effect	The concomitant use of <e10> diflunisal </e10> tablets and other <e22> NSAIDs </e22> is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
effect	<e12> Potassium-depleting_diuretics </e12> are a major contributing factor to <e22> digitalis </e22> toxicity.
effect	Concomitant use of <e10> digoxin </e10> and <e22> sympathomimetics </e22> increases the risk of cardiac arrhythmias.
effect	Vasoconstrictors : <e11> D,H,E,_45 </e11> ( dihydroergotamine_mesylate ) Injection, USP should not be used with <e22> peripheral_vasoconstrictors </e22> because the combination may cause synergistic elevation of blood pressure.
effect	Vasoconstrictors : D,H,E,_45 ( <e10> dihydroergotamine_mesylate </e10> ) Injection, USP should not be used with <e22> peripheral_vasoconstrictors </e22> because the combination may cause synergistic elevation of blood pressure.
effect	Sumatriptan : <e10> Sumatriptan </e10> has been reported to cause coronary artery vasospasm, and its effect could be additive with <e21> D,H,E,_45 </e21> ( dihydroergotamine_mesylate ) Injection, USP.
effect	Sumatriptan : <e10> Sumatriptan </e10> has been reported to cause coronary artery vasospasm, and its effect could be additive with D,H,E,_45 ( <e20> dihydroergotamine_mesylate </e20> ) Injection, USP.
effect	Beta_Blockers : Although the results of a clinical study did not indicate a safe problem associated with the administration of D,H,E,_45 ( dihydroergotamine_mesylate ) Injection, USP to subjects already receiving propranolol , there have been reports that <e10> propranolol </e10> may potentiate the vasoconstrictive action of <e20> ergotamine </e20> by blocking the vasodilating property of epinephrine.
effect	Nicotine : <e10> Nicotine </e10> may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to <e22> ergot </e22> therapy.
effect	Vasospastic reactions have been reported with therapeutic doses of <e10> ergotamine </e10> -containing drugs when co-administered with these <e22> antibiotics </e22> .
effect	SSRIs : Weakness hyperreflexia, and incoordination have been reported rarely when <e12> 5-HT1_agonists </e12> have been co-administered with <e22> SSRIs </e22> (e, g.
effect	Administration of <e12> thiazide_diuretics </e12> to hypoparathyroid patients who are concurrently being treated with <e20> dihydrotachysterol </e20> may cause hypercalcemia.
effect	Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using <e12> beta-blockers </e12> or digitalis concomitantly with <e21> Tiazac </e21> .
effect	Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or <e12> digitalis </e12> concomitantly with <e21> Tiazac </e21> .
effect	The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with <e12> anesthetics </e12> may be potentiated by <e22> calcium_channel_blockers </e22> .
effect	These pharmacokinetic effects seen during <e10> diltiazem </e10> coadministration can result in increased clinical effects (e,g,, prolonged sodation)of both <e20> midazolam </e20> and triazolam .
effect	These pharmacokinetic effects seen during <e10> diltiazem </e10> coadministration can result in increased clinical effects (e,g,, prolonged sodation)of both midazolam and <e20> triazolam </e20> .
effect	<e10> Dimenhydrinate </e10> may decrease emetic response to <e20> apomorphine </e20> .
effect	<e10> Oxytocin </e10> or other oxytocics (concurrent use with <e20> dinoprost </e20> may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
effect	Oxytocin or other <e12> oxytocics </e12> (concurrent use with <e20> dinoprost </e20> may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
effect	<e11> PROSTIN_E2 </e11> may augment the activity of other <e22> oxytocic_drugs </e22> .
effect	<e10> Diphenhydramine_hydrochloride </e10> has additive effects with <e20> alcohol </e20> and other CNS_depressants ( hypnotics , sedatives , tranquilizers , etc).
effect	<e10> Diphenhydramine_hydrochloride </e10> has additive effects with alcohol and other <e22> CNS_depressants </e22> ( hypnotics , sedatives , tranquilizers , etc).
effect	<e10> Diphenhydramine_hydrochloride </e10> has additive effects with alcohol and other CNS_depressants ( <e22> hypnotics </e22> , sedatives , tranquilizers , etc).
effect	<e10> Diphenhydramine_hydrochloride </e10> has additive effects with alcohol and other CNS_depressants ( hypnotics , <e22> sedatives </e22> , tranquilizers , etc).
effect	<e10> Diphenhydramine_hydrochloride </e10> has additive effects with alcohol and other CNS_depressants ( hypnotics , sedatives , <e22> tranquilizers </e22> , etc).
effect	<e12> MAO_inhibitors </e12> prolong and intensify the anticholinergic (drying) effects of <e22> antihistamines </e22> .
effect	apomorphine - prior ingestion of <e10> diphenidol </e10> may decrease the emetic response to <e20> apomorphine </e20> in the treatment of poisoning.
effect	Cholinesterase_Inhibitors : <e10> Dipyridamole </e10> may counteract the anticholinesterase effect of <e22> cholinesterase_inhibitors </e22> , thereby potentially aggravating myasthenia gravis.
effect	The mean QT c interval (msec) was # with terfenadine alone and # with <e10> terfenadine </e10> plus <e20> dirithromycin </e20> .
effect	Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving <e10> terfenadine </e10> concomitantly with other <e22> macrolide_antibiotics </e22> .
effect	Triazolam : <e10> Erythromycin </e10> has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of <e20> triazolam </e20> .
effect	Anticoagulants : There have been reports of increased anticoagulant effects when <e10> erythromycin </e10> and oral <e22> anticoagulants </e22> were used concomitantly.
effect	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING <e10> DISULFIRAM </e10> TO A PATIENT ON <e20> PHENYTOIN </e20> THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.
effect	In rats, simultaneous ingestion of <e10> disulfiram </e10> and <e20> nitrite </e20> in the diet for # weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
effect	In rats, simultaneous ingestion of disulfiram and nitrite in the diet for # weeks has been reported to cause tumors, and it has been suggested that <e10> disulfiram </e10> may react with <e22> nitrites </e22> in the rat stomach to form a nitrosamine, which is tumorigenic.
effect	Animal studies indicate that <e10> dobutamine </e10> may be ineffective if the patient has recently received a <e22> b-blocking_drug </e22> .
effect	Preliminary studies indicate that the concomitant use of <e10> dobutamine </e10> and <e20> nitroprusside </e20> results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
effect	In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of <e10> verapamil </e10> with <e20> dofetilide </e20> was associated with a higher occurrence of torsade de pointes.
effect	In patients, the concomitant administration of <e10> digoxin </e10> with <e20> dofetilide </e20> was associated with a higher occurrence of torsade de pointes.
effect	Concurrent administration of low-dose <e10> dopamine_HCl </e10> and <e22> diuretic_agents </e22> may produce an additive or potentiating effect on urine flow.
effect	Cardiac effects of <e10> dopamine </e10> are antagonized by <e22> beta-adrenergic_blocking_agents </e22> , such as propranolol and metoprolol .
effect	Cardiac effects of <e10> dopamine </e10> are antagonized by beta-adrenergic_blocking_agents , such as <e20> propranolol </e20> and metoprolol .
effect	Cardiac effects of <e10> dopamine </e10> are antagonized by beta-adrenergic_blocking_agents , such as propranolol and <e20> metoprolol </e20> .
effect	The peripheral vasoconstriction caused by high doses of <e10> dopamine_HCl </e10> is antagonized by <e22> alpha-adrenergic_blocking_agents </e22> .
effect	<e12> Butyrophenones </e12> (such as haloperidol ) and phenothiazines can suppress the <e20> dopamine </e20> rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.
effect	Butyrophenones (such as <e10> haloperidol </e10> ) and phenothiazines can suppress the <e20> dopamine </e20> rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.
effect	Butyrophenones (such as haloperidol ) and <e12> phenothiazines </e12> can suppress the <e20> dopamine </e20> rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.
effect	<e10> Cyclopropane </e10> or halogenated_hydrocarbon_anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered <e22> catecholamines </e22> , such as dopamine .
effect	<e10> Cyclopropane </e10> or halogenated_hydrocarbon_anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines , such as <e20> dopamine </e20> .
effect	Cyclopropane or <e12> halogenated_hydrocarbon_anesthetics </e12> increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered <e22> catecholamines </e22> , such as dopamine .
effect	Cyclopropane or <e12> halogenated_hydrocarbon_anesthetics </e12> increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines , such as <e20> dopamine </e20> .
effect	It has been reported that results of studies in animals indicate that <e10> dopamine </e10> -induced ventricular arrhythmias during anesthesia can be reversed by <e20> propranolol </e20> .
effect	The concomitant use of vasopressor s, vasoconstricting agents (such as <e10> ergonovine </e10> ) and some <e22> oxytocic_drugs </e22> may result in severe hypertension.
effect	Administration of <e10> phenytoin </e10> to patients receiving <e20> dopamine_HCl </e20> has been reported to lead to hypotension and bradycardia.
effect	Although acid-base and electrolyte disturbances were not reported in the clinical trials with <e10> dorzolamide </e10> , these disturbances have been reported with oral <e22> carbonic_anhydrase_inhibitors </e22> and have, in some instances, resulted in drug interactions (e,g,, toxicity associated with high-dose salicylate therapy).
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain <e22> antibiotics </e22> (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, <e22> aminoglycosides </e22> , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , <e22> tetracyclines </e22> , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , <e20> bacitracin </e20> , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , <e22> polymyxins </e22> , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , <e20> lincomycin </e20> , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , <e20> clindamycin </e20> , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , <e20> colistin </e20> , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and <e20> sodium_colistimethate </e20> ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), <e20> magnesium </e20> salts, lithium , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, <e20> lithium </e20> , local anesthetics , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local <e22> anesthetics </e22> , procainamide , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , <e20> procainamide </e20> , and quinidine .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e11> NUROMAX </e11> include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistimethate ), magnesium salts, lithium , local anesthetics , procainamide , and <e20> quinidine </e20> .
effect	As with some other <e12> nondepolarizing_neuromuscular_blocking_agents </e12> , the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving <e20> phenytoin </e20> or carbamazepine .
effect	As with some other <e12> nondepolarizing_neuromuscular_blocking_agents </e12> , the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or <e20> carbamazepine </e20> .
effect	As with some other nondepolarizing_neuromuscular_blocking_agents , the time of onset of neuromuscular block induced by <e11> NUROMAX </e11> is lengthened and the duration of block is shortened in patients receiving <e20> phenytoin </e20> or carbamazepine .
effect	As with some other nondepolarizing_neuromuscular_blocking_agents , the time of onset of neuromuscular block induced by <e11> NUROMAX </e11> is lengthened and the duration of block is shortened in patients receiving phenytoin or <e20> carbamazepine </e20> .
effect	Administration of <e10> doxapram </e10> to patients who are receiving <e22> sympathomimetic </e22> or monoamine_oxidase_inhibiting_drugs may result in an additive pressor effect .
effect	Administration of <e10> doxapram </e10> to patients who are receiving sympathomimetic or <e22> monoamine_oxidase_inhibiting_drugs </e22> may result in an additive pressor effect .
effect	In patients who have received muscle_relaxants , <e10> doxapram </e10> may temporarily mask the residual effects of <e22> muscle_relaxant_drugs </e22> .
effect	Serious anticholinergic symptoms (i,e,, severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of <e12> tricyclic_antidepressant </e12> when <e20> cimetidine </e20> therapy is initiated.
effect	Tolazamide : A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on <e10> tolazamide </e10> (1 gm/day) # days after the addition of <e20> doxepin </e20> (75 mg/day).
effect	The concurrent use of <e10> tetracycline </e10> and <e21> Penthrane </e21> ( methoxyflurane ) has been reported to result in fatal renal toxicity.
effect	The concurrent use of <e10> tetracycline </e10> and Penthrane ( <e20> methoxyflurane </e20> ) has been reported to result in fatal renal toxicity.
effect	Concurrent use of <e10> tetracycline </e10> may render oral <e22> contraceptives </e22> less effective.
effect	Potential drug interactions for doxylamine include, increased sedation if <e10> doxylamine </e10> is combined with other <e22> CNS_depressant_drugs </e22> .
effect	<e10> Antihistamines </e10> may partially counteract the anticoagulation effects of <e20> heparin </e20> or warfarin .
effect	<e10> Antihistamines </e10> may partially counteract the anticoagulation effects of heparin or <e20> warfarin </e20> .
effect	<e10> Doxylamine </e10> may enhance the effects of <e20> epinephrine </e20> .
effect	In diabetic patients, the metabolic effects of <e12> androgens </e12> may decrease blood glucose and therefore, <e20> insulin </e20> requirements.
effect	Other <e12> CNS_depressant_drugs </e12> (e,g, barbiturates , tranquilizers , opioids and general anesthetics ) have additive or potentiating effects with <e21> INAPSINE </e21> .
effect	Other CNS_depressant_drugs (e,g, <e12> barbiturates </e12> , tranquilizers , opioids and general anesthetics ) have additive or potentiating effects with <e21> INAPSINE </e21> .
effect	Other CNS_depressant_drugs (e,g, barbiturates , <e12> tranquilizers </e12> , opioids and general anesthetics ) have additive or potentiating effects with <e21> INAPSINE </e21> .
effect	Other CNS_depressant_drugs (e,g, barbiturates , tranquilizers , <e12> opioids </e12> and general anesthetics ) have additive or potentiating effects with <e21> INAPSINE </e21> .
effect	Other CNS_depressant_drugs (e,g, barbiturates , tranquilizers , opioids and general <e12> anesthetics </e12> ) have additive or potentiating effects with <e21> INAPSINE </e21> .
effect	Synergism between <e12> xanthine_bronchodilators </e12> (e,g,, theophylline ), ephedrine , and other <e22> sympathomimetic_bronchodilators </e22> has been reported.
effect	Synergism between xanthine_bronchodilators (e,g,, <e10> theophylline </e10> ), ephedrine , and other <e22> sympathomimetic_bronchodilators </e22> has been reported.
effect	Synergism between xanthine_bronchodilators (e,g,, theophylline ), <e10> ephedrine </e10> , and other <e22> sympathomimetic_bronchodilators </e22> has been reported.
effect	<e10> Phospholine_Iodide </e10> potentiates other <e22> cholinesterase_inhibitors </e22> such as succinylcholine or organophosphate_insecticide and carbamate_insecticide .
effect	<e10> Phospholine_Iodide </e10> potentiates other cholinesterase_inhibitors such as <e20> succinylcholine </e20> or organophosphate_insecticide and carbamate_insecticide .
effect	<e10> Phospholine_Iodide </e10> potentiates other cholinesterase_inhibitors such as succinylcholine or <e23> organophosphate_insecticide </e23> and carbamate_insecticide .
effect	<e10> Phospholine_Iodide </e10> potentiates other cholinesterase_inhibitors such as succinylcholine or organophosphate_insecticide and <e23> carbamate_insecticide </e23> .
effect	<e12> Steroids </e12> enhance the renal toxicity of <e20> edetate_calcium_disodium </e20> in animals, # Edetate_calcium_disodium interferes with the action of zinc_insulin preparations by chelating the zinc , 7
effect	In uninfected volunteers, 46% developed rash while receiving <e11> SUSTIVA </e11> and <e20> clarithromycin </e20> .
effect	Hypotension: Patients on Diuretic Therapy: Patients on <e12> diuretics </e12> and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with <e20> enalapril </e20> or enalaprilat .
effect	Hypotension: Patients on Diuretic Therapy: Patients on <e12> diuretics </e12> and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or <e20> enalaprilat </e20> .
effect	The possibility of hypotensive effects with <e10> enalapril </e10> or enalaprilat can be minimized by either discontinuing the <e22> diuretic </e22> or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat .
effect	The possibility of hypotensive effects with enalapril or <e10> enalaprilat </e10> can be minimized by either discontinuing the <e22> diuretic </e22> or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat .
effect	Agents Causing Renin Release: The antihypertensive effect of <e10> enalapril </e10> and enalapril IV is augmented by <e22> antihypertensive_agents </e22> that cause renin release (e,g,, diuretics ).
effect	Agents Causing Renin Release: The antihypertensive effect of <e10> enalapril </e10> and enalapril IV is augmented by antihypertensive_agents that cause renin release (e,g,, <e22> diuretics </e22> ).
effect	Agents Causing Renin Release: The antihypertensive effect of enalapril and <e10> enalapril </e10> IV is augmented by <e22> antihypertensive_agents </e22> that cause renin release (e,g,, diuretics ).
effect	Agents Causing Renin Release: The antihypertensive effect of enalapril and <e10> enalapril </e10> IV is augmented by antihypertensive_agents that cause renin release (e,g,, <e22> diuretics </e22> ).
effect	Non-steroidal_Anti-inflammatory_Agents : In some patients with compromised renal function who are being treated with <e12> nonsteroidal_anti-inflammatory_drugs </e12> , the co-administration of <e20> enalapril </e20> may result in a further deterioration of renal function.
effect	However, reports suggest that <e12> NSAIDs </e12> may diminish the antihypertensive effect of <e22> ACE_inhibitors </e22> .
effect	Agents Increasing Serum Potassium: <e10> Enalapril </e10> and enalapril IV attenuate potassium loss caused by <e22> thiazide-type_diuretics </e22> .
effect	Agents Increasing Serum Potassium: Enalapril and <e10> enalapril </e10> IV attenuate potassium loss caused by <e22> thiazide-type_diuretics </e22> .
effect	Lithium : Lithium toxicity has been reported in patients receiving <e10> lithium </e10> concomitantly with drugs which cause elimination of sodium, including <e22> ACE_inhibitors </e22> .
effect	Caffeine -related adverse effects have occurred in patients consuming <e10> caffeine </e10> while on therapy with <e20> enoxacin </e20> .
effect	If signs and symptoms suggestive of digoxin toxicity occur when <e10> enoxacin </e10> and <e20> digoxin </e20> are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.
effect	Non-steroidal_anti-inflammatory_agents : Seizures have been reported in patients taking <e10> enoxacin </e10> concomitantly with the nonsteroidal_anti-inflammatory_drug <e20> fenbufen </e20> .
effect	Theophylline -related adverse effects have occurred in patients when <e10> theophylline </e10> and <e20> enoxacin </e20> were coadministered.
effect	Administration of <e10> epinephrine </e10> to patients receiving <e20> cyclopropane </e20> or halogenated_hydrocarbon_general_anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia,.
effect	Administration of <e10> epinephrine </e10> to patients receiving cyclopropane or <e22> halogenated_hydrocarbon_general_anesthetics </e22> such as halothane which sensitize the myocardium, may induce cardiac arrhythmia,.
effect	Administration of <e10> epinephrine </e10> to patients receiving cyclopropane or halogenated_hydrocarbon_general_anesthetics such as <e20> halothane </e20> which sensitize the myocardium, may induce cardiac arrhythmia,.
effect	<e12> Diuretic_agents </e12> may decrease vascular response to pressor drugs such as <e20> epinephrine </e20> .
effect	<e10> Epinephrine </e10> may antagonize the neuron blockade produced by <e20> guanethidine </e20> resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
effect	ACE_Inhibitors and Angiotensin_II_Receptor_Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of <e11> INSPRA </e11> # to # mg to <e22> ACE_inhibitors </e22> and angiotensin_II_receptor_antagonists increased mean serum potassium slightly (about ## mEq/L).
effect	ACE_Inhibitors and Angiotensin_II_Receptor_Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of <e11> INSPRA </e11> # to # mg to ACE_inhibitors and <e22> angiotensin_II_receptor_antagonists </e22> increased mean serum potassium slightly (about ## mEq/L).
effect	In a study in diabetics with microalbuminuria <e11> INSPRA </e11> # mg combined with the ACE_inhibitor <e20> enalapril </e20> # mg increased the frequency of hyperkalemia (serum potassium # mEq/L) from 17% on enalapril alone to 38%.
effect	The administration of other <e12> potassium-sparing_antihypertensives </e12> with <e22> NSAIDs </e22> has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.
effect	Additional reductions in blood pressure may occur when <e11> FLOLAN </e11> is administered with <e22> diuretics </e22> , antihypertensive_agents , or other vasodilators .
effect	Additional reductions in blood pressure may occur when <e11> FLOLAN </e11> is administered with diuretics , <e22> antihypertensive_agents </e22> , or other vasodilators .
effect	Additional reductions in blood pressure may occur when <e11> FLOLAN </e11> is administered with diuretics , antihypertensive_agents , or other <e22> vasodilators </e22> .
effect	When other <e12> antiplatelet_agents </e12> or anticoagulants are used concomitantly, there is the potential for <e21> FLOLAN </e21> to increase the risk of bleeding.
effect	When other antiplatelet_agents or <e12> anticoagulants </e12> are used concomitantly, there is the potential for <e21> FLOLAN </e21> to increase the risk of bleeding.
effect	Administration of <e12> thiazide_diuretics </e12> to hypoparathyroid patients who are concurrently being treated with <e20> ergocalciferol </e20> may cause hypercalcemia.
effect	The pressor effects of <e11> ERGOMAR </e11> and other <e22> vasoconstrictor_drugs </e22> can combine to cause dangerous hypertension.
effect	<e10> Erythromycin </e10> use in patients who are receiving high doses of <e20> theophylline </e20> may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
effect	There have been reports of increased anticoagulant effects when <e10> erythromycin </e10> and oral <e22> anticoagulants </e22> were used concomitantly.
effect	<e10> Erythromycin </e10> has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these <e22> benzodiazepines </e22> .
effect	In addition, deaths have been reported rarely with concomitant administration of <e10> terfenadine </e10> and <e20> erythromycin </e20> .
effect	There have been postmarketing reports of drug interactions when <e10> erythromycin </e10> is coadministered with <e20> cisapride </e20> , resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin .
effect	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of <e12> psychotropic_drugs </e12> that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an <e22> NSAID </e22> or aspirin potentiated the risk of bleeding.
effect	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of <e12> psychotropic_drugs </e12> that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or <e21> aspirin </e21> potentiated the risk of bleeding.
effect	Because <e10> lithium </e10> may enhance the serotonergic effects of <e20> escitalopram </e20> , caution should be exercised when LEXAPRO and lithium are coadministered.
effect	Pimozide and Celexa - In a controlled study, a single dose of <e10> pimozide </e10> # mg co-administered with racemic <e20> citalopram </e20> # mg given once daily for # days was associated with a mean increase in QTc values of approximately # msec compared to pimozide given alone.
effect	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a <e12> selective_serotonin_reuptake_inhibitor </e12> ( SSRI ) and <e20> sumatriptan </e20> .
effect	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective_serotonin_reuptake_inhibitor ( <e12> SSRI </e12> ) and <e20> sumatriptan </e20> .
effect	Catecholamine-depleting drugs, e,g,, <e10> reserpine </e10> , may have an additive effect when given with <e22> beta_blocking_agents </e22> .
effect	The onset of neuromuscular blockade by <e10> succinylcholine </e10> was unaffected by <e21> BREVIBLOC </e21> , but the duration of neuromuscular blockade was prolonged from # minutes to # minutes.
effect	Patients treated with <e12> proton_pump_inhibitors </e12> and <e20> warfarin </e20> concomitantly may need to be monitored for increases in INR and prothrombin time.
effect	The action of the <e12> benzodiazepines </e12> may be potentiated by <e22> anticonvulsants </e22> , antihistamines , alcohol , barbiturates , monoamine_oxidase_inhibitors , narcotics , phenothiazines , psychotropic_medications , or other drugs that produce CNS depression.
effect	The action of the <e12> benzodiazepines </e12> may be potentiated by anticonvulsants , <e22> antihistamines </e22> , alcohol , barbiturates , monoamine_oxidase_inhibitors , narcotics , phenothiazines , psychotropic_medications , or other drugs that produce CNS depression.
effect	The action of the <e12> benzodiazepines </e12> may be potentiated by anticonvulsants , antihistamines , <e20> alcohol </e20> , barbiturates , monoamine_oxidase_inhibitors , narcotics , phenothiazines , psychotropic_medications , or other drugs that produce CNS depression.
effect	The action of the <e12> benzodiazepines </e12> may be potentiated by anticonvulsants , antihistamines , alcohol , <e22> barbiturates </e22> , monoamine_oxidase_inhibitors , narcotics , phenothiazines , psychotropic_medications , or other drugs that produce CNS depression.
effect	The action of the <e12> benzodiazepines </e12> may be potentiated by anticonvulsants , antihistamines , alcohol , barbiturates , <e22> monoamine_oxidase_inhibitors </e22> , narcotics , phenothiazines , psychotropic_medications , or other drugs that produce CNS depression.
effect	The action of the <e12> benzodiazepines </e12> may be potentiated by anticonvulsants , antihistamines , alcohol , barbiturates , monoamine_oxidase_inhibitors , <e22> narcotics </e22> , phenothiazines , psychotropic_medications , or other drugs that produce CNS depression.
effect	The action of the <e12> benzodiazepines </e12> may be potentiated by anticonvulsants , antihistamines , alcohol , barbiturates , monoamine_oxidase_inhibitors , narcotics , <e22> phenothiazines </e22> , psychotropic_medications , or other drugs that produce CNS depression.
effect	The action of the <e12> benzodiazepines </e12> may be potentiated by anticonvulsants , antihistamines , alcohol , barbiturates , monoamine_oxidase_inhibitors , narcotics , phenothiazines , <e22> psychotropic_medications </e22> , or other drugs that produce CNS depression.
effect	CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of <e10> eszopiclone </e10> and <e20> ethanol </e20> # g/kg for up to # hours after ethanol administration.
effect	Olanzapine : Coadministration of <e10> eszopiclone </e10> # mg and <e20> olanzapine </e20> # mg produced a decrease in DSST scores.
effect	In a study in which patients with active RA were treated for up to # weeks with concurrent <e11> ENBREL </e11> and <e20> anakinra </e20> therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL alone (0%).
effect	Two percent of patients treated concurrently with <e11> ENBREL </e11> and <e20> anakinra </e20> developed neutropenia (ANC # x 109/L).
effect	Patients in a clinical study who were on established therapy with <e10> sulfasalazine </e10> , to which <e21> ENBREL </e21> was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.
effect	<e11> EDECRIN </e11> may increase the ototoxic potential of other drugs such as <e22> aminoglycoside </e22> and some cephalosporin_antibiotics .
effect	<e11> EDECRIN </e11> may increase the ototoxic potential of other drugs such as aminoglycoside and some <e22> cephalosporin_antibiotics </e22> .
effect	In some patients, the administration of a <e12> non-_steroidal_antiinflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of <e22> loop_diuretics </e22> , potassium-_sparing_diuretics and thiazide_diuretics .
effect	In some patients, the administration of a <e12> non-_steroidal_antiinflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , <e22> potassium-_sparing_diuretics </e22> and thiazide_diuretics .
effect	In some patients, the administration of a <e12> non-_steroidal_antiinflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-_sparing_diuretics and <e22> thiazide_diuretics </e22> .
effect	Therefore, when <e11> EDECRIN </e11> and <e22> non-_steroidal_anti-_inflammatory_agents </e22> are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
effect	Other depressasnts such as <e10> alcohol </e10> , barbiturates , and MAOIs may enhance CNS depression when administered with <e20> ethchlorvynol </e20> .
effect	Other depressasnts such as alcohol , <e12> barbiturates </e12> , and MAOIs may enhance CNS depression when administered with <e20> ethchlorvynol </e20> .
effect	Other depressasnts such as alcohol , barbiturates , and <e12> MAOIs </e12> may enhance CNS depression when administered with <e20> ethchlorvynol </e20> .
effect	<e11> Trecator </e11> may potentiate the adverse effects of other <e22> antituberculous_drugs </e22> administered concomitantly.
effect	In particular, convulsions have been reported when <e10> ethionamide </e10> is administered with <e20> cycloserine </e20> and special care should be taken when the treatment regimen includes both of these drugs.
effect	<e10> Ethopropazine </e10> may interact with <e20> alcohol </e20> or other CNS_depressants , causing increased sedative effects.
effect	<e10> Ethopropazine </e10> may interact with alcohol or other <e22> CNS_depressants </e22> , causing increased sedative effects.
effect	<e10> Ethoxzolamide </e10> may increase the action of <e22> tricyclics </e22> , amphetamines , procainamide , and quinidine .
effect	<e10> Ethoxzolamide </e10> may increase the action of tricyclics , <e20> amphetamines </e20> , procainamide , and quinidine .
effect	<e10> Ethoxzolamide </e10> may increase the action of tricyclics , amphetamines , <e20> procainamide </e20> , and quinidine .
effect	<e10> Ethoxzolamide </e10> may increase the action of tricyclics , amphetamines , procainamide , and <e20> quinidine </e20> .
effect	Coadministration of <e10> ethoxzolamide </e10> with other <e22> diuretics </e22> , amphotericin_B , and corticosteroids may cause hypokalemia.
effect	Coadministration of <e10> ethoxzolamide </e10> with other diuretics , <e20> amphotericin_B </e20> , and corticosteroids may cause hypokalemia.
effect	Coadministration of <e10> ethoxzolamide </e10> with other diuretics , amphotericin_B , and <e22> corticosteroids </e22> may cause hypokalemia.
effect	<e10> Acitretin </e10> : Interferes with the contraceptive effect of microdosed <e22> progestin </e22> -containing minipill preparations.
effect	Anticoagulants : Combination <e12> hormonal_contraceptives </e12> may increase or decrease the effects of <e22> coumarin_derivatives </e22> .
effect	ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if <e12> combination_hormonal_contraceptives </e12> are used concurrently with <e20> caffeine </e20> .
effect	There have been isolated reports of patients experiencing increases in their prothrombin times when <e10> etidronate </e10> was added to <e20> warfarin </e20> therapy.
effect	ACE-inhibitors Reports suggest that <e12> NSAIDs </e12> may diminish the antihypertensive effect of <e22> ACE-inhibitors </e22> .
effect	Nevertheless, clinical studies, as well as postmarketing observations have shown that <e11> Lodine </e11> can reduce the natriuretic effect of <e20> furosemide </e20> and thiazides in some patients.
effect	Nevertheless, clinical studies, as well as postmarketing observations have shown that <e11> Lodine </e11> can reduce the natriuretic effect of furosemide and <e22> thiazides </e22> in some patients.
effect	Thus, when <e12> NSAIDs </e12> and <e20> lithium </e20> are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
effect	Warfarin : The effects of <e10> warfarin </e10> and <e22> NSAIDs </e22> on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.
effect	However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in <e10> etodolac </e10> -treated patients receiving concomitant <e20> warfarin </e20> therapy.
effect	<e10> Fenfluramine </e10> may increase slightly the effect of <e22> antihypertensive_drugs </e22> , e,g,, guanethidine , methyldopa , reserpine .
effect	<e10> Fenfluramine </e10> may increase slightly the effect of antihypertensive_drugs , e,g,, <e20> guanethidine </e20> , methyldopa , reserpine .
effect	<e10> Fenfluramine </e10> may increase slightly the effect of antihypertensive_drugs , e,g,, guanethidine , <e20> methyldopa </e20> , reserpine .
effect	<e10> Fenfluramine </e10> may increase slightly the effect of antihypertensive_drugs , e,g,, guanethidine , methyldopa , <e20> reserpine </e20> .
effect	Cyclosporine : Because <e10> cyclosporine </e10> can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of <e22> fibrate_drugs </e22> including TRICOR , there is a risk that an interaction will lead to deterioration.
effect	Cyclosporine : Because <e10> cyclosporine </e10> can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate_drugs including <e21> TRICOR </e21> , there is a risk that an interaction will lead to deterioration.
effect	In patients receiving <e12> coumarin-type_anticoagulants </e12> , the addition of <e21> Nalfon </e21> to therapy could prolong the prothrombin time.
effect	Patients treated with <e11> Nalfon </e11> may be resistant to the effects of <e22> loop_diuretics </e22> .
effect	Central_Nervous_System_Depressants : The concomitant use of <e11> DURAGESIC </e11> ( fentanyl transdermal system) with other <e22> central_nervous_system_depressants </e22> , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of <e11> DURAGESIC </e11> ( fentanyl transdermal system) with other central_nervous_system_depressants , including but not limited to other <e22> opioids </e22> , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of <e11> DURAGESIC </e11> ( fentanyl transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , <e22> sedatives </e22> , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of <e11> DURAGESIC </e11> ( fentanyl transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , <e22> hypnotics </e22> , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of <e11> DURAGESIC </e11> ( fentanyl transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , <e22> tranquilizers </e22> (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of <e11> DURAGESIC </e11> ( fentanyl transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, <e22> benzodiazepines </e22> ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of <e11> DURAGESIC </e11> ( fentanyl transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general <e22> anesthetics </e22> , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of <e11> DURAGESIC </e11> ( fentanyl transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , <e22> phenothiazines </e22> , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of <e11> DURAGESIC </e11> ( fentanyl transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , <e22> skeletal_muscle_relaxants </e22> , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of <e11> DURAGESIC </e11> ( fentanyl transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and <e20> alcohol </e20> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of DURAGESIC ( <e10> fentanyl </e10> transdermal system) with other <e22> central_nervous_system_depressants </e22> , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of DURAGESIC ( <e10> fentanyl </e10> transdermal system) with other central_nervous_system_depressants , including but not limited to other <e22> opioids </e22> , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of DURAGESIC ( <e10> fentanyl </e10> transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , <e22> sedatives </e22> , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of DURAGESIC ( <e10> fentanyl </e10> transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , <e22> hypnotics </e22> , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of DURAGESIC ( <e10> fentanyl </e10> transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , <e22> tranquilizers </e22> (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of DURAGESIC ( <e10> fentanyl </e10> transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, <e22> benzodiazepines </e22> ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of DURAGESIC ( <e10> fentanyl </e10> transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general <e22> anesthetics </e22> , phenothiazines , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of DURAGESIC ( <e10> fentanyl </e10> transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , <e22> phenothiazines </e22> , skeletal_muscle_relaxants , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of DURAGESIC ( <e10> fentanyl </e10> transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , <e22> skeletal_muscle_relaxants </e22> , and alcohol , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central_Nervous_System_Depressants : The concomitant use of DURAGESIC ( <e10> fentanyl </e10> transdermal system) with other central_nervous_system_depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers (e,g,, benzodiazepines ), general anesthetics , phenothiazines , skeletal_muscle_relaxants , and <e20> alcohol </e20> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	The effects of concomitant administration of <e11> TAMBOCOR </e11> and <e20> propranolol </e20> on the PR interval were less than additive.
effect	Nevertheless, the possibility of additive negative inotropic effects of <e12> beta_blockers </e12> and <e20> flecainide </e20> should be recognized.
effect	<e10> Cytosine_arabinoside </e10> , a cytostatic_agent , has been reported to inactivate the antifungal activity of <e20> flucytosine </e20> by competitive inhibition.
effect	Rarely salicylate toxicity may occur in patients who discontinue <e12> steroids </e12> after concurrent high-dose <e21> aspirin </e21> therapy.
effect	Particular caution is necessary when using <e11> ROMAZICON </e11> in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially <e22> cyclic_antidepressants </e22> ) may emerge with the reversal of the benzodiazepine effect by flumazenil .
effect	The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as <e10> zopiclone </e10> , triazolopyridazines and others, are also blocked by <e21> ROMAZICON </e21> .
effect	In diabetic patients, the metabolic effects of <e12> androgens </e12> may decrease blood glucose and therefore, <e20> insulin </e20> requirements.
effect	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine_oxidase_inhibitors ( MAOI ): <e12> MAOI </e12> could theoretically affect <e20> flupenthixol </e20> pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic_antidepressants : Flupenthixol increases the effect of Tricyclic_antidepressants
effect	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine_oxidase_inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : <e10> Flupenthixol </e10> and <e20> Ethanol </e20> cause additive CNS depression - Tricyclic_antidepressants : Flupenthixol increases the effect of Tricyclic_antidepressants
effect	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine_oxidase_inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic_antidepressants : <e10> Flupenthixol </e10> increases the effect of <e22> Tricyclic_antidepressants </e22>
effect	Anticoagulants : <e10> Flurbiprofen </e10> like other nonsteroidal_anti-inflammatory_drugs , has been shown to affect bleeding parameters in patients receiving <e22> anti-coagulants </e22> , and serious clinical bleeding has been reported.
effect	Anticoagulants : Flurbiprofen like other <e12> nonsteroidal_anti-inflammatory_drugs </e12> , has been shown to affect bleeding parameters in patients receiving <e22> anti-coagulants </e22> , and serious clinical bleeding has been reported.
effect	<e10> Flurbiprofen </e10> pretreatment attenuated the hypotensive effect of a single dose of <e20> propranolol </e20> but not atenolol .
effect	Diuretics : Studies in normal volunteers have shown that <e10> flurbiprofen </e10> like other nonsteroidal_anti-inflammatory_drugs , can interfere with the effects of <e20> furosemide </e20> .
effect	Diuretics : Studies in normal volunteers have shown that flurbiprofen like other <e12> nonsteroidal_anti-inflammatory_drugs </e12> , can interfere with the effects of <e20> furosemide </e20> .
effect	Other <e12> nonsteroidal_anti-inflammatory_drugs </e12> that inhibit prostaglandin synthesis have been shown to interfere with <e22> thiazide_diuretics </e22> in some studies and with potassium-sparing_diuretics .
effect	Other <e12> nonsteroidal_anti-inflammatory_drugs </e12> that inhibit prostaglandin synthesis have been shown to interfere with thiazide_diuretics in some studies and with <e22> potassium-sparing_diuretics </e22> .
effect	Although there was a slight reduction in blood sugar concentrations during concomitant administration of <e10> flurbiprofen </e10> and <e22> hypoglycemic_agents </e22> , there were no signs or symptoms of hypoglycemia.
effect	Increases in prothrombin time have been noted in patients receiving long- term <e10> warfarin </e10> therapy after <e20> flutamide </e20> was initiated.
effect	In patients receiving another <e12> serotonin_reuptake_inhibitor_drug </e12> in combination with <e22> monoamine_oxidase_inhibitors </e22> ( MAOI ), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
effect	In patients receiving another <e12> serotonin_reuptake_inhibitor_drug </e12> in combination with monoamine_oxidase_inhibitors ( <e22> MAOI </e22> ), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
effect	Moreover, as noted with <e10> alprazolam </e10> , the effect of <e20> fluvoxamine </e20> may even be more pronounced when it is administered at higher doses.
effect	Concomitant administration of other <e12> sympathomimetic_agents </e12> may potentiate the undesirable effects of <e21> FORADIL </e21> .
effect	Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with <e12> xanthine_derivatives </e12> , steroids , or diuretics may potentiate a possible hypokalemic effect of <e22> beta2-agonists, </e22>
effect	Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , <e12> steroids </e12> , or diuretics may potentiate a possible hypokalemic effect of <e22> beta2-agonists, </e22>
effect	Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine_derivatives , steroids , or <e12> diuretics </e12> may potentiate a possible hypokalemic effect of <e22> beta2-agonists, </e22>
effect	Concomitant treatment of four patients in the United Kingdom with <e11> FOSCAVIR </e11> and intravenous <e20> pentamidine </e20> may have caused hypocalcemia;
effect	Diuretics : Patients on <e12> diuretics </e12> , especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with <e20> fosinopril_sodium </e20> .
effect	The possibility of hypotensive effects can be minimized by either discontinuing the <e12> diuretic </e12> or increasing salt intake prior to initiation of treatment with <e20> fosinopril_sodium </e20> .
effect	Potassium Supplements and Potassium-Sparing_Diuretics : <e10> Fosinopril_sodium </e10> can attenuate potassium loss caused by <e22> thiazide_diuretics </e22> .
effect	Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <e12> ACE_inhibitors </e12> during therapy with <e20> lithium </e20> .
effect	Similarly, the effects of <e10> phenytoin </e10> on <e20> phenobarbital </e20> , valproic_acid and sodium plasma valproate concentrations are unpredictable
effect	Similarly, the effects of <e10> phenytoin </e10> on phenobarbital , <e20> valproic_acid </e20> and sodium plasma valproate concentrations are unpredictable
effect	Similarly, the effects of <e10> phenytoin </e10> on phenobarbital , valproic_acid and sodium plasma <e20> valproate </e20> concentrations are unpredictable
effect	- Although not a true drug interaction, <e12> tricyclic_antidepressants </e12> may precipitate seizures in susceptible patients and <e21> Cerebyx </e21> dosage may need to be adjusted
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: <e22> anticoagulants </e22> , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D .
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: anticoagulants , <e22> corticosteroids </e22> , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D .
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: anticoagulants , corticosteroids , <e22> coumarin </e22> , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D .
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: anticoagulants , corticosteroids , coumarin , <e20> digitoxin </e20> , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D .
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: anticoagulants , corticosteroids , coumarin , digitoxin , <e20> doxycycline </e20> , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D .
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , <e22> estrogens </e22> , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D .
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , <e20> furosemide </e20> , oral contraceptives , rifampin , quinidine , theophylline , vitamin_D .
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral <e22> contraceptives </e22> , rifampin , quinidine , theophylline , vitamin_D .
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , <e20> rifampin </e20> , quinidine , theophylline , vitamin_D .
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , <e20> quinidine </e20> , theophylline , vitamin_D .
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , <e20> theophylline </e20> , vitamin_D .
effect	- Drugs whose efficacy is impaired by <e10> phenytoin </e10> include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , <e22> vitamin_D </e22> .
effect	<e12> Selective_serotonin_reuptake_inhibitors </e12> ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e22> 5-HT1_agonists </e22> .
effect	Selective_serotonin_reuptake_inhibitors ( <e12> SSRIs </e12> ) (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e22> 5-HT1_agonists </e22> .
effect	Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, <e10> fluoxetine </e10> , fluvoxamine , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e22> 5-HT1_agonists </e22> .
effect	Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , <e10> fluvoxamine </e10> , paroxetine , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e22> 5-HT1_agonists </e22> .
effect	Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , <e10> paroxetine </e10> , sertraline ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e22> 5-HT1_agonists </e22> .
effect	Selective_serotonin_reuptake_inhibitors ( SSRIs ) (e,g,, fluoxetine , fluvoxamine , paroxetine , <e10> sertraline </e10> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e22> 5-HT1_agonists </e22> .
effect	<e10> Furosemide </e10> may increase the ototoxic potential of <e22> aminoglycoside_antibiotics </e22> , especially in the presence of impaired renal function.
effect	Patients receiving high doses of <e12> salicylates </e12> concomitantly with <e20> furosemide </e20> , as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
effect	<e10> Furosemide </e10> has a tendency to antagonize the skeletal muscle relaxing effect of <e20> tubocurarine </e20> and may potentiate the action of succinylcholine .
effect	<e10> Furosemide </e10> has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of <e20> succinylcholine </e20> .
effect	<e10> Furosemide </e10> may add to or potentiate the therapeutic effect of other <e22> antihypertensive_drugs </e22> .
effect	<e10> Furosemide </e10> may decrease arterial responsiveness to <e20> norepinephrine </e20> .
effect	Tablets Simultaneous administration of <e10> sucralfate </e10> and <e20> furosemide </e20> tablets may reduce the natriuretic and antihypertensive effects of furosemide .
effect	Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of <e10> furosemide </e10> and <e20> acetylsalicylic_acid </e20> temporarily reduced creatinine clearance in patients with chronic renal insufficiency.
effect	There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when <e10> furosemide </e10> was used in conjunction with <e22> NSAIDs </e22> .
effect	Literature reports indicate that coadministration of <e10> indomethacin </e10> may reduce the natriuretic and antihypertensive effects of <e20> furosemide </e20> in some patients by inhibiting prostaglandin synthesis.
effect	International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking <e10> warfarin </e10> while on <e21> IRESSA </e21> therapy.
effect	Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that <e11> IRESSA </e11> may exacerbate the neutropenic effect of <e20> vinorelbine </e20> .
effect	However, because some <e12> quinolones </e12> have been reported to enhance the anticoagulant effects of <e20> warfarin </e20> or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone_antimicrobial is administered concomitantly with warfarin or its derivatives.
effect	The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including <e22> nonsteroidal_anti-inflammatory_agents </e22> and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, <e22> salicylates </e22> , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , <e22> sulfonamides </e22> , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , <e20> chloramphenicol </e20> , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , <e20> probenecid </e20> , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , <e22> coumarins </e22> , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , <e22> monoamine_oxidase_inhibitors </e22> , and beta_adrenergic_blocking_agents .
effect	The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and <e22> beta_adrenergic_blocking_agents </e22> .
effect	A potential interaction between oral <e10> miconazole </e10> and oral <e22> hypoglycemic_agents </e22> leading to severe hypoglycemia has been reported.
effect	Immediate and Extended Release Tablets The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including <e22> nonsteroidal_anti-inflammatory_agents </e22> , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	Immediate and Extended Release Tablets The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some <e22> azoles </e22> and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	Immediate and Extended Release Tablets The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, <e22> salicylates </e22> , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	Immediate and Extended Release Tablets The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , <e22> sulfonamides </e22> , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	Immediate and Extended Release Tablets The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , <e20> chloramphenicol </e20> , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	Immediate and Extended Release Tablets The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , <e20> probenecid </e20> , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	Immediate and Extended Release Tablets The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , <e22> coumarins </e22> , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents .
effect	Immediate and Extended Release Tablets The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , <e22> monoamine_oxidase_inhibitors </e22> , and beta_adrenergic_blocking_agents .
effect	Immediate and Extended Release Tablets The hypoglycemic action of <e12> sulfonylureas </e12> may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents , some azoles and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and <e22> beta_adrenergic_blocking_agents </e22> .
effect	The concurrent use of <e11> Robinul </e11> Injection with other <e22> anticholinergics </e22> or medications with anticholinergic activity, such as phenothiazines , antiparkinson_drugs , or tricyclic_antidepressants , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
effect	The concurrent use of <e11> Robinul </e11> Injection with other anticholinergics or medications with anticholinergic activity, such as <e22> phenothiazines </e22> , antiparkinson_drugs , or tricyclic_antidepressants , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
effect	The concurrent use of <e11> Robinul </e11> Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines , <e22> antiparkinson_drugs </e22> , or tricyclic_antidepressants , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
effect	The concurrent use of <e11> Robinul </e11> Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines , antiparkinson_drugs , or <e22> tricyclic_antidepressants </e22> , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
effect	The response to <e11> Factrel </e11> may be blunted by <e22> phenothiazines </e22> and dopamine_antagonists which cause a rise in prolactin.
effect	The response to <e11> Factrel </e11> may be blunted by phenothiazines and <e22> dopamine_antagonists </e22> which cause a rise in prolactin.
effect	However, because some <e12> quinolones </e12> have been reported to enhance the effects of <e20> warfarin </e20> or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone_antimicrobial is administered with warfarin or its derivatives.
effect	Nonsteroidal_Anti-inflammatory_Drugs ( NSAIDs ): The concomitant administration of a <e12> nonsteroidal_anti_inflammatory_drug </e12> with a <e22> quinolone </e22> may increase the risks of CNS stimulation and convulsions.
effect	Antidiabetic_Agents : Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with <e12> quinolones </e12> and an <e22> antidiabetic_agent </e22> .
effect	Concomitant use of <e12> barbiturates </e12> usually depresses <e20> griseofulvin </e20> activity and may necessitate raising the dosage.
effect	The concomitant administration of <e10> griseofulvin </e10> has been reported to reduce the efficacy of oral <e22> contraceptives </e22> and to increase the incidence of breakthrough bleeding.
effect	The use of <e10> codeine </e10> may result in additive CNS depressant effects when coadministered with <e20> alcohol </e20> , antihistamines , psychotropics or other drugs that produce CNS depression.
effect	The use of <e10> codeine </e10> may result in additive CNS depressant effects when coadministered with alcohol , <e22> antihistamines </e22> , psychotropics or other drugs that produce CNS depression.
effect	The use of <e10> codeine </e10> may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , <e22> psychotropics </e22> or other drugs that produce CNS depression.
effect	Serious toxicity may result if <e10> dextromethorphan </e10> is coadministered with <e22> monoamine_oxidase_inhibitors </e22> ( MAOIs ).
effect	Serious toxicity may result if <e10> dextromethorphan </e10> is coadministered with monoamine_oxidase_inhibitors ( <e22> MAOIs </e22> ).
effect	The use of <e10> dextromethorphan_hydrobromide </e10> may result in additive CNS depressant effects when coadministered with <e20> alcohol </e20> , antihistamines , psychotropics or other drugs that produce CNS depression.
effect	The use of <e10> dextromethorphan_hydrobromide </e10> may result in additive CNS depressant effects when coadministered with alcohol , <e22> antihistamines </e22> , psychotropics or other drugs that produce CNS depression.
effect	The use of <e10> dextromethorphan_hydrobromide </e10> may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , <e22> psychotropics </e22> or other drugs that produce CNS depression.
effect	The potential for increased sedation when <e10> guanfacine </e10> is given with other <e22> CNS-depressant_drug </e22> should be appreciated.
effect	<e12> TCAs </e12> decrease the hypotensive effect of <e20> guanfacine </e20> .
effect	<e12> Noncardioselective_beta-blockers </e12> ( nadolol ,porpranolol, timolol ) may exacerbate rebound hypertension when <e20> guanfacine </e20> is withdrawn.
effect	Noncardioselective_beta-blockers ( <e10> nadolol </e10> ,porpranolol, timolol ) may exacerbate rebound hypertension when <e20> guanfacine </e20> is withdrawn.
effect	Noncardioselective_beta-blockers ( nadolol ,porpranolol, <e10> timolol </e10> ) may exacerbate rebound hypertension when <e20> guanfacine </e20> is withdrawn.
effect	An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with <e10> lithium </e10> plus <e21> HALDOL </e21> .
effect	As with other <e12> antipsychotic_agents </e12> , it should be noted that HALDOL may be capable of potentiating <e22> CNS_depressants </e22> such as anesthetics , opiates , and alcohol .
effect	As with other <e12> antipsychotic_agents </e12> , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as <e22> anesthetics </e22> , opiates , and alcohol .
effect	As with other <e12> antipsychotic_agents </e12> , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , <e22> opiates </e22> , and alcohol .
effect	As with other <e12> antipsychotic_agents </e12> , it should be noted that HALDOL may be capable of potentiating CNS_depressants such as anesthetics , opiates , and <e20> alcohol </e20> .
effect	As with other antipsychotic_agents , it should be noted that <e11> HALDOL </e11> may be capable of potentiating <e22> CNS_depressants </e22> such as anesthetics , opiates , and alcohol .
effect	As with other antipsychotic_agents , it should be noted that <e11> HALDOL </e11> may be capable of potentiating CNS_depressants such as <e22> anesthetics </e22> , opiates , and alcohol .
effect	As with other antipsychotic_agents , it should be noted that <e11> HALDOL </e11> may be capable of potentiating CNS_depressants such as anesthetics , <e22> opiates </e22> , and alcohol .
effect	As with other antipsychotic_agents , it should be noted that <e11> HALDOL </e11> may be capable of potentiating CNS_depressants such as anesthetics , opiates , and <e20> alcohol </e20> .
effect	<e11> FLUOTHANE </e11> augments the action of <e22> non-depolarising_muscle_relaxant </e22> s and the muscle relaxant effects of aminoglycosides .
effect	<e11> FLUOTHANE </e11> augments the action of non-depolarising_muscle_relaxant s and the muscle relaxant effects of <e22> aminoglycosides </e22> .
effect	<e11> FLUOTHANE </e11> may augment the hypotension caused by the ganglionic-blocking effect of <e20> tubocurarine </e20> .
effect	Platelet_inhibitors : Drugs such as <e10> acetylsalicylic_acid </e10> , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <e20> heparin_sodium </e20> .
effect	Platelet_inhibitors : Drugs such as acetylsalicylic_acid , <e10> dextran </e10> , phenylbutazone , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <e20> heparin_sodium </e20> .
effect	Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , <e10> phenylbutazone </e10> , ibuprofen , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <e20> heparin_sodium </e20> .
effect	Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , <e10> ibuprofen </e10> , indomethacin , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <e20> heparin_sodium </e20> .
effect	Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , <e10> indomethacin </e10> , dipyridamole , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <e20> heparin_sodium </e20> .
effect	Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , <e10> dipyridamole </e10> , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <e20> heparin_sodium </e20> .
effect	Platelet_inhibitors : Drugs such as acetylsalicylic_acid , dextran , phenylbutazone , ibuprofen , indomethacin , dipyridamole , <e10> hydroxychloroquine </e10> and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <e20> heparin_sodium </e20> .
effect	The anticoagulant effect of <e10> heparin </e10> is enhanced by concurrent treatment with <e20> antithrombin_III </e20> (human) in patients with hereditary antithrombin III deficiency.
effect	Drugs Decreasing Heparin Effect: <e12> Digitalis </e12> , tetracyclines , nicotine , or antihistamines may partially counteract the anticoagulant action of <e20> heparin_sodium </e20> .
effect	Drugs Decreasing Heparin Effect: Digitalis , <e12> tetracyclines </e12> , nicotine , or antihistamines may partially counteract the anticoagulant action of <e20> heparin_sodium </e20> .
effect	Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , <e10> nicotine </e10> , or antihistamines may partially counteract the anticoagulant action of <e20> heparin_sodium </e20> .
effect	Drugs Decreasing Heparin Effect: Digitalis , tetracyclines , nicotine , or <e12> antihistamines </e12> may partially counteract the anticoagulant action of <e20> heparin_sodium </e20> .
effect	In combination with other <e12> central_nervous_system_depressants </e12> , <e23> heroin </e23> may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.
effect	Toxicology studies of <e13> heroin </e13> -related deaths reveal frequent involvement of other <e22> central_nervous_system_depressants </e22> , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone .
effect	Toxicology studies of <e13> heroin </e13> -related deaths reveal frequent involvement of other central_nervous_system_depressants , including <e20> alcohol </e20> , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, methadone .
effect	Toxicology studies of <e13> heroin </e13> -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , <e22> benzodiazepines </e22> such as diazepam ( Valium ), and, to a rising degree, methadone .
effect	Toxicology studies of <e13> heroin </e13> -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as <e20> diazepam </e20> ( Valium ), and, to a rising degree, methadone .
effect	Toxicology studies of <e13> heroin </e13> -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( <e21> Valium </e21> ), and, to a rising degree, methadone .
effect	Toxicology studies of <e13> heroin </e13> -related deaths reveal frequent involvement of other central_nervous_system_depressants , including alcohol , benzodiazepines such as diazepam ( Valium ), and, to a rising degree, <e20> methadone </e20> .
effect	<e10> Cocaine </e10> sometimes proves to be fatal when used in combination with <e23> heroin </e23> .
effect	<e12> Barbiturates </e12> may decrease the effectiveness of oral <e22> contraceptives </e22> , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta_blockers .
effect	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain <e22> antibiotics </e22> , quinidine , theophylline , corticosteroids , anticoagulants , and beta_blockers .
effect	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain antibiotics , <e20> quinidine </e20> , theophylline , corticosteroids , anticoagulants , and beta_blockers .
effect	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , <e20> theophylline </e20> , corticosteroids , anticoagulants , and beta_blockers .
effect	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , <e22> corticosteroids </e22> , anticoagulants , and beta_blockers .
effect	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , <e22> anticoagulants </e22> , and beta_blockers .
effect	<e12> Barbiturates </e12> may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and <e22> beta_blockers </e22> .
effect	When other potent parental <e12> antihypertensive_drugs </e12> , such as <e20> diazoxide </e20> , are used in combination with hydralazine , patients should be continuously observed for several hours for any excessive fall in blood pressure.
effect	When other potent parental <e12> antihypertensive_drugs </e12> , such as diazoxide , are used in combination with <e20> hydralazine </e20> , patients should be continuously observed for several hours for any excessive fall in blood pressure.
effect	Profound hypotensive episodes may occur when <e10> diazoxide </e10> infection and <e20> hydralazine </e20> are used concomitantly.
effect	<e12> NSAIDs </e12> may decrease the hemodynamic effects of <e20> hydralazine </e20> ;
effect	<e12> Diuretic_agents </e12> reduce the renal clearance of lithium and add a high risk of <e20> lithium </e20> toxicity.
effect	Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a <e12> non-steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of <e22> loop_diuretics </e22> , potassium-sparing_diuretics and thiazide_diuretics .
effect	Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a <e12> non-steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , <e22> potassium-sparing_diuretics </e22> and thiazide_diuretics .
effect	Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a <e12> non-steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and <e22> thiazide_diuretics </e22> .
effect	Patients receiving other <e12> narcotic_analgesics </e12> , antipsychotics , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with <e20> hydrocodone </e20> and acetaminophen tablets may exhibit an additive CNS depression.
effect	Patients receiving other narcotic_analgesics , <e12> antipsychotics </e12> , antianxiety_agents , or other CNS_depressants (including alcohol ) concomitantly with <e20> hydrocodone </e20> and acetaminophen tablets may exhibit an additive CNS depression.
effect	Patients receiving other narcotic_analgesics , antipsychotics , <e12> antianxiety_agents </e12> , or other CNS_depressants (including alcohol ) concomitantly with <e20> hydrocodone </e20> and acetaminophen tablets may exhibit an additive CNS depression.
effect	Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other <e12> CNS_depressants </e12> (including alcohol ) concomitantly with <e20> hydrocodone </e20> and acetaminophen tablets may exhibit an additive CNS depression.
effect	Patients receiving other narcotic_analgesics , antipsychotics , antianxiety_agents , or other CNS_depressants (including <e10> alcohol </e10> ) concomitantly with <e20> hydrocodone </e20> and acetaminophen tablets may exhibit an additive CNS depression.
effect	The use of <e12> MAO_inhibitors </e12> or tricyclic_antidepressants with <e20> hydrocodone </e20> preparations may increase the effect of either the antidepressant or hydrocodone .
effect	The use of MAO_inhibitors or <e12> tricyclic_antidepressants </e12> with <e20> hydrocodone </e20> preparations may increase the effect of either the antidepressant or hydrocodone .
effect	The concurrent use of <e12> anticholinergics </e12> with <e20> hydrocodone </e20> may produce paralytic ileus.
effect	(Concurrent use with <e12> thiazide_diuretics </e12> may enhance the possibility of <e22> digitalis </e22> toxicity associated with hypokalemia.
effect	(In some patients, the <e12> steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of <e22> loop_diuretics </e22> , potassium_sparing_diuretics , and thiazide_diuretics .
effect	(In some patients, the <e12> steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , <e22> potassium_sparing_diuretics </e22> , and thiazide_diuretics .
effect	(In some patients, the <e12> steroidal_anti-inflammatory_agent </e12> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium_sparing_diuretics , and <e22> thiazide_diuretics </e22> .
effect	( <e12> Thiazides </e12> may decrease arterial responsiveness to <e20> norepinephrine </e20> .
effect	( <e12> Thiazide_drugs </e12> may increase the responsiveness to <e20> tubocurarine </e20> .
effect	Patients receiving other <e12> narcotic_analgesic </e12> s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with <e21> DILAUDID </e21> may exhibit an additive CNS depression.
effect	Patients receiving other narcotic_analgesic s, general <e12> anesthetics </e12> , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with <e21> DILAUDID </e21> may exhibit an additive CNS depression.
effect	Patients receiving other narcotic_analgesic s, general anesthetics , <e12> phenothiazines </e12> , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with <e21> DILAUDID </e21> may exhibit an additive CNS depression.
effect	Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , <e12> tranquilizers </e12> , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with <e21> DILAUDID </e21> may exhibit an additive CNS depression.
effect	Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , <e12> sedative-hypnotics </e12> , tricyclic_antidepressants or other CNS_depressants (including alcohol ) concomitantly with <e21> DILAUDID </e21> may exhibit an additive CNS depression.
effect	Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , <e12> tricyclic_antidepressants </e12> or other CNS_depressants (including alcohol ) concomitantly with <e21> DILAUDID </e21> may exhibit an additive CNS depression.
effect	Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other <e12> CNS_depressants </e12> (including alcohol ) concomitantly with <e21> DILAUDID </e21> may exhibit an additive CNS depression.
effect	Patients receiving other narcotic_analgesic s, general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic_antidepressants or other CNS_depressants (including <e10> alcohol </e10> ) concomitantly with <e21> DILAUDID </e21> may exhibit an additive CNS depression.
effect	Since <e10> hydroxyurea </e10> may raise the serum uric acid level, dosage adjustment of <e22> uricosuric_medication </e22> may be necessary
effect	THE POTENTIATING ACTION OF <e10> HYDROXYZINE </e10> MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH <e22> CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS </e22> SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND BARBITURATES .
effect	THE POTENTIATING ACTION OF <e10> HYDROXYZINE </e10> MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS <e22> NARCOTICS </e22> , NON-NARCOTIC_ANALGESICS AND BARBITURATES .
effect	THE POTENTIATING ACTION OF <e10> HYDROXYZINE </e10> MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , <e22> NON-NARCOTIC_ANALGESICS </e22> AND BARBITURATES .
effect	THE POTENTIATING ACTION OF <e10> HYDROXYZINE </e10> MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS SUCH AS NARCOTICS , NON-NARCOTIC_ANALGESICS AND <e22> BARBITURATES </e22> .
effect	Additive adverse effects resulting from cholinergic blockade may occur when <e11> LEVSIN </e11> is administered concomitantly with other <e22> antimuscarinics </e22> , amantadine , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines .
effect	Additive adverse effects resulting from cholinergic blockade may occur when <e11> LEVSIN </e11> is administered concomitantly with other antimuscarinics , <e20> amantadine </e20> , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines .
effect	Additive adverse effects resulting from cholinergic blockade may occur when <e11> LEVSIN </e11> is administered concomitantly with other antimuscarinics , amantadine , <e20> haloperidol </e20> , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines .
effect	Additive adverse effects resulting from cholinergic blockade may occur when <e11> LEVSIN </e11> is administered concomitantly with other antimuscarinics , amantadine , haloperidol , <e22> phenothiazines </e22> , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some antihistamines .
effect	Additive adverse effects resulting from cholinergic blockade may occur when <e11> LEVSIN </e11> is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , <e22> monoamine_oxidase_(MAO)_inhibitors </e22> , tricyclic_antidepressants or some antihistamines .
effect	Additive adverse effects resulting from cholinergic blockade may occur when <e11> LEVSIN </e11> is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , <e22> tricyclic_antidepressants </e22> or some antihistamines .
effect	Additive adverse effects resulting from cholinergic blockade may occur when <e11> LEVSIN </e11> is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine_oxidase_(MAO)_inhibitors , tricyclic_antidepressants or some <e22> antihistamines </e22> .
effect	However, because bleeding has been reported when <e10> ibuprofen </e10> and other nonsteroidal_anti-inflammatory_agents have been administered to patients on <e22> coumarin-type_anticoagulants </e22> , the physician should be cautious when administering ibuprofen to patients on anticoagulants .
effect	However, because bleeding has been reported when ibuprofen and other <e12> nonsteroidal_anti-inflammatory_agents </e12> have been administered to patients on <e22> coumarin-type_anticoagulants </e22> , the physician should be cautious when administering ibuprofen to patients on anticoagulants .
effect	Aspirin : Animal studies wshow that <e11> aspirin </e11> given with <e22> nonsteroidal_anti-inflammatory_agents </e22> , including ibuprofen , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
effect	Aspirin : Animal studies wshow that <e11> aspirin </e11> given with nonsteroidal_anti-inflammatory_agents , including <e20> ibuprofen </e20> , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
effect	This may indicate that <e10> ibuprofen </e10> could enhance the toxicity of <e20> methotrexate </e20> .
effect	Furosemide : Clinical studies, as well as random observations, have shown that <e10> ibuprofen </e10> can reduce the natriuretic effect of <e20> furosemide </e20> and thiazides in some patients.
effect	Furosemide : Clinical studies, as well as random observations, have shown that <e10> ibuprofen </e10> can reduce the natriuretic effect of furosemide and <e22> thiazides </e22> in some patients.
effect	However, <e10> iloprost </e10> has the potential to increase the hypotensive effect of <e22> vasodilators </e22> and antihypertensive_agents .
effect	However, <e10> iloprost </e10> has the potential to increase the hypotensive effect of vasodilators and <e22> antihypertensive_agents </e22> .
effect	Since <e10> iloprost </e10> inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on <e22> anticoagulants </e22> .
effect	<e10> Imipramine_hydrochloride </e10> may potentiate the effects of <e22> CNS_depressant_drugs </e22> .
effect	Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving <e10> indinavir </e10> in combination with <e20> ritonavir </e20> than those receiving CRIXIVAN # mg q8h.
effect	<e11> CRIXIVAN </e11> may not be effective due to decreased <e20> indinavir </e20> concentrations in patients taking these agents concomitantly.
effect	In some patients, combined use of <e11> INDOCIN </e11> and <e20> diflunisal </e20> has been associated with fatal gastrointestinal hemorrhage.
effect	In post-marketing experience, bleeding has been reported in patients on concomitant treatment with <e12> anticoagulants </e12> and <e21> INDOCIN </e21> .
effect	Administration of <e12> non-steroidal_anti-inflammatory_drugs </e12> concomitantly with <e20> cyclosporine </e20> has been associated with an increase in cyclosporine -induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
effect	In some patients, the administration of <e11> INDOCIN </e11> can reduce the diuretic, natriuretic, and antihypertensive effects of <e22> loop_diuretics </e22> , potassium-sparing_diuretics , and thiazide_diuretics .
effect	In some patients, the administration of <e11> INDOCIN </e11> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , <e22> potassium-sparing_diuretics </e22> , and thiazide_diuretics .
effect	In some patients, the administration of <e11> INDOCIN </e11> can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics , and <e22> thiazide_diuretics </e22> .
effect	It has been reported that the addition of <e10> triamterene </e10> to a maintenance schedule of <e21> INDOCIN </e21> resulted in reversible acute renal failure in two of four healthy volunteers.
effect	The potential effects of <e11> INDOCIN </e11> and <e22> potassium-sparing_diuretics </e22> on potassium kinetics and renal function should be considered when these agents are administered concurrently.
effect	Most of the above effects concerning <e12> diuretics </e12> have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by <e21> INDOCIN </e21> .
effect	Blunting of the antihypertensive effect of <e12> beta-adrenoceptor_blocking_agents </e12> by <e22> non-steroidal_antiinflammatory_drugs </e22> including INDOCIN has been reported.
effect	Blunting of the antihypertensive effect of <e12> beta-adrenoceptor_blocking_agents </e12> by non-steroidal_antiinflammatory_drugs including <e21> INDOCIN </e21> has been reported.
effect	<e11> INDOCIN </e11> can reduce the antihypertensive effects of <e20> captopril </e20> and losartan .
effect	<e11> INDOCIN </e11> can reduce the antihypertensive effects of captopril and <e20> losartan </e20> .
effect	Concurrent administration of <e10> etanercept </e10> (another TNF -blocking agent) and <e20> anakinra </e20> (an interleukin-1_antagonist ) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
effect	Other <e12> TNFa-blocking_agents </e12> (including REMICADE ) used in combination with <e20> anakinra </e20> may also result in similar toxicities.
effect	Other TNFa-blocking_agents (including <e11> REMICADE </e11> ) used in combination with <e20> anakinra </e20> may also result in similar toxicities.
effect	<e12> Beta-blockers </e12> , clonidine , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of <e20> insulin </e20> .
effect	Beta-blockers , <e10> clonidine </e10> , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of <e20> insulin </e20> .
effect	Beta-blockers , clonidine , <e10> lithium </e10> salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of <e20> insulin </e20> .
effect	Beta-blockers , clonidine , lithium salts, and <e10> alcohol </e10> may either potentiate or weaken the blood-glucose-lowering effect of <e20> insulin </e20> .
effect	<e12> Beta-blockers </e12> , clonidine , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of <e20> insulin </e20> .
effect	Beta-blockers , <e10> clonidine </e10> , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of <e20> insulin </e20> .
effect	Beta-blockers , clonidine , <e10> lithium </e10> salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of <e20> insulin </e20> .
effect	Beta-blockers , clonidine , lithium salts, and <e10> alcohol </e10> may either potentiate or weaken the blood-glucose-lowering effect of <e20> insulin </e20> .
effect	Anticholinergic_agents : Although <e10> ipratropium_bromide </e10> is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used <e22> anticholinergic_medications </e22> .
effect	The adverse effects of <e11> CAMPTOSAR </e11> , such as myelosuppression and diarrhea, would be expected to be exacerbated by other <e22> antineoplastic_agents </e22> having similar adverse effects.
effect	Lymphocytopenia has been reported in patients receiving <e11> CAMPTOSAR </e11> , and it is possible that the administration of <e20> dexamethasone </e20> as antiemetic prophylaxis may have enhanced the likelihood of this effect.
effect	The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (#%, 4/47 patients) when <e10> prochlorperazine </e10> was administered on the same day as <e21> CAMPTOSAR </e21> than when these drugs were given on separate days (#%, 1/80 patients).
effect	It would be expected that <e12> laxative </e12> use during therapy with <e21> CAMPTOSAR </e21> would worsen the incidence or severity of diarrhea, but this has not been studied.
effect	In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR , the physician may wish to withhold <e12> diuretics </e12> during dosing with <e21> CAMPTOSAR </e21> and, certainly, during periods of active vomiting or diarrhea.
effect	In a single study, rats given high intraperitoneal doses of an <e12> MAO_inhibitor </e12> plus <e20> disulfiram </e20> experienced severe toxicity, including convulsions and death.
effect	<e10> Isoflurane </e10> potentiates the muscle relaxant effect of all <e22> muscle_relaxants </e22> , most notably nondepolarizing_muscle_relaxants , and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
effect	<e10> Isoflurane </e10> potentiates the muscle relaxant effect of all muscle_relaxants , most notably <e22> nondepolarizing_muscle_relaxants </e22> , and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
effect	Acetaminophen : A report of severe <e10> acetaminophen </e10> toxicity was reported in a patient receiving <e20> Isoniazid </e20> .
effect	It is believed that the toxicity may have resulted from a previously unrecognized interaction between <e10> isoniazid </e10> and <e20> acetaminophen </e20> and a molecular basis for this interaction has been proposed.
effect	The vasodilating effects of <e10> isosorbide_dinitrate </e10> may be additive with those of other <e22> vasodilators </e22> .
effect	The vasodilating effects of <e10> isosorbide_mononitrate </e10> may be additive with those of other <e22> vasodilators </e22> .
effect	Marked symptomatic orthostatic hypotension has been reported when <e12> calcium_channel_blockers </e12> and <e22> organic_nitrates </e22> were used in combination.
effect	Vitamin_A : Because of the relationship of <e11> Accutane </e11> to <e22> vitamin_A </e22> , patients should be advised against taking vitamin_supplements containing vitamin_A to avoid additive toxic effects
effect	Tetracyclines : Concomitant treatment with Accutane and tetracyclines should be avoided because <e11> Accutane </e11> use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of <e22> tetracyclines </e22>
effect	Micro-dosed Progesterone Preparations: Micro-dosed <e10> progesterone </e10> preparations (minipills that do not contain an estrogen ) may be an inadequate method of contraception during <e21> Accutane </e21> therapy.
effect	Fentanyl Anesthesia: Severe hypotension has been reported during <e10> fentanyl </e10> anesthesia with concomitant use of a <e22> beta_blocker </e22> and a calcium_channel_blocker .
effect	Fentanyl Anesthesia: Severe hypotension has been reported during <e10> fentanyl </e10> anesthesia with concomitant use of a beta_blocker and a <e22> calcium_channel_blocker </e22> .
effect	Data suggest that coadministration of oral <e10> ketoconazole </e10> and <e20> cisapride </e20> can result in prolongation of the QT interval on the ECG.
effect	Rhabdomyolysis has been observed in patients receiving <e12> HMG-CoA_reductase_inhibitors </e12> administered alone (at recommended dosages) or concomitantly with <e22> immunosuppressive_drugs </e22> including cyclosporine .
effect	Rhabdomyolysis has been observed in patients receiving <e12> HMG-CoA_reductase_inhibitors </e12> administered alone (at recommended dosages) or concomitantly with immunosuppressive_drugs including <e20> cyclosporine </e20> .
effect	It has been reported that <e10> Itraconazole </e10> enhances the anticoagulant effect of <e22> coumarin </e22> -like drugs.
effect	Severe hypoglycemia has been reported in patients concomitantly receiving <e12> azole_antifungal_agents </e12> and oral <e22> hypoglycemic_agents </e22> .
effect	Tinnitus and decreased hearing have been reported in patients concomitantly receiving <e10> Itraconazole </e10> and <e20> quinidine </e20> .
effect	Edema has been reported in patients concomitantly receiving <e10> Itraconazole </e10> and <e22> dihydropyridine_calcium_channel_blockers </e22> .
effect	In vitro mixing of an <e12> aminoglycoside </e12> with beta-lactamtype <e22> antibiotics </e22> ( penicillins or cephalosporins ) may result in a significant mutual inactivation.
effect	In vitro mixing of an <e12> aminoglycoside </e12> with beta-lactamtype antibiotics ( <e22> penicillins </e22> or cephalosporins ) may result in a significant mutual inactivation.
effect	In vitro mixing of an <e12> aminoglycoside </e12> with beta-lactamtype antibiotics ( penicillins or <e22> cephalosporins </e22> ) may result in a significant mutual inactivation.
effect	Prolonged recovery time may occur if <e12> barbiturates </e12> and/or narcotics are used concurrently with <e20> ketamine </e20> .
effect	Prolonged recovery time may occur if barbiturates and/or <e12> narcotics </e12> are used concurrently with <e20> ketamine </e20> .
effect	Pharmacokinetic data indicate that oral <e10> ketoconazole </e10> inhibits the metabolism of <e20> astemizole </e20> , resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.
effect	Data suggest that coadministration of oral <e10> ketoconazole </e10> and <e20> cisapride </e20> can result in prolongation of the QT interval on the ECG.
effect	When taken orally , <e12> imidazole_compounds </e12> like ketoconazole may enhance the anticoagulant effect of <e22> coumarin </e22> -like drugs.
effect	When taken orally , imidazole_compounds like <e10> ketoconazole </e10> may enhance the anticoagulant effect of <e22> coumarin </e22> -like drugs.
effect	Because severe hypoglycemia has been reported in patients concomitantly receiving oral <e10> miconazole </e10> (an imidazole ) and oral <e22> hypoglycemic_agents </e22> , such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole ) can not be ruled out.
effect	Diuretic : <e10> Hydrochlorothiazide </e10> , given concomitantly with <e20> ketoprofen </e20> , produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.
effect	Furosemide : <e11> TORADOL </e11> IV/IM reduced the diuretic response to <e20> furosemide </e20> in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
effect	Antiepileptic_Drugs : Sporadic cases of seizures have been reported during concomitant use of <e11> TORADOL </e11> and <e22> antiepileptic_drugs </e22> ( phenytoin , carbamazepine ).
effect	Antiepileptic_Drugs : Sporadic cases of seizures have been reported during concomitant use of <e11> TORADOL </e11> and antiepileptic_drugs ( <e20> phenytoin </e20> , carbamazepine ).
effect	Antiepileptic_Drugs : Sporadic cases of seizures have been reported during concomitant use of <e11> TORADOL </e11> and antiepileptic_drugs ( phenytoin , <e20> carbamazepine </e20> ).
effect	Psychoactive_Drugs : Hallucinations have been reported when <e11> TORADOL </e11> was used in patients taking <e22> psychoactive_drugs </e22> ( fluoxetine , thiothixene , alprazolam ).
effect	Psychoactive_Drugs : Hallucinations have been reported when <e11> TORADOL </e11> was used in patients taking psychoactive_drugs ( <e20> fluoxetine </e20> , thiothixene , alprazolam ).
effect	Psychoactive_Drugs : Hallucinations have been reported when <e11> TORADOL </e11> was used in patients taking psychoactive_drugs ( fluoxetine , <e20> thiothixene </e20> , alprazolam ).
effect	Psychoactive_Drugs : Hallucinations have been reported when <e11> TORADOL </e11> was used in patients taking psychoactive_drugs ( fluoxetine , thiothixene , <e20> alprazolam </e20> ).
effect	Cyclosporine - <e10> L-arginine </e10> may counteract the antinaturetic effect of <e20> cyclosporin </e20> .
effect	Organic nitrates - <e10> L-arginine </e10> supplements theoretically may potentiate the effects of organic <e22> nitrates </e22> if taken concomitantly.
effect	Sildenafil_citrate - Theoretically, <e10> L-arginine </e10> supplements taken concomitantly with <e20> sildenafil_citrate </e20> , may potentiate the effects of the drug.
effect	Indomethacin - Concomitant use of <e10> L-glutamine </e10> and <e20> indomethacin </e20> may ameliorate increased intestinal permeability caused by indomethacin .
effect	Methotrexate - There is one report that <e10> methotrexate </e10> may decrease the possible effectiveness of supplemental <e20> L-glutamine </e20> for chemotherapy-induced mucositis.
effect	In another report, nine patients with breast cancer were reported to have decreased symptoms of <e10> methotrexate </e10> -related toxicity when given supplemental <e20> L-glutamine </e20> at a dose of # gram/kilogram/day.
effect	Paclitaxel - In one report, <e10> L-glutamine </e10> at a dose of # grams three times daily, given # hours after receiving <e20> paclitaxel </e20> , appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel .
effect	Medroxyprogesterone_Acetate - <e10> L-histidine </e10> was observed to enhance (in tissue culture) the effect of <e20> medroxyprogesterone_acetate </e20> in reducing the number of human breast cancer cells that were in the S phase.
effect	H1_Blockers and H2_Blockers - Although not reported, <e10> L-histidine </e10> , via its metabolism to histamine, might decrease the efficacy of <e22> H1_blockers </e22> and H2_blockers .
effect	H1_Blockers and H2_Blockers - Although not reported, <e10> L-histidine </e10> , via its metabolism to histamine, might decrease the efficacy of H1_blockers and <e22> H2_blockers </e22> .
effect	Acetaminophen and methotrexate - <e10> L-methionine </e10> may decrease hepatic toxicity in those with <e20> acetaminophen </e20> overdosage or in those taking methotrexate .
effect	Acetaminophen and methotrexate - <e10> L-methionine </e10> may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking <e20> methotrexate </e20> .
effect	Gentamicin - <e10> Methionine </e10> may protect against the ototoxic effects of <e20> gentamicin </e20> .
effect	Concomitant use of <e10> L-phenylalanine </e10> and <e22> non-selective_MAO_inhibitors </e22> may cause hypertension.
effect	Selegiline - <e10> L-phenylalanine </e10> and the selective_MAO_inhibitor <e20> selegiline </e20> may have synergistic antidepressant activity if used concomitantly.
effect	<e12> Neuroleptic_Drugs </e12> - <e20> L-phenylalanine </e20> may potentiate the tardive dyskinesia side reactions of neuroleptic_drugs if used concomitantly with them.
effect	Non-selective_MAO_inhibitors including tranylcypromine_sulfate , phenelzine_sulfate , and pargyline HC1: Concomitant use of <e10> L-tyrosine </e10> and non-selective <e22> MAO_inhibitors </e22> may cause hypertension.
effect	In one survey, #% of patients taking <e10> labetalol_HCl </e10> in combination with <e22> tricyclic_antidepressants </e22> experienced tremor, as compared to #% reported to occur with labetalol_HCl alone.
effect	Synergism has been shown between <e10> halothane </e10> anesthesia and intravenously administered <e20> labetalol_HCl </e20> .
effect	During controlled hypotensive anesthesia using <e10> labetalol_HCl </e10> in association with <e20> halothane </e20> , high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.
effect	<e10> Labetalol_HCl </e10> blunts the reflex tachycardia produced by <e20> nitroglycerin </e20> without preventing its hypotensive effect.
effect	If <e10> labetalol_HCl </e10> is used with <e20> nitroglycerin </e20> in patients with angina pectoris, additional antihypertensive effects may occur.
effect	<e10> Lamivudine </e10> and <e20> zalcitabine </e20> may inhibit the intracellular phosphorylation of one another.
effect	In a small (n=30) combination study of <e11> ARAVA </e11> with <e20> methotrexate </e20> , a 2- to 3-fold elevation in liver enzymes was seen in # of # patients.
effect	Warfarin : Increased INR (International Normalized Ratio) when <e11> ARAVA </e11> and <e20> warfarin </e20> were co-administered has been rarely reported.
effect	<e10> Folic_acid </e10> in large amounts may counteract the antiepileptic effect of <e20> phenobarbital </e20> , phenytoin and primidone , and increase the frequency of seizures in susceptible pediatric patients.
effect	<e10> Folic_acid </e10> in large amounts may counteract the antiepileptic effect of phenobarbital , <e20> phenytoin </e20> and primidone , and increase the frequency of seizures in susceptible pediatric patients.
effect	<e10> Folic_acid </e10> in large amounts may counteract the antiepileptic effect of phenobarbital , phenytoin and <e20> primidone </e20> , and increase the frequency of seizures in susceptible pediatric patients.
effect	However, high doses of <e10> leucovorin </e10> may reduce the efficacy of intrathecally administered <e20> methotrexate </e20> .
effect	<e10> Leucovorin </e10> may enhance the toxicity of <e20> 5-fluorouracil </e20> .
effect	<e11> ERGAMISOL </e11> ( levamisole_hydrochloride ) has been reported to produce ANTABUSE-like side effects when given concomitantly with <e20> alcohol </e20> .
effect	ERGAMISOL ( <e10> levamisole_hydrochloride </e10> ) has been reported to produce ANTABUSE-like side effects when given concomitantly with <e20> alcohol </e20> .
effect	Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with <e11> BETAGAN </e11> and <e20> epinephrine </e20> may occur.
effect	The concomitant use of <e12> beta-adrenergic_blocking_agents </e12> with <e22> digitalis </e22> and calcium_antagonist s may have additive effects on prolonging atrioventricular conduction time.
effect	The concomitant use of <e12> beta-adrenergic_blocking_agents </e12> with digitalis and <e22> calcium_antagonist </e22> s may have additive effects on prolonging atrioventricular conduction time.
effect	However, the systemic administration of some <e12> quinolones </e12> has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant <e20> warfarin </e20> and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
effect	However, the systemic administration of some <e12> quinolones </e12> has been shown to elevate plasma concentrations of theophylline , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic <e20> cyclosporine </e20> concomitantly.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all <e22> central_nervous_system_depressants </e22> (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all central_nervous_system_depressants (eg, <e20> alcohol </e20> , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all central_nervous_system_depressants (eg, alcohol , <e22> sedatives </e22> , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all central_nervous_system_depressants (eg, alcohol , sedatives , <e22> hypnotics </e22> , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other <e22> opioids </e22> , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general <e22> anesthetics </e22> , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , <e22> barbiturates </e22> , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , <e22> tricyclic_antidepressants </e22> , phenothiazines , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , <e22> phenothiazines </e22> , tranquilizers , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , <e22> tranquilizers </e22> , skeletal_muscle_relaxants and antihistamines ) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , <e22> skeletal_muscle_relaxants </e22> and antihistamines ) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of <e11> Levo-Dromoran </e11> with all central_nervous_system_depressants (eg, alcohol , sedatives , hypnotics , other opioids , general anesthetics , barbiturates , tricyclic_antidepressants , phenothiazines , tranquilizers , skeletal_muscle_relaxants and <e22> antihistamines </e22> ) may result in additive central nervous system depressant effects.
effect	Ketamine : Marked hypertension and tachycardia have been reported in association with concomitant administration of <e10> levothyroxine_sodium </e10> and <e20> ketamine </e20> .
effect	The administration of local anesthetic_solutions containing <e10> epinephrine </e10> or norepinephrine to patients receiving <e22> monoamine_oxidase_inhibitors </e22> or tricyclic_antidepressants may produce severe, prolonged hypertension.
effect	The administration of local anesthetic_solutions containing <e10> epinephrine </e10> or norepinephrine to patients receiving monoamine_oxidase_inhibitors or <e22> tricyclic_antidepressants </e22> may produce severe, prolonged hypertension.
effect	The administration of local anesthetic_solutions containing epinephrine or <e10> norepinephrine </e10> to patients receiving <e22> monoamine_oxidase_inhibitors </e22> or tricyclic_antidepressants may produce severe, prolonged hypertension.
effect	The administration of local anesthetic_solutions containing epinephrine or <e10> norepinephrine </e10> to patients receiving monoamine_oxidase_inhibitors or <e22> tricyclic_antidepressants </e22> may produce severe, prolonged hypertension.
effect	<e12> Phenothiazines </e12> and butyrophenones may reduce or reverse the pressor effect of <e20> epinephrine </e20> .
effect	Phenothiazines and <e12> butyrophenones </e12> may reduce or reverse the pressor effect of <e20> epinephrine </e20> .
effect	<e10> Lincomycin </e10> has been shown to have neuromuscular blocking properties that may enhance the action of other <e22> neuromuscular_blocking_agents </e22> .
effect	Antagonism between <e10> lincomycin </e10> and <e20> erythromycin </e20> in vitro has been demonstrated.
effect	Adrenergic_Agents :Some individuals receiving <e11> ZYVOX </e11> may experience a reversible enhancement of the pressor response to indirect-acting <e22> sympathomimetic_agents </e22> , vasopressor or dopaminergic_agents .
effect	Adrenergic_Agents :Some individuals receiving <e11> ZYVOX </e11> may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic_agents , <e22> vasopressor </e22> or dopaminergic_agents .
effect	Adrenergic_Agents :Some individuals receiving <e11> ZYVOX </e11> may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic_agents , vasopressor or <e22> dopaminergic_agents </e22> .
effect	Spontaneous reports of serotonin syndrome associated with co-administration of <e11> ZYVOX </e11> and <e22> serotonergic_agents </e22> , including antidepressants such as selective_serotonin_reuptake_inhibitors ( SSRIs ), have been reported.
effect	Spontaneous reports of serotonin syndrome associated with co-administration of <e11> ZYVOX </e11> and serotonergic_agents , including <e22> antidepressants </e22> such as selective_serotonin_reuptake_inhibitors ( SSRIs ), have been reported.
effect	Spontaneous reports of serotonin syndrome associated with co-administration of <e11> ZYVOX </e11> and serotonergic_agents , including antidepressants such as <e22> selective_serotonin_reuptake_inhibitors </e22> ( SSRIs ), have been reported.
effect	Spontaneous reports of serotonin syndrome associated with co-administration of <e11> ZYVOX </e11> and serotonergic_agents , including antidepressants such as selective_serotonin_reuptake_inhibitors ( <e22> SSRIs </e22> ), have been reported.
effect	Patients who are treated with <e11> ZYVOX </e11> and concomitant <e22> serotonergic_agents </e22> should be closely observed for signs and symptoms of serotonin syndrome (e,g,, cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).
effect	Tricyclic_Antidepressants : Use of <e12> thyroid_products </e12> with <e20> imipramine </e20> and other tricyclic_antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
effect	Tricyclic_Antidepressants : Use of <e12> thyroid_products </e12> with imipramine and other <e22> tricyclic_antidepressants </e22> may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
effect	Digitalis : <e12> Thyroid_preparations </e12> may potentiate the toxic effects of <e22> digitalis </e22> .
effect	Ketamine : When administered to patients on a <e12> thyroid_preparation </e12> , this parenteral <e22> anesthetic </e22> may cause hypertension and tachycardia.
effect	Vasopressor s: <e10> Thyroxine </e10> increases the adrenergic effect of catecholamines such as <e20> epinephrine </e20> and norepinephrine .
effect	Vasopressor s: <e10> Thyroxine </e10> increases the adrenergic effect of catecholamines such as epinephrine and <e20> norepinephrine </e20> .
effect	Adrenergic_blockers <e12> Adrenergic_blockers </e12> are inhibited by <e20> amphetamines </e20> .
effect	Antidepressants , tricyclic <e12> Amphetamines </e12> may enhance the activity of <e22> tricyclic_antidepressants </e22> or sympathomimetic_agents ;
effect	Antidepressants , tricyclic <e12> Amphetamines </e12> may enhance the activity of tricyclic_antidepressants or <e22> sympathomimetic_agents </e22> ;
effect	Antihistamines : <e12> Amphetamines </e12> may counteract the sedative effect of <e22> antihistamines </e22> .
effect	Antihypertensives : <e12> Amphetamines </e12> may antagonize the hypotensive effects of <e20> antihypertensives </e20> .
effect	Chlorpromazine : <e10> Chlorpromazine </e10> blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of <e20> amphetamines </e20> and can be used to treat amphetamine poisoning.
effect	Haloperidol : <e10> Haloperidol </e10> blocks dopamine receptors, thus inhibiting the central stimulant effects of <e20> amphetamines </e20> .
effect	Lithium_carbonate : The anorectic and stimulatory effects of <e10> amphetamines </e10> may be inhibited by <e20> lithium_carbonate </e20> .
effect	Meperidine : <e12> Amphetamines </e12> potentiate the analgesic effect of <e20> meperidine </e20> .
effect	Norepinephrine : <e12> Amphetamines </e12> enhance the adrenergic effect of <e20> norepinephrine </e20> .
effect	Propoxyphene : In cases of <e10> propoxyphene </e10> overdosage, <e20> amphetamine </e20> CNS stimulation is potentiated and fatal convulsions can occur.
effect	Veratrum_alkaloids : <e12> Amphetamines </e12> inhibit the hypotensive effect of <e22> veratrum_alkaloids </e22> .
effect	Hypotension - Patients on Diuretic Therapy: Patients on <e12> diuretics </e12> , and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with <e21> PRINIVIL </e21> .
effect	The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the <e12> diuretic </e12> or increasing the salt intake prior to initiation of treatment with <e21> PRINIVIL </e21> .
effect	When a <e12> diuretic </e12> is added to the therapy of a patient receiving <e21> PRINIVIL </e21> , an additional antihypertensive effect is usually observed.
effect	Non-steroidal_Anti-inflammatory_Agents : In some patients with compromised renal function who are being treated with <e12> non-steroidal_anti-inflammatory_drugs </e12> , the co-administration of <e20> lisinopril </e20> may result in a further deterioration of renal function.
effect	Reports suggest that <e12> NSAIDs </e12> may diminish the antihypertensive effect of <e22> ACE_inhibitors </e22> , including lisinopril .
effect	Reports suggest that <e12> NSAIDs </e12> may diminish the antihypertensive effect of ACE_inhibitors , including <e20> lisinopril </e20> .
effect	Agents Increasing Serum Potassium: <e11> PRINIVIL </e11> attenuates potassium loss caused by <e22> thiazide-type_diuretics </e22> .
effect	Use of <e11> PRINIVIL </e11> with <e22> potassium-sparing_diuretics </e22> (e,g,, spironolactone , triamterene , or amiloride ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
effect	Use of <e11> PRINIVIL </e11> with potassium-sparing_diuretics (e,g,, <e20> spironolactone </e20> , triamterene , or amiloride ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
effect	Use of <e11> PRINIVIL </e11> with potassium-sparing_diuretics (e,g,, spironolactone , <e20> triamterene </e20> , or amiloride ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
effect	Use of <e11> PRINIVIL </e11> with potassium-sparing_diuretics (e,g,, spironolactone , triamterene , or <e20> amiloride </e20> ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
effect	Use of <e11> PRINIVIL </e11> with potassium-sparing_diuretics (e,g,, spironolactone , triamterene , or amiloride ), <e20> potassium </e20> supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
effect	Lithium : Lithium toxicity has been reported in patients receiving <e10> lithium </e10> concomitantly with drugs which cause elimination of sodium, including <e22> ACE_inhibitors </e22> .
effect	Lithium toxicity was usually reversible upon discontinuation of <e10> lithium </e10> and the <e22> ACE_inhibitor </e22> .
effect	- <e10> Lofexidine </e10> may enhance the CNS depressive effects of <e20> alcohol </e20> , barbiturates and other sedatives
effect	- <e10> Lofexidine </e10> may enhance the CNS depressive effects of alcohol , <e22> barbiturates </e22> and other sedatives
effect	- <e10> Lofexidine </e10> may enhance the CNS depressive effects of alcohol , barbiturates and other <e22> sedatives </e22>
effect	- <e10> Lofexidine </e10> may enhance the effects of <e22> anti-hypertensive_drug </e22> therapy
effect	- Concomitant use of <e12> tricyclic_antidepressants </e12> may reduce the efficacy of <e20> lofexidine </e20> .
effect	Warfarin : <e12> Quinolones </e12> may enhance the effects of the oral <e22> anticoagulant </e22> , warfarin , or its derivatives.
effect	Warfarin : <e12> Quinolones </e12> may enhance the effects of the oral anticoagulant , <e20> warfarin </e20> , or its derivatives.
effect	Tablets: The <e12> benzodiazepines </e12> , including lorazepam , produce CNS-depressant effects when administered with such medications as <e22> barbiturates </e22> or alcohol .
effect	Tablets: The <e12> benzodiazepines </e12> , including lorazepam , produce CNS-depressant effects when administered with such medications as barbiturates or <e20> alcohol </e20> .
effect	Tablets: The benzodiazepines , including <e10> lorazepam </e10> , produce CNS-depressant effects when administered with such medications as <e22> barbiturates </e22> or alcohol .
effect	Tablets: The benzodiazepines , including <e10> lorazepam </e10> , produce CNS-depressant effects when administered with such medications as barbiturates or <e20> alcohol </e20> .
effect	Injection: <e10> Lorazepam </e10> injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with <e20> ethyl_alcohol </e20> , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection: <e10> Lorazepam </e10> injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , <e22> phenothiazines </e22> , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection: <e10> Lorazepam </e10> injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , <e22> barbiturates </e22> , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection: <e10> Lorazepam </e10> injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , <e22> MAO_inhibitors </e22> , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection: <e10> Lorazepam </e10> injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other <e22> antidepressants </e22> ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection: Lorazepam injection, like other injectable <e12> benzodiazepines </e12> , produces depression of the central nervous system when administered with <e20> ethyl_alcohol </e20> , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection: Lorazepam injection, like other injectable <e12> benzodiazepines </e12> , produces depression of the central nervous system when administered with ethyl_alcohol , <e22> phenothiazines </e22> , barbiturates , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection: Lorazepam injection, like other injectable <e12> benzodiazepines </e12> , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , <e22> barbiturates </e22> , MAO_inhibitors , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection: Lorazepam injection, like other injectable <e12> benzodiazepines </e12> , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , <e22> MAO_inhibitors </e22> , and other antidepressants ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection: Lorazepam injection, like other injectable <e12> benzodiazepines </e12> , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other <e22> antidepressants </e22> ,When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection: Lorazepam injection, like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl_alcohol , phenothiazines , barbiturates , MAO_inhibitors , and other antidepressants ,When <e10> scopolamine </e10> is used concomitantly with injectable <e20> lorazepam </e20> , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	As with other antihypertensive_agents , the antihypertensive effect of <e10> losartan </e10> may be blunted by the non-steroidal_anti-inflammatory_drug <e20> indomethacin </e20>
effect	Danazol : The risk of myopathy/rhabdomyolysis is increased by concomitant administration of <e10> danazol </e10> particularly with higher doses of <e20> lovastatin </e20> (see WARNINGS, Myopathy/Rhabdomyolysis).
effect	Amiodarone or Verapamil : The risk of myopathy/rhabdomyolysis is increased when either <e10> amiodarone </e10> or verapamil is used concomitantly with a closely related member of the <e22> HMG-CoA_reductase_inhibitor_class </e22> (see WARNINGS, Myopathy/Rhabdomyolysis).
effect	Amiodarone or Verapamil : The risk of myopathy/rhabdomyolysis is increased when either amiodarone or <e10> verapamil </e10> is used concomitantly with a closely related member of the <e22> HMG-CoA_reductase_inhibitor_class </e22> (see WARNINGS, Myopathy/Rhabdomyolysis).
effect	However, another <e12> HMG-CoA_reductase_inhibitor </e12> has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of <e20> warfarin </e20> .
effect	Also, bleeding and/or increased prothrombin time have been reported in a few patients taking <e12> coumarin_anticoagulant </e12> s concomitantly with <e20> lovastatin </e20> .
effect	There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of <e10> loxapine </e10> and <e20> lorazepam </e20> .
effect	Oral <e12> contraceptives </e12> may be less effective while you are taking <e20> lymecycline </e20> .
effect	ACE_inhibitors : Reports suggest that <e12> NSAIDs </e12> may diminish the antihypertensive effect of <e22> ACE_inhibitors </e22> .
effect	Furosemide : Clinical studies, as well as post-marketing observations, have shown that <e12> NSAIDs </e12> can reduce the natriuretic effect of <e20> furosemide </e20> and thiazides in some patients.
effect	Furosemide : Clinical studies, as well as post-marketing observations, have shown that <e12> NSAIDs </e12> can reduce the natriuretic effect of furosemide and <e22> thiazides </e22> in some patients.
effect	Warfarin : The effects of <e10> warfarin </e10> and <e22> NSAIDs </e22> on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
effect	Concomitant administration of <e10> Mefloquine </e10> and other related compounds (eg, <e20> quinine </e20> , quinidine and chloroquine ) may produce electrocardiographic abnormalities and increase the risk of convulsions.
effect	Concomitant administration of <e10> Mefloquine </e10> and other related compounds (eg, quinine , <e20> quinidine </e20> and chloroquine ) may produce electrocardiographic abnormalities and increase the risk of convulsions.
effect	Concomitant administration of <e10> Mefloquine </e10> and other related compounds (eg, quinine , quinidine and <e20> chloroquine </e20> ) may produce electrocardiographic abnormalities and increase the risk of convulsions.
effect	This appears to be the only clinically relevant interaction of this kind with <e10> Mefloquine </e10> , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, <e20> anti-arrhythmic </e20> or beta-adrenergic_blocking_agents , calcium_channel_blockers , antihistamines or H1-blocking_agents , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval.
effect	This appears to be the only clinically relevant interaction of this kind with <e10> Mefloquine </e10> , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or <e22> beta-adrenergic_blocking_agents </e22> , calcium_channel_blockers , antihistamines or H1-blocking_agents , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval.
effect	This appears to be the only clinically relevant interaction of this kind with <e10> Mefloquine </e10> , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , <e22> calcium_channel_blockers </e22> , antihistamines or H1-blocking_agents , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval.
effect	This appears to be the only clinically relevant interaction of this kind with <e10> Mefloquine </e10> , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , calcium_channel_blockers , <e22> antihistamines </e22> or H1-blocking_agents , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval.
effect	This appears to be the only clinically relevant interaction of this kind with <e10> Mefloquine </e10> , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , calcium_channel_blockers , antihistamines or <e22> H1-blocking_agents </e22> , tricyclic_antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval.
effect	This appears to be the only clinically relevant interaction of this kind with <e10> Mefloquine </e10> , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , calcium_channel_blockers , antihistamines or H1-blocking_agents , <e22> tricyclic_antidepressants </e22> and phenothiazines ) might also contribute to a prolongation of the QTc interval.
effect	This appears to be the only clinically relevant interaction of this kind with <e10> Mefloquine </e10> , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic_blocking_agents , calcium_channel_blockers , antihistamines or H1-blocking_agents , tricyclic_antidepressants and <e22> phenothiazines </e22> ) might also contribute to a prolongation of the QTc interval.
effect	In patients taking an <e12> anticonvulsant </e12> (eg, valproic_acid , carbamazepine , phenobarbital or phenytoin ), the concomitant use of <e20> Mefloquine </e20> may reduce seizure control by lowering the plasma levels of the anticonvulsant .
effect	In patients taking an anticonvulsant (eg, <e10> valproic_acid </e10> , carbamazepine , phenobarbital or phenytoin ), the concomitant use of <e20> Mefloquine </e20> may reduce seizure control by lowering the plasma levels of the anticonvulsant .
effect	In patients taking an anticonvulsant (eg, valproic_acid , <e10> carbamazepine </e10> , phenobarbital or phenytoin ), the concomitant use of <e20> Mefloquine </e20> may reduce seizure control by lowering the plasma levels of the anticonvulsant .
effect	In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , <e10> phenobarbital </e10> or phenytoin ), the concomitant use of <e20> Mefloquine </e20> may reduce seizure control by lowering the plasma levels of the anticonvulsant .
effect	In patients taking an anticonvulsant (eg, valproic_acid , carbamazepine , phenobarbital or <e10> phenytoin </e10> ), the concomitant use of <e20> Mefloquine </e20> may reduce seizure control by lowering the plasma levels of the anticonvulsant .
effect	When <e10> Mefloquine </e10> is taken concurrently with oral <e22> live_typhoid_vaccines </e22> , attenuation of immunization cannot be excluded.
effect	Warfarin - <e12> Vitamin_K </e12> can antagonize the effect of <e20> warfarin </e20>
effect	<e10> Nabilone </e10> has been shown to have an additive CNS depressant effect when given with either <e20> diazepam </e20> , secobarbitone_sodium , alcohol or codeine .
effect	<e10> Nabilone </e10> has been shown to have an additive CNS depressant effect when given with either diazepam , <e21> secobarbitone_sodium </e21> , alcohol or codeine .
effect	<e10> Nabilone </e10> has been shown to have an additive CNS depressant effect when given with either diazepam , secobarbitone_sodium , <e20> alcohol </e20> or codeine .
effect	<e10> Nabilone </e10> has been shown to have an additive CNS depressant effect when given with either diazepam , secobarbitone_sodium , alcohol or <e20> codeine </e20> .
effect	<e10> Tetracycline </e10> , a bacteriostatic_antibiotic , may antagonize the bactericidal effect of <e20> penicillin </e20> and concurrent use of these drugs should be avoided.
effect	There have been reports of theophylline -related side effects in patients on concomitant therapy with <e12> quinolones </e12> and <e20> theophylline </e20> .
effect	<e12> Quinolones </e12> , including nalidixic_acid , may enhance the effects of the oral anticoagulant <e20> warfarin </e20> or its derivatives.
effect	Quinolones , including <e10> nalidixic_acid </e10> , may enhance the effects of the oral anticoagulant <e20> warfarin </e20> or its derivatives.
effect	<e10> Nitrofurantoin </e10> interferes with the therapeutic action of <e20> nalidixic_acid </e20> .
effect	The safety and efficacy of concomitant use of <e11> REVIA </e11> and <e20> disulfiram </e20> is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.
effect	Lethargy and somnolence have been reported following doses of <e11> REVIA </e11> and <e20> thioridazine </e20> .
effect	Patients taking <e11> REVIA </e11> may not benefit from <e22> opioid </e22> containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid_analgesics .
effect	Patients taking <e11> REVIA </e11> may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and <e22> opioid_analgesics </e22> .
effect	In an emergency situation when opioid analgesia must be administered to a patient receiving <e11> REVIA </e11> , the amount of <e22> opioid </e22> required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.
effect	The use of <e12> NSAIDs </e12> in patients who are receiving <e22> ACE_inhibitors </e22> may potentiate renal disease states.
effect	<e10> Naproxen </e10> and other NSAIDs can reduce the antihypertensive effect of <e20> propranolol </e20> and other beta-blockers .
effect	<e10> Naproxen </e10> and other NSAIDs can reduce the antihypertensive effect of propranolol and other <e22> beta-blockers </e22> .
effect	Naproxen and other <e12> NSAIDs </e12> can reduce the antihypertensive effect of <e20> propranolol </e20> and other beta-blockers .
effect	Naproxen and other <e12> NSAIDs </e12> can reduce the antihypertensive effect of propranolol and other <e22> beta-blockers </e22> .
effect	Certain drugs, including <e12> nonsteroidal_anti-inflammatory_agents </e12> ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of <e21> Starlix </e21> and other oral antidiabetic_drugs .
effect	Certain drugs, including <e12> nonsteroidal_anti-inflammatory_agents </e12> ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral <e22> antidiabetic_drugs </e22> .
effect	Certain drugs, including nonsteroidal_anti-inflammatory_agents ( <e12> NSAIDs </e12> ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of <e21> Starlix </e21> and other oral antidiabetic_drugs .
effect	Certain drugs, including nonsteroidal_anti-inflammatory_agents ( <e12> NSAIDs </e12> ), salicylates , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral <e22> antidiabetic_drugs </e22> .
effect	Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), <e12> salicylates </e12> , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of <e21> Starlix </e21> and other oral antidiabetic_drugs .
effect	Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), <e12> salicylates </e12> , monoamine_oxidase_inhibitors , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral <e22> antidiabetic_drugs </e22> .
effect	Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , <e12> monoamine_oxidase_inhibitors </e12> , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of <e21> Starlix </e21> and other oral antidiabetic_drugs .
effect	Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , <e12> monoamine_oxidase_inhibitors </e12> , and non-selective_beta-adrenergic-blocking_agents may potentiate the hypoglycemic action of Starlix and other oral <e22> antidiabetic_drugs </e22> .
effect	Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and <e12> non-selective_beta-adrenergic-blocking_agents </e12> may potentiate the hypoglycemic action of <e21> Starlix </e21> and other oral antidiabetic_drugs .
effect	Certain drugs, including nonsteroidal_anti-inflammatory_agents ( NSAIDs ), salicylates , monoamine_oxidase_inhibitors , and <e12> non-selective_beta-adrenergic-blocking_agents </e12> may potentiate the hypoglycemic action of Starlix and other oral <e22> antidiabetic_drugs </e22> .
effect	Certain drugs including <e12> thiazides </e12> , corticosteroids , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of <e21> Starlix </e21> and other oral antidiabetic_drugs .
effect	Certain drugs including <e12> thiazides </e12> , corticosteroids , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral <e22> antidiabetic_drugs </e22> .
effect	Certain drugs including thiazides , <e12> corticosteroids </e12> , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of <e21> Starlix </e21> and other oral antidiabetic_drugs .
effect	Certain drugs including thiazides , <e12> corticosteroids </e12> , thyroid_products , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral <e22> antidiabetic_drugs </e22> .
effect	Certain drugs including thiazides , corticosteroids , <e12> thyroid_products </e12> , and sympathomimetics may reduce the hypoglycemic action of <e21> Starlix </e21> and other oral antidiabetic_drugs .
effect	Certain drugs including thiazides , corticosteroids , <e12> thyroid_products </e12> , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral <e22> antidiabetic_drugs </e22> .
effect	Certain drugs including thiazides , corticosteroids , thyroid_products , and <e12> sympathomimetics </e12> may reduce the hypoglycemic action of <e21> Starlix </e21> and other oral antidiabetic_drugs .
effect	Certain drugs including thiazides , corticosteroids , thyroid_products , and <e12> sympathomimetics </e12> may reduce the hypoglycemic action of Starlix and other oral <e22> antidiabetic_drugs </e22> .
effect	Oral <e10> neomycin_sulfate </e10> may enhance the effect of <e22> coumarin </e22> in anticoagulants by decreasing vitamin K availability.
effect	Oral <e10> neomycin_sulfate </e10> may enhance the effect of coumarin in <e22> anticoagulants </e22> by decreasing vitamin K availability.
effect	aBased on reports of narcotic withdrawal syndrome in patients treated with <e10> nevirapine </e10> and <e20> methadone </e20> concurrently, and evidence of decreased plasma concentrations of methadone .
effect	Interactions for Vitamin_B3 ( Niacin ): Antihypertensive Therapy: <e10> Nicotinic_acid </e10> may potentiate the effects of <e22> ganglionic_blocking_agents </e22> and vasoactive drugs resulting in postural hypotension.
effect	Beta-adrenergic_Blocking_Agents : Experience in over # patients in a non-comparative clinical trial has shown that concomitant administration of <e10> nifedipine </e10> and <e22> beta-blocking_agents </e22> is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.
effect	Coumarin_Anticoagulants : There have been rare reports of increased prothrombin time in patients taking <e12> coumarin_anticoagulants </e12> to whom <e20> nifedipine </e20> was administered.
effect	It is possible that the cardiovascular action of other <e12> calcium_channel_blockers </e12> could be enhanced by the addition of <e21> Nimotop </e21> .
effect	In Europe, <e11> Nimotop </e11> was observed to occasionally intensify the effect of <e22> antihypertensive_compounds </e22> taken concomitantly by patients suffering from hypertension;
effect	<e10> Propranolol </e10> attenuated the heart rate increase following administration of immediate release <e20> nisoldipine </e20> .
effect	The blood pressure effect of <e11> SULAR </e11> tended to be greater in patients on <e20> atenolol </e20> than in patients on no other antihypertensive therapy.
effect	Although there are no study data to evaluate the possibility, <e12> nitric_oxide_donor_compounds </e12> , including sodium_nitroprusside and nitroglycerin , may have an additive effect with <e21> INOmax </e21> on the risk of developing methemoglobinemia.
effect	Although there are no study data to evaluate the possibility, nitric_oxide_donor_compounds , including <e10> sodium_nitroprusside </e10> and nitroglycerin , may have an additive effect with <e21> INOmax </e21> on the risk of developing methemoglobinemia.
effect	Although there are no study data to evaluate the possibility, nitric_oxide_donor_compounds , including sodium_nitroprusside and <e10> nitroglycerin </e10> , may have an additive effect with <e21> INOmax </e21> on the risk of developing methemoglobinemia.
effect	The vasodilating effects of <e10> nitroglycerin </e10> may be additive with those of other <e22> vasodilators </e22> .
effect	Marked symptomatic orthostatic hypotension has been reported when <e12> calcium_channel_blockers </e12> and organic <e22> nitrates </e22> were used in combination.
effect	The hypotensive effect of <e10> sodium_nitroprusside </e10> is augmented by that of most other <e22> hypotensive_drugs </e22> , including ganglionic_blocking_agents , negative inotropic agents, and inhaled anesthetics .
effect	The hypotensive effect of <e10> sodium_nitroprusside </e10> is augmented by that of most other hypotensive_drugs , including <e22> ganglionic_blocking_agents </e22> , negative inotropic agents, and inhaled anesthetics .
effect	The hypotensive effect of <e10> sodium_nitroprusside </e10> is augmented by that of most other hypotensive_drugs , including ganglionic_blocking_agents , negative inotropic agents, and inhaled <e22> anesthetics </e22> .
effect	The effectiveness of <e12> progestin </e12> -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants <e20> phenytoin </e20> , carbamazepine , and barbiturates , and the antituberculosis_drug rifampin .
effect	The effectiveness of <e12> progestin </e12> -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin , <e20> carbamazepine </e20> , and barbiturates , and the antituberculosis_drug rifampin .
effect	The effectiveness of <e12> progestin </e12> -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin , carbamazepine , and <e22> barbiturates </e22> , and the antituberculosis_drug rifampin .
effect	The effectiveness of <e12> progestin </e12> -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin , carbamazepine , and barbiturates , and the antituberculosis_drug <e20> rifampin </e20> .
effect	There have been reports of theophylline -related side effects in patients on concomitant therapy with <e10> norfloxacin </e10> and <e20> theophylline </e20> .
effect	<e12> Quinolones </e12> , including norfloxacin , may enhance the effects of oral <e22> anticoagulants </e22> , including warfarin or its derivatives or similar agents.
effect	<e12> Quinolones </e12> , including norfloxacin , may enhance the effects of oral anticoagulants , including <e20> warfarin </e20> or its derivatives or similar agents.
effect	Quinolones , including <e10> norfloxacin </e10> , may enhance the effects of oral <e22> anticoagulants </e22> , including warfarin or its derivatives or similar agents.
effect	Quinolones , including <e10> norfloxacin </e10> , may enhance the effects of oral anticoagulants , including <e20> warfarin </e20> or its derivatives or similar agents.
effect	The concomitant administration of <e12> quinolones </e12> including norfloxacin with <e20> glyburide </e20> (a sulfonylurea_agent ) has, on rare occasions, resulted in severe hypoglycemia.
effect	The concomitant administration of quinolones including <e10> norfloxacin </e10> with <e20> glyburide </e20> (a sulfonylurea_agent ) has, on rare occasions, resulted in severe hypoglycemia.
effect	The concomitant use of nitrofurantoin is not recommended since <e10> nitrofurantoin </e10> may antagonize the antibacterial effect of <e20> Norfloxacin </e20> in the urinary tract.
effect	Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of <e12> tricyclic_antidepressants </e12> when <e20> cimetidine </e20> is added to the drug regimen.
effect	The therapeutic efficacy of <e12> tricyclic_antidepressants </e12> may be compromised in these patients when <e20> cimetidine </e20> is discontinued.
effect	Administration of <e10> reserpine </e10> during therapy with a <e22> tricyclic_antidepressant </e22> has been shown to produce a stimulating effect in some depressed patients.
effect	Therefore, concurrent use of <e11> Trileptal </e11> with <e22> hormonal_contraceptives </e22> may render these contraceptives less effective.
effect	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or # mg/m2) given as sequential infusions, myelosuppression was more profound when <e11> TAXOL </e11> was given after <e20> cisplatin </e20> than with the alternate sequence (ie, TAXOL before cisplatin ).
effect	Stavudine and Zidovudine <e10> Ribavirin </e10> can antagonize the in vitro antiviral activity of <e20> stavudine </e20> and zidovudine against HIV.
effect	Stavudine and Zidovudine <e10> Ribavirin </e10> can antagonize the in vitro antiviral activity of stavudine and <e20> zidovudine </e20> against HIV.
effect	Aminoglycosides : The mixing of <e10> piperacillin </e10> with an <e22> aminoglycoside </e22> in vitro can result in substantial inactivation of the aminoglycoside .
effect	Vecuronium : When used in the perioperative period, <e10> piperacillin </e10> has been implicated in the prolongation of the neuromuscular blockade of <e20> vecuronium </e20> .
effect	In one controlled clinical study, the ureidopenicillins, including <e10> piperacillin </e10> , were reported to prolong the action of <e20> vecuronium </e20> .
effect	Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the <e12> non-depolarizing_muscle_relaxants </e12> could be prolonged in the presence of <e20> piperacillin </e20> .
effect	Phenothiazines - Taking <e10> piperazine </e10> and a <e22> phenothiazine </e22> together may increase the risk of convulsions (seizures).
effect	Pyrantel (e,g,, Antiminth ) - Taking <e10> piperazine </e10> and <e20> pyrantel </e20> together may decrease the effects of piperazine .
effect	ACE_inhibitors : Reports suggest that <e12> NSAIDs </e12> may diminish the antihypertensive effect of <e22> Angiotensin_Converting_Enzyme_(ACE)_inhibitors </e22> .
effect	In patients with mild to moderate hypertension, administration of # mg daily of <e11> VIOXX </e11> with the ACE_inhibitor <e20> benazepril </e20> , # to # mg for # weeks, was associated with an average increase in mean arterial pressure of about # mm Hg compared to ACE_inhibitor alone.
effect	Aspirin : Concomitant administration of low-dose <e11> aspirin </e11> with <e21> VIOXX </e21> may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
effect	Furosemide : Clinical studies, as well as post-marketing observations, have shown that <e12> NSAIDs </e12> can reduce the natriuretic effect of <e20> furosemide </e20> and thiazides in some patients.
effect	Furosemide : Clinical studies, as well as post-marketing observations, have shown that <e12> NSAIDs </e12> can reduce the natriuretic effect of furosemide and <e22> thiazides </e22> in some patients.
effect	In single and multiple dose studies in healthy subjects receiving both <e10> warfarin </e10> and <e20> rofecoxib </e20> , prothrombin time (measured as INR) was increased by approximately 8% to 11%.
effect	In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving <e11> VIOXX </e11> concurrently with <e20> warfarin </e20> .
effect	- Antidiabetics , oral (diabetes medicine you take by mouth) Use of oral <e12> antidiabetics </e12> with <e20> sulfapyridine </e20> may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics
effect	- Methotrexate (e,g,, Mexate ) Use of <e10> methotrexate </e10> with <e20> sulfapyridine </e20> may increase the chance of side effects affecting the liver and/or the side effects of methotrexate
effect	- Methyldopa (e,g,, Aldomet ) Use of <e10> methyldopa </e10> with <e20> sulfapyridine </e20> may increase the chance of side effects affecting the liver and/or the blood
effect	- Phenytoin (e,g,, Dilantin ) Use of <e10> phenytoin </e10> with <e20> sulfapyridine </e20> may increase the chance of side effects affecting the liver and/or the side effects of phenytoin
effect	Aspirin : Concomitant administration of <e11> aspirin </e11> with <e20> valdecoxib </e20> may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
effect	ACE-inhibitors :Reports suggest that <e12> NSAIDs </e12> may diminish the antihypertensive effect of <e22> ACE-inhibitors </e22> .
effect	Furosemide : Clinical studies, as well as post-marketing observations, have shown that <e12> NSAIDs </e12> can reduce the natriuretic effect of <e20> furosemide </e20> and thiazides in some patients.
effect	Furosemide : Clinical studies, as well as post-marketing observations, have shown that <e12> NSAIDs </e12> can reduce the natriuretic effect of furosemide and <e22> thiazides </e22> in some patients.
effect	<e10> Valdecoxib </e10> caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of <e20> warfarin </e20> .
effect	Although the magnitude of changes in diazepam plasma exposure when coadministered with <e10> valdecoxib </e10> were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of <e20> diazepam </e20> under this circumstance.
effect	In these patients whose hypertension was controlled with <e10> nifedipine </e10> , <e20> Vardenafil </e20> # mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.
effect	Alpha-blockers : When <e10> Vardenafil </e10> # or # mg was given to healthy volunteers either simultaneously or # hours after a # mg dose of <e20> terazosin </e20> , significant hypotension developed in a substantial number of subjects.
effect	With simultaneous dosing of <e10> Vardenafil </e10> # mg and <e20> terazosin </e20> # mg, # of # subjects experienced a standing systolic blood pressure of less than # mm Hg.
effect	With simultaneous dosing of <e10> Vardenafil </e10> # mg and <e20> terazosin </e20> # mg, # of # subjects experienced a standing systolic blood pressure of less than # mm Hg.
effect	When <e10> Vardenafil </e10> dosing was separated from <e20> terazosin </e20> # mg by # hours, # of # subjects who received # mg of Vardenafil experienced a decrease in standing systolic blood pressure below # mm Hg.
effect	In a similar study with tamsulosin in healthy volunteers, # of # subjects dosed with <e10> Vardenafil </e10> # mg and <e20> tamsulosin </e20> # mg separated by # hours experienced a standing systolic blood pressure below # mm Hg.
effect	Two of # subjects dosed simultaneously with <e10> Vardenafil </e10> # mg and <e20> tamsulosin </e20> # mg experienced a standing systolic blood pressure below # mm Hg.
effect	<e10> Zalcitabine </e10> also has no significant effect on the intracellular phosphorylation of <e20> ZDV </e20> , as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).
effect	Lamivudine : In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that <e10> lamivudine </e10> significantly inhibited <e20> zalcitabine </e20> phosphorylation in a dose dependent manner.
effect	<e10> Zalcitabine </e10> inhibited <e20> lamivudine </e20> phosphorylation at high concentration ratios (10 and 100);
effect	These in vitro studies suggest that concomitant administration of <e10> zalcitabine </e10> and <e20> lamivudine </e20> in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine .
effect	Death due to fulminant pancreatitis possibly related to intravenous <e10> pentamidine </e10> and <e20> HIVID </e20> has been reported.
effect	Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as <e10> amphotericin </e10> , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other <e20> HIVID </e20> -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
effect	Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , <e10> foscarnet </e10> , and aminoglycosides may increase the risk of developing peripheral neuropathy or other <e20> HIVID </e20> -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
effect	Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and <e12> aminoglycosides </e12> may increase the risk of developing peripheral neuropathy or other <e20> HIVID </e20> -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
effect	Doxorubicin : <e10> Doxorubicin </e10> caused a decrease in <e20> zalcitabine </e20> phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt # cells.
effect	CNS-Active Drugs Ethanol : <e11> Sonata </e11> # mg potentiated the CNS-impairing effects of <e20> ethanol </e20> # g/kg on balance testing and reaction time for # hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for # hours after ethanol administration.
effect	Imipramine : Coadministration of single doses of <e11> Sonata </e11> # mg and <e20> imipramine </e20> # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration.
effect	Thioridazine : Coadministration of single doses of <e11> Sonata </e11> # mg and <e20> thioridazine </e20> # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration.
